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Abstract 
 
Background: 
Systemic amyloidosis is a rare, progressive and fatal disorder of protein folding, treatment of 
which requires definitive amyloid fibril typing. Cardiac and renal involvement are common and 
are not only leading causes of mortality and morbidity, but also give rise to major challenges, 
complications and adverse effects of therapies aiming to suppress amyloid fibril precursor 
protein production.  
Aims: 
To refine and improve diagnosis, typing and management of patients with amyloidosis, through: 
proteomic analysis; development of novel biomarker-based risk stratification in patients with 
cardiorenal syndrome; evaluation of changes in body composition and cardiac dysfunction 
during and after systemic chemotherapy; and measures to support amyloidotic organ function.  
Results and Conclusions: 
I confirmed and extended previous studies demonstrating that proteomic analysis of amyloidotic 
tissue is superior overall to IHC for typing amyloid, but identified important limitations relating 
to certain tissues and amyloid types.  
I characterised the complex combined cardiac and renal phenotypes that occur in one 
third of patients with AL amyloidosis, and performed new analyses of biomarkers that are 
widely used to guide chemotherapy. Very encouragingly I have shown that rapid and deep 
clonal responses to chemotherapy can result in meaningful improvements in patient and renal 
survival in individuals with advanced kidney disease, which has previously been considered 
beyond salvage. 
Heart and kidney dysfunction both cause ECV overload and sarcopenia, which cannot 
be quantified clinically but contribute to poor outcomes. I used bioimpedence vector analysis to 
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comprehensively estimate body composition at diagnosis and to aid clinical assessment during 
treatment.   
Despite these improvements in clinical monitoring and in chemotherapy generally, 
sudden cardiac death is common in amyloidosis. Sadly, ICD implantation in 15 patients 
described in my final chapter failed to translate into clinical benefit.   
Patients with amyloidosis continue to have unmet needs, many of which stem from 
heart and kidney involvement, but outcomes are gradually improving.  
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Impact Statement 
 
The work in my thesis focuses on diagnosis, monitoring and outcomes of patients with systemic 
amyloidosis. This is a rare and fatal disorder in which diagnosis is often delayed for years, associated 
with advanced organ failure in many cases. Despite advances in treatment, cardiac involvement 
remains the commonest cause of death and management and treatment of patients remains a major 
challenge.  
The work described here has led to a number of publications and international presentations 
that have improved awareness of amyloidosis, along with improved diagnostic and monitoring 
techniques, which have resulted in improved clinical outcomes. 
 Comparison of traditional histological diagnostic techniques with the state-of-the-art, costly 
and less available mass spectrometry based  proteomic analysis has provided clinicians and medical 
scientists an understanding of the strengths and limitations of each method and when and how they 
should be used in tandem, in conjunction with specialist clinical assessment.   
Management and prognosis of patients with systemic immunoglobulin amyloidosis is 
strongly influenced by cardiac involvement using the Mayo staging system. Despite the multisystem 
nature of the disease, risk stratification and response to treatment is currently defined according to 
individual organ involvement. This is a challenge for clinicians, predominantly haematologists, in 
interpreting the significance of individual renal and cardiac biomarkers, in the ongoing care of such 
patients. The work presented in this thesis has characterised Type 5 cardiorenal syndrome in 
immunoglobulin light chain amyloidosis and the value of key cardiac and renal biomarkers NT-
proBNP and eGFR at baseline and the following year for predicting major outcomes of death and 
dialysis.  Additionally, whilst clonal response to treatment is well recognised as a predictor of both 
overall and renal survival, we show here, that in patients with advanced CKD at presentation, 
previously deemed to be too high risk for chemotherapy or otherwise unsalvageable, a rapid and deep 
clonal response is indeed beneficial resulting in a change clinical practice at our national centre and 
elsewhere. . 
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Novel work studying the role of bioimpedance vector analysis for the quantification and 
monitoring of body composition in patients with systemic immunoglobulin light chain amyloidosis 
receiving systemic chemotherapy has characterised a high incidence of sarcopenia and extracellular 
volume overload in patients at the time of diagnosis, which impact substantially on clinical 
management and overall survival. Whilst  plasma NT-proBNP concentration remains the key 
biomarker for assessing early response to treatment, its relationship with extracellular volume 
overload, and its correlation with bioimpedance vector analysis provides novel information on the 
manner in which volume status influences NT-proBNP; this work also highlights the importance of 
seeking novel methods for tracking cardiac organ response in AL amyloidosis.  
Lastly, whilst survival in systemic AL amyloidosis has improved substantially during the last 
decade, early and sudden cardiac death remains common. Intracardiac defibrillator implantation, 
whilst ostensibly appearing to be an attractive option, is invasive and expensive. Based upon our 
cohort of 15 patients who received ICD implantation and a review of the available literature, we were 
able to propose a pathway for patient selection for ICD implantation. Nevertheless, we sadly 
concluded that whilst ICDs may deliver appropriate lifesaving therapy in the short term, evidence 
supporting long term benefit remains unclear. 
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Chapter One: Introduction 
The amyloidosis are a rare group of diseases that result from the extracellular distribution of 
amyloid, a fibrillar material derived from a range of precursor fibrils that aggregate with a 
highly abnormal cross B sheet confirmation (1, 2). These deposits progressively disrupt the 
structure of tissues and this in turn affects organ function throughout the body (3). Amyloid type 
is classified according to the fibril protein and there have been over 30 fibril proteins identified 
in vivo (Table 1.1) (4). Amyloid is identified by the pathognomonic finding of apple-green 
dichroism when tissue is stained with the dye Congo red and visualised under cross-polarised 
light. The characteristic appearance of amyloid fibrils under the electron microscope is that of 
rigid non-branching fibrils with a diameter of ~10 nm (5). Amyloidosis is a heterogenous 
condition in which the deposition of amyloid can range from incidental localised deposits in a 
range of different organs to a rapid and fatal systemic disease. The most commonly affected 
vital organs are the kidneys and heart respectively. In light of this, accurate diagnosis and a 
comprehensive approach to identifying organ involvement is imperative to ensure best clinical 
care. 
 
Fibril Formation and Amyloid Proteins 
The fibrillogenesis of amyloidosis remains poorly understood. Experiments have shown that in 
vitro under specific laboratory conditions, nearly any polypeptide chain can be misfolded with 
subsequent aggregation (6). Nonetheless relatively few proteins have been shown to be 
amyloidogenic in vivo.  
Despite the heterogeneity of precursor proteins which form amyloid fibrils, all amyloid deposits 
have remarkably similar morphological structure and histological properties. The common core 
structure is one of anti-parallel B-strands (and less commonly parallel B-strands) that form 
sheets (7, 8). These B-sheets run parallel to the axis of the protofilament with their component B 
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strands perpendicular to the fibril axis. (9) When visualised with an electron microscope, 
amyloid fibrils are characteristically straight, non-branching and 7-10nm in diameter (10) 
All amyloid deposits also contain numerous non-fibrillary constituents including 
glycosaminoglycans (GAG’s), suphate proteoglycans, heparin sulphate, apolipoprotein E, type 
IV collagen and serum amyloid P component (SAP) (11, 12). Glycosaminoglycans are located 
primarily on the cell surface in the extracellular matrix and although universal to all amyloid 
deposits, their role remains unclear. SAP (which is identical and derived from normal plasma 
SAP) is another non-fibrillar part of the amyloid deposit which is bound in a reversible calcium 
dependant manner to a ligand present on all amyloid fibrils. It is a member of the pentraxin 
group of plasma proteins (13) and is resistant to proteolysis. In vitro binding of SAP to amyloid 
fibrils prevents degradation of amyloid by phagocytic cells and proteolytic enzymes (14). In 
systemic amyloidosis circulating SAP exists in a dynamic equilibrium with SAP bound to 
amyloid fibrils and it is only circulating SAP that undergoes catabolism. The role of SAP in 
amyloidogenesis has been proven by the inability to induce AA amyloidosis in SAP knockout 
mice (15)  
There are three main circumstances in which amyloid deposition occurs. The first is in the 
presence of an abnormal protein with a distinctly amyloidogenic structure such as monoclonal 
immunoglobulin light chains in AL amyloidosis and genetic variants of transthyretin, fibrinogen 
Aa chain, apolipoprotein AI, apolipoprotein A2, apolipoprotein C3, apolipoprotein C2, gelsolin 
and lyzosyme in the hereditary causes of systemic amyloidosis. The second is when there is an 
abnormally high concentration of a ‘normal’ protein such as elevated serum amyloid A protein 
(SAA) in a chronic inflammatory state leading to a predisposition of AA amyloidosis or beta 2 
microglobulin β2M in dialysis related amyloidosis. Lastly, amyloid deposits can occur when 
there is a normal quantity of a ‘normal’ protein that in advanced age and over a long period of 
time becomes amyloidogenic such as TTR in wildtype transthyretin amyloidosis (previously 
known as senile systemic amyloidosis). 
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Pathogenesis of Amyloidosis and Degradation 
The mechanism of tissue damage in amyloidosis remains poorly understood. It is well known 
that the process of amyloid formation can result in organ dysfunction both due to a physical 
replacement of parenchymal tissue by amyloid deposits as well as cellular injury. There is a 
growing hypothesis that pre-fibrillar oligomers rather than the fibrillary form may themselves 
have the primary toxic effects. This has been demonstrated with the direct toxicity of the 
amyloidodgenic Ig light chains to cardiac cells(16) as well as transthyretin monomers in ATTR 
amyloidosis (17). Thus organ damage is most likely due to a combination of mechanisms 
including the physical disruption of amyloid on tissues and the possible toxicity of fibrils and 
prefibrillar aggregates which may depend on both the type of amyloidosis as well as the organ 
affected.  
The factors that dictate the pattern of organ involvement in amyloidosis is still poorly 
understood. This exists both within and between different forms of amyloidosis. For example, 
there are clear phenotypic differences in family members within the same kindred with the same 
genetic mutation encoding a variant protein in hereditary forms of amyloidosis.  
It is established that amyloid fibrils act as an amyloid-enhancing factor (AEF) and form a 
template to which further precursor proteins deposit. This theory has been supported by a study 
which showed that in mice, in which amyloid laden tissue from other AA amyloid-laden mice 
was injected, in the context of an inflammatory stimulus, the development of AA amyloidosis 
was markedly accelerated (18). This has been reiterated in human studies where patients who 
have AA amyloidosis and have a relapse of their underlying inflammatory condition rapidly 
deposit amyloid (19). Alongside this in patients with familial amyloid polyneuropathy (FAP) 
who undergo orthotropic liver transplantation (OLT) it has been shown that if cardiac 
amyloidosis exists pre-transplantation, cardiac amyloidosis progresses more rapidly, which is 
thought to be due to the enhanced deposition of wildtype TTR on a template of amyloid derived 
from variant TTR(20). 
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Untreated amyloidosis is invariably associated with progressive accumulation of amyloid often 
characterised by organ failure and death. Amyloid deposits are dynamic and so with adequate 
suppression of the precursor fibril one can see regression of amyloid from infiltrated organs 
(21). Studies have established that amyloid deposits are dynamic with a continuous process of 
amyloid formation and deposition to regression. It has been shown that macrophages play a key 
role in amyloid regression. Macrophages infiltrate amyloid deposits and through the formation 
of multinucleate giant cells which surround and engulf amyloid are key to amyloid clearance. 
This has been demonstrated in vivo by mouse models in which macrophage depletion with 
liposomal clodronate has shown to slow amyloid regression (22). The rate of clearance varies 
widely between individuals with some having rapid clearance of amyloid by SAP scintigraphy 
when there is suppression of the precursor fibril and others no regression despite complete 
suppression of the precursor fibril. This has led to the hypothesis that it is perhaps the different 
phenotype and function of macrophages between individuals that explains the heterogeneity of 
amyloid regression. 
One striking feature of amyloid when viewed histologically is the relative absence of a cellular 
infiltrate or macrophages. Pepys hypothesised that coating of amyloid by SAP acts as an anti-
opsonisn, further supported by the fibrillogenesis studies performed in SAP knockout mice.  
CPHPC, ((R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexa-noyl] pyrrolidine-2 carboxylic 
acid), a novel bis (D-proline) drug was developed with the aim of eluting SAP from amyloid 
and thus promote removal of amyloid via macrophage infiltration of amyloid deposits.  
Administration of CPHPC failed to rapidly elute SAP from amyloid although prolonged therapy 
was shown to deplete >95% of circulation SAP in the plasma and via re-equilibration, circa 90% 
of the SAP component of amyloidotic organs was achieved (23). Clinical studies have shown 
that whilst CPHPC is safe and well tolerated, the gradual depletion of SAP from amyloid 
deposits is insufficient to bring about major clinical benefit in visceral organ function. In mice, 
with systemic AA amyloidosis that are transgenic for human SAP, IgG anti-human SAP 
antibodies can be safely administered after treatment with CPHPC which depletes the plasma 
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SAP. These antibodies localise rapidly to the outstanding amyloid-bound human SAP and 
trigger clearance of the deposits (24). A combination of CPHPC and anti-SAP antibody has 
been shown in a human first into man (proof of concept) trial to result in swift and marked 
removal of liver amyloid deposits (25). This therapy is currently being tested in a phase 2 trial 
of patients with systemic amyloidosis and cardiac involvement.  
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Table 1.1 Classification of Systemic Amyloidosis by Precursor Protein  
Fibril 
protein 
Precursor  
protein 
Systemic  
and/or 
localized 
Acquired 
 or 
hereditary Target organs 
AL Immunoglobulin Light 
Chain 
S, L A, H All organs except 
CNS 
AH Immunoglobulin 
Heavy Chain 
S, L A All organs except 
CNS 
AA (Apo) Serum Amyloid 
A 
S A All organs except 
CNS 
ATTR Transthyretin, wild 
type 
S A Heart mainly in 
males, Ligaments, 
Tenosynovium 
  Transthyretin, variants S H PNS, ANS, heart, 
eye, leptomen. 
Aβ2M β2-Microglobulin, 
wild type 
L A Musculoskeletal 
System 
  β2-Microglobulin, 
variant 
S H ANS 
AApoAI Apolipoprotein A I, 
variants 
S H Heart, liver, 
kidney, PNS, testis, 
larynx (C terminal 
variants), skin (C 
terminal variants) 
AApoAII Apolipoprotein A II, 
variants 
S H Kidney 
AApoAIV Apolipoprotein A IV, 
wild type 
S A Kidney medulla 
and systemic 
  
31 
Fibril 
protein 
Precursor  
protein 
Systemic  
and/or 
localized 
Acquired 
 or 
hereditary Target organs 
AGel Gelsolin, variants S H PNS, cornea 
ALys Lysozyme, variants S H Kidney 
ALECT2 Leukocyte 
Chemotactic Factor-2 
S A Kidney, primarily 
AFib Fibrinogen α, variants S H Kidney, primarily 
ACys Cystatin C, variants S H PNS, skin 
ABri ABriPP, variants S H CNS 
ADan* ADanPP, variants L H CNS 
Aβ Aβ protein precursor, 
wild type 
L A CNS 
  Aβ protein precursor, 
variant 
L H CNS 
APrP Prion protein, wild 
type 
L A CJD, Fatal 
insomnia 
  Prion protein variants L H CJD, GSS 
syndrome, Fatal 
insomnia 
ACal (Pro)calcitonin L A C-cell thyroid 
tumors 
AIAPP Islet Amyloid 
Polypeptide† 
L A Islets of 
Langerhans, 
Insulinomas 
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Fibril 
protein 
Precursor  
protein 
Systemic  
and/or 
localized 
Acquired 
 or 
hereditary Target organs 
AANF Atrial Natriuretic 
Factor 
L A Cardiac atria 
APro Prolactin L A Pituitary 
prolactinomas, 
aging pituitary 
AIns Insulin L A Iatrogenic, local 
injection 
ASPC‡ Lung Surfactant 
Protein 
L A Lung 
AGal7 Galectin 7 L A Skin 
ACor Corneodesmosin L A Cornified epithelia, 
Hair follicles 
AMed Lactadherin L A Senile aortic, 
Media 
Aker Kerato-epithelin L A Cornea, hereditary 
ALac Lactoferrin L A Cornea 
AOAAP Odontogenic 
Ameloblast-
Associated Protein 
L A Odontogenic 
tumors 
ASem1 Semenogelin 1 L A Vesicula seminalis 
AEnf Enfurvitide L A Iatrogenic 
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Epidemiology 
Amyloidosis is a rare condition for which there is a paucity of epidemiological studies. It has 
been loosely estimated that 0.5-1.0 deaths per 1000 in the UK (26). The most common form of 
systemic amyloidosis seen in the UK is systemic AL amyloidosis with some studies suggesting 
an incidence of 5.1-12.8 per million person-years (27).  It is estimated that approximately 800 
new patients a year are referred to the NAC. Previous work at our centre has shown that the 
estimated minimum incidence of systemic amyloidosis in the English population in 2008 based 
upon new referrals to the NAC was 0.4/100,000 population. The incidence peaked at 60-79 
years with systemic AL amyloidosis being the commonest type with a minimum incidence of 
0.3/100,000 (28) 
Non-hereditary, i.e. wildtype, transthyretin amyloidosis, which predominantly causes a 
cardiomyopathy in older individuals and was previously known as senile systemic/cardiac 
amyloidosis, is lately being diagnosed much more frequently than hitherto. This reflects the 
remarkable diagnostic value of cardiac MRI (CMR) and repurposing of bone scintigraphy for 
this indication. The true prevalence of cardiac ATTR amyloidosis remains unknown, but may be 
much higher than is currently apparent since post-mortem studies have long demonstrated that 
some ATTR deposits are present in the hearts of up to 20% of people over the age of 80 years 
(29). Diagnosis of wildtype ATTR amyloidosis at the NAC has risen exponentially in recent 
years and currently exceeds 200 patients per year. 
 
Types of Amyloidosis  
Systemic AA amyloidosis 
Reactive systemic (AA) amyloidosis, in which the fibrils are composed of AA protein derived 
from the acute phase protein SAA, occurs as a rare complication of many chronic inflammatory 
disorders. The AA amyloid precursor protein is the N terminal fragment of the acute phase 
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reactant SAA, an apolipoprotein constituent of high-density lipoprotein. SAA is synthesized 
by hepatocytes and its concentration may rise 1000-fold from healthy values of less than 3 
mg/L in response to inflammation. Gene transcription of SAA is regulated by cytokines, in 
particular interleukin (IL)-1 and IL-6. 
The lifetime incidence of AA amyloidosis in patients with chronic inflammatory conditions 
is less than 1-5% (30). In Western Europe and the United States of America the most 
frequent predisposing conditions are idiopathic rheumatic diseases, notably rheumatoid 
arthritis and juvenile idiopathic arthritis. AA amyloidosis has become increasingly rare, 
reflecting improved treatment of chronic inflammatory disorders, and for reasons that are 
not clear, the incidence is lower in the United States than in Europe. Amyloidosis is 
exceptionally rare in systemic lupus erythematosus, related connective tissue diseases, and 
in ulcerative colitis in which there is a blunted acute phase response of SAA. Longstanding, 
though not necessarily constant elevation of SAA, is a prerequisite to the development of 
AA amyloidosis. Tuberculosis and leprosy are important causes of AA amyloidosis where 
these infections remain endemic. Chronic osteomyelitis, bronchiectasis, chronically 
infected burns, and decubitus ulcers are other well-recognized associations. Hodgkin 
disease and renal cell carcinoma, which often cause an acute phase response, are the 
malignancies most commonly associated with systemic AA amyloidosis. 
Intriguingly, at least 10% of patients with AA amyloidosis do not have a clinically obvious 
chronic inflammatory disease, and may erroneously be assumed to have AL amyloidosis. 
The most common identifiable diseases found in our experience in such cases have been 
inherited autoinflammatory syndromes and cytokine-secreting Castleman disease tumors of 
the solitary plasma cell type, located either in the mediastinum or the gut mesentery. 
However, in the majority of these challenging patients the precise nature of the causative 
inflammatory disorder cannot be determined. 
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Autoinflammatory diseases and amyloidosis 
The hereditary periodic fever/autoinflammatory syndromes are a well-described cause of 
AA amyloidosis, among which four are most commonly implicated. These are familial 
Mediterranean fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), the 
cryopyrin-associated autoinflammatory syndrome (CAPS) and to a lesser extent 
mevalonate kinase deficiency (MKD) . FMF is the most common of these diseases. It is 
characterised by recurrent self-limiting attacks of fever, serositis and sometimes arthritis or 
rash (31). There is a clear ethnic preponderance of FMF being prevalent in the Eastern 
Mediterranean where it is the commonest genetic disease. CAPS comprises a continuous 
spectrum of three disorders, familial cold autoinflammatory syndrome (FCAS), Muckle-
Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease 
(NOMID), also known as chronic inflammatory neurological cutaneous articular 
syndrome (CINCA).  
AA amyloidosis can complicate all types of autoinflammatory disease and whilst persistent 
and sustained inflammation is the key risk factor for the development of AA amyloidosis, 
studies have shown (predominantly in FMF) the contribution of serum amyloid A1 (SAA1) 
polymorphisms, differing gene mutations and birthplace. Most of these studies are small and 
subject to confounding influences such as increased investigation of patients who present with 
AA amyloidosis and more recently a significant impact from the availability of and 
concordance with effective long term prophylactic treatment. 
SAA1 has 5 polymorphic coding alleles, SAA1.1, SAA1.2, SAA1.3, SAA1.4 and SAA1.5 
(32). The gene products of these coding alleles vary by only a few amino acids at different 
positions of the mature SAA1 protein. Despite these minor differences, the allelic variants of 
SAA1 have shown differences in both in vitro assays as well as correlation with various 
diseases (33). The importance of polymorphisms in SAA1 differs between populations. In 
Japan homozygosity for SAA1.3 has been known to increase the risk of AA amyloid in 
rheumatoid arthritis for many years (34). In other populations with a different distribution of 
polymorphism, homozygosity for SAA1.1 is a risk factor. This is the case in Turkish patients 
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with FMF who have an increased incidence of SAA1.1 homozygosity in FMF-amyloidosis 
patients (56%) compared to FMF non-amyloidosis patients (31%) suggesting a 2.5 fold 
increased risk (35). 
MEFV M694V variant has been associated with the most severe form of FMF and a higher risk 
of AA amyloidosis (36).  In 170 Armenian patients with FMF; 60% had a concurrent diagnosis 
of AA amyloidosis. The commonest genotype in this cohort was M694V/M694V which was 
present in 36% of patients and M694V homozygosity compared to heterozygosity was 
associated with an increased risk of AA amyloidosis (37).  
Whilst M694V was previously thought to be the key risk factor for AA amyloidosis; in a large 
online study of 35 centres in 14 countries, 2482 cases of FMF were identified of whom 260 
developed renal amyloidosis. Interestingly, country of recruitment rather than MEFV genotype 
was the leading risk factor for the manifestation of renal amyloidosis which may indicate a 
potential environmental origin of amyloidosis susceptibility (38). 
In TRAPS the international Eurofever/Eurotraps registry identified 158 patients in whom the 
commonest TNFRSF1SA variants was R92Q (34% of cases) and T50M (10%) with disrupted 
cysteine residues in 27% of cases. AA amyloidosis developed in 16 (10%) patients at a median 
age of 43 years. This group included 7 cysteine variants (44%), two T50M (13%) and no 
patients with R92Q. Patients who developed AA amyloidosis had significantly longer disease 
duration than those who did not (39). 
Retrospective literature review of all cases of CAPS from the French network for rare diseases 
identified 67 patients with diagnosed CAPS and AA amyloidosis. The NLRP3 gene was 
sequenced in 30 patients (46%) and whilst AA amyloidosis can occur in all CAPS phenotypes 
it appeared to be more common in MWS (Georgin-Lavialle; 2015; Paediatric Rheum Online). 
It is important to recognise that these genetic associations are weak and not useful predictors 
of risk in individual patients.  The remarkably high risk of AA amyloidosis in systemic auto 
inflammatory diseases reflects persistent and uncontrolled inflammation. Although small 
series have identified increased risks with specific genotypes in FMF and perhaps with 
mutations affecting cysteine residues in TRAPS there are no guaranteed ‘safe’ mutations and 
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all patients should be treated to completely supress chronic inflammatory disease and SAA 
production. The same point is true for the data on SAA polymorphisms and cases of AA 
amyloidosis. 
 
Clinical features of AA amyloidosis 
AA amyloid involves the viscera, but may be widely distributed without causing symptoms. 
It predominantly affects the kidneys with more than 95% of patients presenting with 
proteinuria and around 10% having already reached end-stage renal failure (ESRF) at 
diagnosis (19). 
The predominant presentation is nephrotic syndrome with non-selective proteinuria from 
glomerular deposition of amyloid and or chronic kidney disease. Splenic involvement is 
evident on SAP scintigraphy in almost all cases and whilst deposits commonly occur in the 
adrenal gland and gastrointestinal tract, this is usually without associated organ dysfunction. 
Liver involvement in AA amyloidosis is a feature of advanced disease and confers a poor 
prognosis (40). Cardiac amyloidosis and amyloid related neuropathy are rare manifestations 
of AA amyloidosis and are seen only in advanced cases. 
 
Systemic AL amyloidosis 
This is the most common form of amyloidosis in the developed world is associated with 
dyscrasias of cells within the B lymphocyte lineage, including multiple myeloma (MM), 
malignant lymphomas and macrogloublinemia. Most cases develop in the context of what 
would otherwise be a low grade monoclonal gammopathy of unknown significance 
(MGUS). The age adjusted incidence in the USA is 8.9 per million person-years (27). 
Amyloidosis occurs in up to 10% of cases of MM and in a lower proportion of other 
malignant B-cell disorders. Approximately 2% of patients with an MGUS eventually 
develop AL amyloidosis (27). The fibrils are formed from the N terminal domain of 
monoclonal lambda (more common) or kappa immunoglobulin light chains, and consist of 
the whole or part of the variable (VL) domain. 
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A monoclonal immunoglobulin can be detected in the serum or urine by immunofixation 
electrophoresis in 65% and 86% of patients, respectively. A monoclonal excess of free light 
chains (FLC) can be identified at baseline in 98% of patients with systemic AL amyloidosis. 
Subnormal levels of some or all serum immunoglobulins, or increased numbers of marrow 
plasma cells may provide less direct clues to the underlying etiology. Until recently, it has 
been the practice to consider apparent primary cases of amyloidosis, with no previous 
predisposing inflammatory condition or family history of amyloidosis, as AL type. 
However, it has now been recognized that some patients with mutations associated with 
autosomal dominant hereditary non-neuropathic amyloidosis, particularly that caused by 
variant fibrinogen α-chain, do not develop the disease,. The coincident occurrence of a 
monoclonal gammopathy, which occurs in more than 10% of the healthy older population, 
may then be gravely misleading and it is essential to exclude other forms of amyloidosis by 
genotyping all known amyloidogenic mutations, and to seek definitive 
immunohistochemical or proteomic identification of the amyloid fibril protein in all cases. 
 
Clinical manifestations of AL amyloidosis 
Clinical suspicion of AL amyloidosis should be raised in any patient with unexplained 
nephropathy, cardiac failure, peripheral and/or autonomic neuropathy or any other 
multisystem disease. Potentially all organs can be directly affected by amyloid deposits in 
systemic AL amyloidosis except the central nervous system. Renal involvement is the most 
common manifestation with approximately 70% of patients presenting with either 
proteinuria or elevated serum creatinine. Cardiac amyloidosis is present in 50% of patients 
at baseline and is the key determinant of mortality. Cardiac amyloidosis typically manifests 
with a restrictive cardiomyopathy; concentric ventricular wall thickening resulting in 
diastolic dysfunction manifesting with congestive cardiac failure and, more often than not, 
hypotension. Autonomic nervous system involvement presents variably and is often 
challenging to diagnose. It can lead to orthostatic hypotension, erectile dysfunction, urinary 
retention and faecal incontinence. In patients in whom a peripheral neuropathy is present 
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there is most commonly a distal sensory deficit which can be subclinical at presentation. 
Systemic chemotherapy aimed at suppressing the monoclonal light chain can cause 
worsening of peripheral and autonomic neuropathy depending upon the neurotoxicity of 
therapy. Liver involvement as a presenting feature is rare but is a quite common finding at 
post mortem examination and on SAP scintigraphy. Hepatomegaly and obstructed liver 
function tests are the most common clinical findings but can be absent in patients despite 
the presence of significant hepatic amyloid deposits (41). 
There are a plethora of soft tissue features in AL amyloidosis with macroglossia and 
periorbital bruising thought to be highly suspicious for AL type. Gastrointestinal 
involvement can result in malabsorption, altered bowel habit and gastrointestinal 
haemorrhage (42). 
 
Hereditary systemic amyloidosis 
 
Familial amyloid polyneuropathy  
Familial amyloid polyneuropathy (FAP) is associated with more than 100 mutations in 
the gene encoding TTR. TTR is predominantly synthesized in the liver and is a 
tetrameric protein which has a role in the transport of thyroxine and retinol binding 
protein. FAP is an autosomal dominant syndrome with onset of symptoms at any point 
from the second decade onwards. It was first described in 1952 in Portuguese kindreds 
(43). It is characterised by progressive peripheral and autonomic neuropathy alongside 
varying involvement of visceral organs. Extra-neural manifestations predominantly 
include cardiomyopathy as well as more rarely vitreous amyloid, renal involvement and 
oculoleptomeningeal amyloid deposition leading to encephaolopathy, seizures and 
dementia. The combination of neuropathy and cardiomyopathy leads to muscle wasting 
and malnutrition that usually results in death within 9-13 years (44). The most common 
encoding mutation is a valine for methionine substitution at position 30 (V30M) and 
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quite large populations occur in Sweden, Japan and Portugal. The T60A variant is most 
common in the UK, and the low penetrance V122I variant associated with predominant 
cardiomyopathy occurs in 3-4% of black individuals. Proposed mechanisms of ATTR 
amyloidogenesis include dissociation of the TTR tetramer into monomers and mechano-
enzymatic cleavage with resulting destabilising of the tetrameric TTR protein (45). 
 
Non neuropathic systemic amyloidosis 
The non-neuropathic forms of hereditary systemic amyloidosis were first described in 1932 
and are derived from variants of apolipoprotein AI, apolipoprotein AII, lysozyme and 
fibrinogen A- α chain. Renal involvement is often the most common manifestation however 
the heart, spleen, liver and bowel may all also be involved. Presentation can vary both 
within and between kindreds. Clinical presentation is usually around the sixth decade 
although can occur in early adulthood or before. Following clinical presentation, there is an 
inexorable progression to organ failure requiring dialysis, organ transplantation or death. In 
fibrinogen A- α chain amyloidosis the median time from presentation to end stage renal 
disease (ESRD) is approximately 5 years (46). The progression of renal disease is much 
more gradual in apolipoprotein AI and lysozyme amyloidosis with a median time from 
presentation to ESRD of greater than 10 years. 
 
Wildtype transthyretin amyloidosis (previously known as senile 
systemic/cardiac amyloidosis) 
Wild type transthyretin amyloidosis (ATTRwt) also known as senile systemic/cardiac 
amyloidosis is a disease of older people with a strong male preponderance. The amyloid 
deposits are composed of wildtype TTR (47). The clinical phenotype comprises 
predominantly of cardiac amyloidosis manifesting as congestive cardiac failure. ATTR 
deposits are present in other sites including the lungs, gut and bladder, where they can 
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occasionally cause symptoms (48). Carpal tunnel syndrome is common and often precedes 
cardiac manifestations by up to a decade or more (49). 
 
Diagnosis and Assessment of organ function 
 
Histology  
The diagnosis of amyloidosis is often made at a late stage in the disease process, long after the 
initial onset of symptoms. Delays in diagnosis are due to a combination of the heterogeneous 
nature of the disease, its perceived rarity and the need for staining of histological sections. The 
gold standard for diagnosis is the histological confirmation of amyloid deposits by Congo-red 
staining and observing the pathognomonic apple green birefringence under cross polarised light 
visualised by light microscopy (50). Correct typing of amyloid deposits is crucial to identify the 
pathological precursor fibril and key to deciding disease appropriate treatment with suppression 
of the protein precursor fibril. Incorrect diagnosis and management can lead to significant 
morbidity and even mortality to the patient (51). 
Congo red staining has an estimated sensitivity of between 60–80% with a specificity of 100% 
(52, 53). Target organ biopsies such as renal, cardiac and GI tissue are usually diagnostic. Rectal 
biopsies have been used in the past as a screening tool for systemic amyloidosis with estimated 
sensitivity rates of 75-94% in published series (54). Abdominal fat pad fine needle aspiration is 
a quick, minimally invasive bedside test that has historically been thought to yield poor 
sensitivity in systemic amyloid (55). The role of fat aspiration is particularly pertinent where 
target organ biopsies (such as endomyocardial biopsies) require technical expertise and carry 
with them a risk of serious complications and high cost, often leading to a delay in diagnosis 
and treatment. We have shown that abdominal fat aspiration can be useful in detecting cardiac 
amyloidosis with a sensitivity that ranges from 84% in patients with cardiac AL amyloidosis to 
15% in those with wildtype ATTR cardiac amyloidosis (56).  
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Determining the fibril precursor protein 
The gold standard method for identifying the amyloid fibril protein is via direct sequencing of 
extracted amyloid. The problem with this technique is the time, cost and necessity for frozen 
tissue. For this reason it is not used in routine clinical practice. Alternative methods for the 
diagnosis of amyloid and typing include identifying the amyloid fibril protein by immuno-
electron microscopy (57) but again this method is not widely available, expensive and rarely 
employed in clinical practice. 
Immunohistochemical staining (IHC) of amyloidotic tissue is widely available for determining 
the amyloid fibril protein. It is a relatively quick procedure and is the preferred method in 
clinical practice (50). IHC in routine clinical practice has variable sensitivity and specificity 
however it is well known that amyloid deposits can sometimes fail to stain or stain with more 
than one antibody. For example, work from our centre has shown that in approximately 30% of 
patients with systemic AL amyloid fail to stain definitively with antibodies against either kappa 
or lambda light chains (58).  
 
Proteomics and Mass Spectrometry  
Proteomic analyses comprising mass spectrometry on amyloid deposits cut by Laser dissection 
of tissue sections is increasingly used to identify the presence of amyloid and subtype. Some 
centres estimate between 98% to 100% specificity and sensitivity (59). It is increasingly used 
for the typing of organ specific biopsies (60). The role of proteomics in identifying amyloid 
from fats has been reported. It has been estimated that in Congo red positive samples, the 
sensitivity of identifying the amyloid subtype is up to 90%(61). Whilst other amyloid centres 
have not necessarily had the same success with proteomics, it has undoubtedly aided in the 
typing of amyloid. 
One of the limitations of proteomics in the subtyping of amyloid is the detection of more than 
one potentially amyloidogenic protein, especially immunoglobulins and transthyretin which are 
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abundant plasma proteins. We have shown here in our centre that in cases where more than one 
amyloidogenic protein is detected, decellularisation of amyloid tissue biopsies can increase the 
accuracy of proteomic typing and enhance the specificity of detecting the culprit protein (62). 
Genetic Sequencing 
It is estimated that between 5-10% of systemic amyloidosis is hereditary. Genetic testing is 
often key to identifying the amyloid subtype but needs to be interpreted in clinical context. 
Variants within genes encoding amyloidogenic proteins such as TTR can present with distinctly 
different phenotypes as both the penetrance is variable and incidental mutations can be 
identified. This is particularly relevant in systemic AL amyloidosis where treatment is aimed at 
suppression of the underlying monoclonal protein and incidental mutations can lead to a delay 
in treatment (63). Conversely, particularly in an aging cohort, the incidence of an MGUS has 
been estimated at over 5% in patients aged greater than 70 years and 7.5% in those 85 or older 
(64). In the context of hereditary amyloidosis this has the potential for misleading clinicians and 
the inappropriate delivery of cytotoxic therapy (51) 
Imaging 
Serum Amyloid P (SAP) Scintigraphy 
SAP scintigraphy is a specialised imaging technique developed by Professor Hawkins at the 
NAC, available in a limited number of specialist centres.  SAP is a non-fibrillar part of the 
amyloid deposit which is thought to be present in all amyloid deposits and makes radiolabelled 
SAP scintigraphy specific(65). Following intravenous injection, radiolabelled SAP tracer can be 
used to identify amyloid deposits in vivo. It identifies amyloid deposits in visceral organs such 
as the spleen, liver, kidneys and adrenal glands (65). Organ involvement by SAP scintigraphy 
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can be pathognomonic of amyloid subtype. For example, bone uptake in the context of clinical 
suspicion is almost always diagnostic of AL amyloidosis (Figure 1.1). 
 
Figure 1.1 (Left) Anterior whole body scintigraphic image following intravenous injection of 123I-
human serum amyloid P in a patient with AL amyloidosis. Uptake is seen in the bones, a finding 
which is pathognomonic for AL amyloidosis, uptake is also seen in the liver and spleen. 
(Right) Posterior whole body SAP scintigraphic image in a patient with hereditary fibrinogen 
amyloidosis. Uptake is seen in the spleen and kidneys. 
 
 
There are limitations to SAP scintigraphy in light of its methodology. Due to the significant 
pool and movement of blood in the lung and hearts it is not adequate for identifying cardiac or 
pulmonary amyloid deposits (66).  Alongside this, there is insufficient resolution to identify 
deposits in hollow, diffuse or very small structures such as the GI tract, skin and nerves.  
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SAP scintigraphy has been used to monitor the progression and regression of visceral amyloid 
deposits and can inform clinicians about response to treatment. It shows the dynamic nature of 
amyloid deposits and proves to be a useful tool in detecting and monitoring the response to 
treatment and amyloid regression (25, 65) 
 
Figure 1.2: Posterior whole body images of SAP scintigraphy scans of a patient with systemic 
monoclonal immunoglobulin type (AL) amyloidosis who presented with major liver 
involvement and proteinuria in 2005. He responded well to chemotherapy with substantial 
regression of amyloid by 2009 when his liver and renal function had returned to normal. 
 
Unfortunately due to the high cost of labelling and the availability of SAP and I123, the use of 
SAP scintigraphy has been limited to a few European centres of which the National 
Amyloidosis Centre has completed over 50,000 scans. 
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Cardiac Imaging 
Cardiac involvement is the key predictor of mortality in systemic amyloidosis (67, 68). Non-
invasive diagnosis of cardiac amyloidosis has historically been based on imaging modalities 
such as transthoracic echocardiography. This classically demonstrates interventricular septal 
diameter (IVSD) thickening and restrictive diastolic physiology. In systemic AL amyloidosis 
cardiac involvement is defined as a mean left ventricular diameter of (LVD) >12mm in the 
absence of an alternative cause of left ventricular hypertrophy (69). Nonetheless there are 
limitations in the use of echocardiography for the diagnosis of cardiac amyloidosis with studies 
showing both a poor sensitivity and specificity, particularly in differentiating cardiac 
amyloidosis from other causes of thickened LVD such as hypertrophic cardiomyopathy and 
hypertensive heart disease (70). 
Cardiac magnetic resonance imaging (CMR) for cardiac amyloidosis was first reported in 2005 
and is now increasingly used in clinical practice to diagnose infiltrative cardiomyopathies. CMR 
demonstrates characteristic late gadolinium enhancement (LGE) in the sub endocardium or in 
some cases more diffusely (71). CMR has been shown to be more informative of both the 
structural and functional changes seen in cardiac amyloidosis than other imaging modalities 
(72). For example in ATTR cardiac amyloidosis CMR demonstrated asymmetrical hypertrophy 
as the commonest pattern of ventricular remodelling and although other morphologies were 
possible, all patients had evidence of characteristic LGE. (73) 
 
Cardiac Rhythm Analysis 
Electrocardiographic changes are common in cardiac amyloidosis. The largest study consisted of 
127 patients with biopsy proven cardiac AL amyloidosis seen at the Mayo clinic and this 
confirmed a characteristic appearance of low QRS (limb leads <5mm) with poor R wave 
progression in the chest leads in approximately 50% of patients (74). Cardiac rhythm analysis is 
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particularly pertinent in patients with cardiac AL amyloidosis due to the very high early mortality 
seen, often within the first few months of diagnosis (30-40%) despite significant improvement in 
treatment regimens (75). The main cause of this early mortality is sudden cardiac death (SCD). 
The prevalence of ventricular arrhythmias has been estimated at up to 30% of patients with 
cardiac AL amyloidosis (76) with both ventricular tachyarrhythmias (77) and bradyarrhythmias 
reported. Work from our centre using loop recorders showed that in 20 patients with advanced 
cardiac AL amyloidosis (Mayo Stage 3b) disease the predominant abnormality detected on 
telemetry was bradycardias, most commonly complete heart block (CHB) and this heralded 
terminal cardiac decompensation in most patients (78) 
Cardiac ATTR amyloidosis is also associated with significant abnormalities on ECG. Low QRS 
voltages are less frequently described in cardiac ATTR estimated at 25-40% (74, 79) however a 
pseudo infarct pattern is seen as commonly as in cardiac AL amyloidosis. The presence of 
conduction system disease is more common in patients with wildtype cardiac ATTR; with atrial 
fibrillation (AF) the most commonly noted rhythm disturbance in approximately 40% of patients 
with cardiac ATTR.(80)  
Biochemical Analysis 
Investigations for Clonal Disease 
AL amyloid fibrils are composed of monoclonal immunoglobulin light chains driven by an 
underlying clonal dyscrasia which may be very subtle. In all patients in whom systemic 
amyloidosis is suspected a full clonal work up should be performed. Monoclonal proteins can be 
detected by serum and urine electrophoresis and immunofixation. Serum free light chains should 
be tested in all patients with suspected systemic amyloidosis and it has been shown that fully 
quantitative high sensitivity serum free light chain immunoassay (Freelite) has improved the 
sensitivity of detection of an underlying clone (81).  Recent data indicates that in approximately 
1% of patients with systemic AL amyloidosis, no systemic clone is identified (82) which can 
make both diagnosis and the monitoring of response to treatment particularly challenging. The 
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clonal dyscrasia in patients with systemic AL amyloidosis can vary from being extremely low 
to frank multiple myeloma (MM). All patients therefore should undergo routine myeloma 
workup including a bone marrow trephine and aspirate in order to assess the baseline plasma 
cell infiltrate and flow cytometry for cytogenetics which may exist and inform outcome (83). 
The translocation t11:14 is thought to be present in up to half of patients with systemic AL 
amyloidosis and less so in 15% of patients with MM (84). Whilst skeletal X-rays were 
previously commonly used for the detection of lytic lesions, monitoring of bone lesions in MM 
is better performed by MRI or increasingly Whole-body low-dose CT scan (85). Accurate 
diagnosis of the plasma cell burden, correct cytogenetic profiling and assessment for multiple 
myeloma in patients with systemic AL amyloidosis is important for both prognosis and 
treatment options. 
 
Cardiac Biomarkers 
The two biomarkers used routinely in the diagnosis and monitoring of patients with cardiac 
amyloidosis are N terminal pro brain naturetic peptide (NT-proBNP) and highly sensitive 
cardiac troponin T (TnT). Both are part of the most widely used staging systemic for cardiac 
AL amyloidosis, the Mayo classification (Table 1.2) (86). Mayo classification has provided 
key information on overall survival (OS) in patients with cardiac AL amyloidosis with an 
estimated median survival of 27.2 months, 11.1 months and 4.1 months in Mayo Stage I, II 
and III respectively. Further sub classification of Mayo Stage III disease into IIIa and IIIb is 
used to identify patients at very high risk of early mortality based upon the presence of systolic 
dysfunction defined as either systolic BP <100mm/Hg and/or NT-proBNP of >8500ng/L (68). 
Both NT-proBNP and cardiac troponin T can be elevated due to a number of other conditions 
including atrial fibrillation, pneumoniae and renal failure (87). The limitations of NT-proBNP 
in patients with systemic AL amyloidosis and advanced renal excretory impairment in 
systemic AL amyloidosis have been noted (88). NT-proBNP is also known to be influenced 
by systemic chemotherapy (89) as well as fluid status. (90). NT-proBNP is specifically relevant 
as it is the key determinant of a response to treatment in systemic AL amyloidosis as per current 
  
49 
consensus criteria. (91) Cardiac ATTR amyloidosis is an increasingly recognized and fatal 
cardiomyopathy and whilst it has been historically felt to have a slowly progressive nature, the 
natural history can vary significantly. Recent work from our centre has identified a new staging 
system for ATTR cardiac amyloidosis based upon a combination of baseline NT-proBNP and 
eGFR. Three disease stages were identified; Stage 1 was defined as NT-proBNP ≤ 3000ng/L 
and eGFR ≥ 45ml/min, Stage 3 as an NT-proBNP of ≥ 3000ng/L and eGFR ≤ 45ml/min and 
the remainder stage 2. Median survival in Stage 1, Stage 2 and Stage 3 disease was 69, 46 and 
24 months respectively. (80) 
 
Table 1.2 Mayo Staging in cardiac AL amyloidosis 
Mayo Stage Cardiac Biomarkers 
Stage 1 NT proBNP < 332ng/L and cardiac troponin T < 0.035mcg/L 
 
Stage 2 NT proBNP ≥ 332ng/L or cardiac troponin T ≥ 0.035mcg/L 
 
Stage 3 NT proBNP ≥ 332ng/L and cardiac troponin T ≥ 0.035mcg/L 
 
 
 
Renal Biomarkers 
Renal involvement in amyloidosis typically manifests with proteinuric CKD, often associated 
with nephrotic syndrome. Nonetheless the degree of proteinuria can be variable both between 
and within different types of renal amyloidosis dependant on the amyloid fibril protein as well 
as stage of CKD and/or urinary output.  
The three key biomarkers for the diagnosis and prognostication of patients with renal 
amyloidosis include serum albumin, proteinuria and serum creatinine/estimated glomerular 
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filtration rate (eGFR). Consensus criteria defines renal involvement in systemic AL amyloidosis 
as non Bence Jones (BJP) proteinuria of >0.5g/24hrs (91). Both renal progression and renal 
response to treatment is dependent upon improvement or worsening or proteinuria in the context 
of a change in eGFR. In light of the need for improved prognostication of the risk of 
requirement for renal replacement therapy in renal AL amyloidosis, revised criteria has been 
proposed by Palladini et al which demonstrated that a ≥ 25% reduction in eGFR at an earlier 6 
month time point predicted a poor renal survival.  
The monitoring of renal amyloidosis based on proteinuria has its limitations in light of 
alternative pathologies that can drive urinary protein leak, including diabetes and hypertension. 
Novel urinary biomarkers have been used in monoclonal gammopathies of renal significance 
(MGRS) to detect renal insult and may offer improved methods of both diagnosis and 
monitoring in renal amyloidosis (92). 
 
Liver function tests 
Despite significant amyloid deposit in the liver displayed by SAP scintigraphy, liver function is 
often preserved in patients with systemic amyloidosis. Whilst the liver seems to tolerate amyloid 
deposits relatively well, it has been shown in systemic AL amyloidosis that an elevated bilirubin 
is associated with an increase in relative risk of almost 2.5 (93)  
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General management principles  
There are three key principles in the management of systemic amyloidosis. Supportive care to 
preserve organ function, reduction, or ideally elimination, of the ongoing supply of the 
respective amyloid fibril precursor protein, and relatively novel therapies aimed at inhibiting the 
formation of amyloid fibrils or removing existing amyloid deposits. 
 
Supportive care 
Best supportive care is vital for patients with all forms of systemic amyloidosis. The aim is to 
support failing amyloidotic organ function and reduce the risk of complications in vulnerable 
organs. 
Kidneys extensively infiltrated by amyloid are exquisitely vulnerable to intercurrent insults such 
as hypo/hyper perfusion and nephrotoxic drugs which should be avoided as much as possible. 
The management of nephrotic syndrome includes meticulous fluid balance encouraging patients 
to pursue a low salt diet in combination with a total fluid restriction of 1.5 litres per day. Diuretic 
therapy is the mainstay of medical management and loop diuretics are often required at high 
doses and/or in combination with either thiazide or potassium sparing diuretics (94). 
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) 
have been shown to reduce proteinuria and reduce the risk of progression to ESRD in patients 
with nephrotic syndrome (95). Nonetheless due to their risk of acute kidney injury they are often 
not used in the initial setting. One study of 44 patients with systemic AA amyloidosis showed a 
reduction in proteinuria in patients treated with ARB although there was no clear long term 
benefit in reducing the risk of progression to ESRD (96). 
Anticoagulation in nephrotic syndrome remains a controversial issue with no clear consensus. 
Patients with systemic amyloidosis have an increased risk of bleeding due to amyloidotic 
vascular fragility whilst patients with heavy proteinuria and associated hypoalbuminemia are at 
an increased risk of venous thromboembolic disease. Decisions regarding anticoagulation 
should be made on an individual basis and in high risk patients low molecular weight heparin 
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treatment can offer a suitable option with a short half-life and easy reversal compared to warfarin 
therapy. 
Management of cardiac amyloidosis is challenging. Patients with cardiac amyloidosis do not 
tolerate hypotension well due to the low cardiac output state and whilst there are no clear 
guidelines on the use of traditional heart failure medication, ACE inhibitors and β-blockers are 
generally best avoided. Arrhythmias are common in AL amyloidosis. The mainstay of therapy 
is with oral anti-arrhythmias, most commonly amiodarone. There are limited data on the role of 
implantable intracardiac defibrillators in patients with cardiac amyloidosis. Appropriate device 
therapy has been reported in a significant proportion of patients and whilst it has been shown to 
be lifesaving in the short term, long term survival benefit remains unclear (97). 
Gastrointestinal involvement can present with chronic diarrhea, malabsorption and cachexia 
with symptoms often becoming debilitating. Gastrointestinal bleeding can occur manifesting 
with melena and anemia. Somatostatin analogues have provided relief in some case studies, but 
if symptoms lead to malnutrition total parenteral nutrition may be needed to support the patient 
until bowel function improves. 
Adrenal involvement in AA amyloidosis is common but frank adrenal insufficiency is rare. 
Patients are often receiving corticosteroid therapy for their underlying inflammatory condition. 
Addisonian symptoms can be difficult to identify, particularly orthostatic hypotension which 
can be explained by alternative pathologies such as nephrotic syndrome and concurrent diuretic 
use.  
Amyloid related autonomic nerve dysfunction is predominantly seen in AL amyloidosis and 
hereditary ATTR amyloidosis. Autonomic failure often manifests predominantly with postural 
hypotension but other symptoms include altered bowel habit, incontinence and erectile 
dysfunction. Anecdotal evidence supports the use of oral inotropes such as midodrine for the 
treatment of postural hypotension. 
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Organ transplantation in hereditary amyloidosis  
Disease modifying treatment for hereditary systemic amyloidosis remains limited. The mainstay 
of treatment is supportive therapy including organ transplantation for the failing amyloidotic 
organ. When the liver is the main source of production of variant precursor protein, liver 
transplantation can be performed to replace the variant protein with the wildtype non 
amyloidogenic protein.  
Fibrinogen, TTR and ApoA1 are predominantly synthesised in the liver. Whilst liver 
transplantation can be been lifesaving in selected patients with hereditary amyloidosis, careful 
consideration needs to be taken due to the considerable peri-operative risk, long term 
immunosuppression, renal toxicity and development of secondary malignancies. 
Hereditary AFib amyloidosis is a predominantly renal disease leading to ESRD within 5-10 
years. Kidney transplantation has been performed in many cases, but recurrence of renal 
amyloidosis within 7-10 years commonly causes graft failure. Whilst combined liver-kidney 
transplantation eliminates the source of the amyloidogenic AFib variant, with potential to 
prevent further amyloid deposition, the procedure is associated with some mortality and is best 
reserved for younger patients (98). 
 
Treatment of AA amyloidosis 
Treatment depends on the nature of the underlying chronic inflammatory disorder and ranges 
from potent anti-inflammatory and immunosuppressive biological drugs in patients with 
rheumatoid arthritis, to lifelong prophylactic colchicine in FMF and surgery in conditions such 
as refractory osteomyelitis and the cytokine secreting tumors of Castleman disease.  
Most patients with AA amyloidosis complicating inflammatory arthritis can now be treated 
effectively with one or other of the many biological agents now available, i.e. anti-cytokine 
(TNF, IL-1, IL-6) and anti-CD20 antibodies.  Nonetheless whilst there have been advances in 
the use of biologic therapies, progressive renal dysfunction remains common in AA amyloidosis 
and the need for renal replacement therapy occurs in up to a 40% of patients with a median time 
to dialysis from diagnosis of 6.5 years. Mortality, amyloid burden and renal prognosis are all 
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significantly correlated with SAA concentration during follow up. In a study of 374 patients 
with systemic AA amyloidosis, the risk of death was 17.7 times higher in patients with SAA 
concentrations ≥155 mg/L compared to <4mg/L. In fact even in patients with AA amyloidosis 
and modestly elevated SAA levels (4-9 mg/L), the risk of death was four fold higher compared 
to those with SAA of <4 mg/L.(19). Complete suppression of inflammation (SAA concentration 
persistently <4 mg/L) is frequently associated with gradual regression of amyloid and 
preservation of renal function  (19). 
Colchicine (in FMF) at the maximum tolerated dose and IL-1 inhibition with biological agents 
has revolutionised the management and prognosis of many patients with inherited 
autoinflammatory/periodic fever syndromes. Work from the National Amyloidosis Centre in 
AA amyloidosis complicating hereditary periodic fever syndromes has shown that that the 
diagnosis of a hereditary periodic fever syndrome had not been considered in half of patients 
prior to presentation with AA amyloidosis, almost 25% had evidence of ESRD at presentation 
and a further 28% developed ESRD over the course of follow up with a median time of 3.3 
years. Of the 46 patients assessed, 24 had FMF, 12 TRAPS and 6 CAPS. The majority of patients 
with FMF (22/24) were treated with high dose colchicine with complete remission in 19 and 
partial remission in 1 of the underlying inflammatory condition. Of the 12 patients with TRAPS, 
6 patients were initially treated with anti-TNF therapy with a transient response seen in 4; all 
switched to IL-1 blockade. 4 patients were treated upfront with IL-1 blockade. Of the 6 patients 
with CAPS, 4 were treated with IL-1 blockade with dramatic clinical and laboratory 
improvement and 2 died before the role of IL-1 therapy in CAPS was recognised. Of the total 
37 patients from the cohort who were treated successfully, or in whom at least partial 
suppression of the underlying autoinflammatory condition was achieved, 17 (46%) showed 
amyloid regression, 14 (38%) showed a stable amyloid load, and 2 (5%) showed increased 
amyloid deposition over the follow up period (99). 
The preferred form of RRT remains renal transplantation and suppression of the underlying 
inflammatory disorder is imperative prior to transplantation. In a study looking at renal 
transplantation in 128 patients with AA amyloidosis and ESRF, 43 underwent renal 
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transplantation with a median time from ESRF to transplantation of 1.5 years. Median estimated 
graft survival noncensored for death was 10.3 years; with 5 and 10 year graft survival of 86% 
and 59% respectively. 16 (37%) of patients died most commonly from infection and median 
SAA levels were higher in patients with recurrent amyloid in the graft compared to those in 
whom amyloid did not recur (100).  
 
Treatment of AL amyloidosis 
The current management of AL amyloidosis is aimed at suppressing the underlying B cell clone 
as quickly and completely as possible with chemotherapy and novel agents. This in turn halts 
the production of amyloidogenic light chains. Remission of the underlying clonal disease, i.e. 
hematological responses, may be associated with preservation of organ function and in some 
cases improvement in organ function, i.e. organ responses, especially when hematological 
remission has been sufficient to facilitate some gradual regression of the amyloid deposits. 
Consensus criteria to define hematological response and organ responses in AL amyloidosis 
have been devised (91). Patients who achieve a complete hematological response have the best 
clinical outcomes (101). This is defined by no detectable monoclonal immunoglobulin [M] band 
in serum or urine by immunofixation and normal free light chains, or a very good partial 
response, defined as the difference between the involved and uninvolved light chains (dFLC) 
<40mg/L. 
Although chemotherapy for AL amyloidosis has very largely been adapted from substantial 
experience in MM, adverse effects of treatment in patients with amyloidosis are much more 
frequent and serious, due to the reduced functional reserve of amyloidotic organs and poor 
performance status of many patients. This has led to risk adapted chemotherapy protocols, with 
most AL amyloidosis patients being classed as intermediate risk and best suited to cyclic 
combination chemotherapy regimens. These have historically included oral melphalan with 
dexamethasone (MDex) as well as a combination of cyclophosphamide, thalidomide and 
dexamethasone (CTDa). More lately, proteasome inhibitors, initially bortezomib and now 
others, have become the cornerstone of treatment (102). First line combination therapy with 
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bortezomib, cyclophosphamide and dexamethasone (CyBorD) has been shown to deliver high 
overall response rates (103). Ixazomib is the first oral proteasome inhibitor and is available in 
combination with lenolidamide and dexamethasone after at least one prior line of therapy. 
Carfilzomib is a novel irreversible proteasome inhibitor approved for relapsed/refractory MM. 
Whilst Phase I/II studies of its use to treat systemic AL amyloidosis have shown promising 
hematological response rates, cardiac, renal and pulmonary toxicity have been noted, warranting 
close monitoring of side effects and dose reduction. 
Autologous stem cell transplantation (ASCT), both in the initial and relapsed disease settings, 
is an effective treatment for AL amyloidosis leading to deep and durable clonal responses with 
an excellent median overall survival of over 5 years. However, this high intensity treatment is 
suitable for only a minority of patients due to significant procedure related morbidity and 
mortality (104). Stringent risk stratification has helped improve outcomes, and use of Mayo 
cardiac staging criteria has resulted recently in procedural mortality rates of 7% or less (104).  
Median survival in AL amyloidosis has improved a great deal over the past decade with a current 
estimated 4 year survival rate of 50%. Sadly, nearly 25% of patients still die from disease related 
complications within the first few months of treatment and this is primarily due to the presence 
and severity of cardiac involvement (75). 
 
Novel therapeutic approaches in clinical trials  
A number of different therapies aimed specifically at inhibiting the formation of amyloid fibrils 
or promoting fibril regression are currently under development, and some have already being 
clinically evaluated.  
In-vitro studies have shown that amyloidogenic misfolding of TTR may be inhibited by 
compounds that bind TTR in the plasma. Tafamadis, which is a TTR stabiliser, has been 
developed specifically to treat ATTR amyloidosis and to slow neuropathic disease in patients 
with V30M familial amyloid polyneuropathy (105). Diflunisal, a non-steroidal anti-
inflammatory drug, has lately been repurposed as an amyloid treatment, unrelated to its anti-
inflammatory properties; it also binds to and stabilises TTR in vitro (106). A randomized 
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controlled trial confirmed that it slows neurological progression in hereditary ATTR 
amyloidosis (107). TTR is almost exclusively synthesized by the liver which presents a target 
for state of the art RNA-inhibiting therapies. Anti-sense oligonucleotide and small interfering 
RNA therapies have been shown to reduce circulating TTR by 70-85% respectively (108), and 
phase 3 studies have lately been completed of both class of agents with great success, showing 
substantial inhibition and even reversal of neuropathic features in FAP (109). 
 
Anti-amyloid antibodies 
The role of therapeutic antibodies to directly target existing amyloid deposits is being 
investigated with vigor. There are currently three monoclonal antibodies that are undergoing 
testing. 
The first antibody approach focuses on the murine monoclonal 11-1F4 antibody prepared 
against human light chain related fibrils and recognised an amyloid-associated conformational 
epitope (110). In animal models of mice bearing human amyloidomas, rapid and complete 
elimination of the masses without toxicity was demonstrated. In an open label, dose escalation 
phase I clinical trial, the drug was tolerated well by participants with no grade 4 or 5 adverse 
events reported. Organ responses were seen in 60% of evaluable patients with a median time to 
response of only two weeks after the start of treatment.  
The second antibody approach, potentially applicable to all types of amyloidosis, targeted SAP.  
SAP binds to and is present in all amyloid deposits, which is believed to protect them from 
degradation by phagocytic cells and proteolytic enzymes (14). ((R)-1-(6-[(R)-2-carboxy-
pyrrolidin-1-yl]-6-oxo-hexa-noyl) pyrrolidine-2 carboxylic acid), a novel bis (D-proline) 
CPHPC, a drug that cross-links pairs of circulating SAP molecules in vivo triggering their 
removal by the liver, rapidly and almost completely eliminates SAP from the bloodstream. By 
contrast, even long term treatment with CPHPC only modestly depletes SAP from amyloid 
deposits. Subsequent work showed that antibodies to SAP can then target the remaining SAP 
present in all amyloid deposits, resulting in their rapid clearance by macrophage and 
complement mediated mechanisms. In an open label Phase I dose escalation study of 16 patients, 
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a combination of CPHPC and anti-SAP antibody has been shown by 123I-SAP scintigraphy to 
result in swift and marked removal of liver amyloid deposits with associated improvement in 
liver function tests (25). This therapy is currently being tested in a phase 2 trial of patients with 
cardiac ATTR and cardiac AL amyloidosis. 
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Aims and Scope of the Thesis 
 
The introduction of this thesis provides a broad overview of the pathogenesis and spectrum of 
amyloidosis. It classifies the different types of amyloidosis, through a range of techniques 
including key imaging modalities to identify visceral organ involvement. Systemic AL 
amyloidosis remains the commonest form of systemic amyloidosis and treatment is focused on 
suppression of the precursor fibril, with systemic chemotherapy, as well as supportive care of 
amyloidotic organ function. 
The premise of this thesis focuses on cardiac and renal amyloidosis. Chapter 3 explores the role 
of proteomics in the diagnosis and typing of amyloid deposits and the aim of this study was to 
compares its use to the more commonly used Congo red and immunohistochemical staining of 
tissue, as well as specialist clinical assessment. 
The second part of this thesis investigated risk stratification and outcomes of patient with 
combined cardiac and renal amyloidotic organ dysfunction in AL amyloidosis. Chapter 5, 
specifically explores outcomes in patients with systemic AL amyloidosis and advanced renal 
excretory impairment (eGFR <20ml/min) at baseline, previously deemed too ‘high risk’ for 
chemotherapy. The aim of this study was to assess whether prompt treatment in such patients 
would improve both renal and overall survival. 
A key feature of systemic AL amyloidosis is its multiorgan involvement. It is a recognised 
cause of Type 5 cardiorenal syndrome and current consensus focuses on individual organ 
involvement as well as response to treatment. The aim of chapter 6 was to assess the incidence 
of combined cardiac and renal amyloidotic organ dysfunction at baseline, test the current renal 
and cardiac staging systems and identify the key biomarkers both at baseline and during follow 
up, that dictate the hard outcomes of death, dialysis and their composite.   
Supportive care is a key part of treatment in systemic AL amyloidosis, most commonly with the 
use of diuretics to correct volume status and nutritional interventions to improve both treatment 
tolerance and quality of life. Proteinuric CKD and congestive cardiac failure can manifest with 
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ECV overload as well as changes in flesh weight. Clinical practice often relies on both 
examination and serial weights to assess patient’s optimal ‘dry’ weight, despite sarcopenia being 
a recognised complication of systemic chemotherapy. The aim of chapter 7 was to explore the 
role of body composition in systemic AL amyloidosis, using biompedance vector analysis 
(BIVA), and whether it may offer insight into changes in weight as well as ECV status and the 
latter’s correlation with the key cardiac biomarker, NT-proBNP. 
The final chapter of this thesis focuses on the most challenging aspect of cardiac AL 
amyloidosis, early sudden cardiac death. Despite a number of studies demonstrating the 
presence of both tachy and brady arrhythmias in cardiac AL amyloidosis, outcomes remain 
poor. This chapter aimed to explore the role of intracardiac defibrillators (ICD’s) and whether 
they provide effective treatment of arrhythmias and more importantly confer a survival benefit. 
The overarching hypothesis of this work is that refinements and improvements in tissue 
diagnosis, biomarker based risk stratification, and supportive management of patients with renal 
and cardiac amyloidosis will result in preservation of organ function and improved overall 
survival.  
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Chapter Two: Materials and Methods 
 
Declaration 
I have designed the studies, carried out the data collection and the analysis of the data. I 
collected the data and performed the statistical analysis in my role as a clinical research fellow 
at the National Amyloidosis Centre, University College Medical School (Royal Free 
Campus). Several diagnostic methods were carried out by other individuals in the department 
they were as follows: 
Histological and immunohistochemical analyses were performed by Janet Gilbertson. 
Gene sequencing was performed by Dorota Rowczenio and Hadija Trojer. 
Echocardiography was performed by Babita Pawarova, Cecil Tabadero and Sevda Ward 
123I-SAP scintigraphy was performed by David Hutt and Raymond Vito. 
ICD monitoring was reviewed by Dr Carol Whelan, Dr Dominic Rogers and Dr Farhar 
Khan. 
Measurement for biochemical and haematological data were performed by the Royal Free 
Hospital laboratory services. 
Statistics advice was given by Aviva Petrie from the Biostatistics Unit at the UCL Eastman 
Dental Institute for chapters 3-7. 
 
Patients 
All patients in this thesis were seen at the UK National Amyloidosis Centre. An access database 
has been kept up to date with details of patients who have been referred to the NAC with 
suspected amyloidosis. All the patients included within the database have given explicit 
informed consent.  
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SAP Scintigraphy  
SAP scintigraphy was performed in all patients seen at the centre with suspected amyloidosis at 
baseline and in those in whom it was clinically indicated at set time points during their follow 
up. Each subject undergoing SAP scintigraphy received approximately 200µg of SAP with 
190MBq of 123I, the equivalent of 3.8 mSV of radiation. Thyroid uptake was blocked by the 
administration of 60mg of potassium iodide immediately prior to the study and 5 further doses 
were given over the following three days. Anterior and posterior imaging was performed at 
either 6 or 24 hours after injection using an IGE-Starcam gamma-camera (IGE Medical 
Systems, Slough, UK). Female patients were asked to confirm that they were not pregnant prior 
to undergoing SAP scintigraphy. 
Amyloid load was classified according to 4 criteria. Normal, small, moderate and large. 
‘Normal’ was defined as no evidence of abnormal tracer localization. ‘Small’ was defined as 
uptake in one or more organs whilst still maintaining normal intensity in the blood pool and 
‘moderate’ when uptake was seen in one or more organs and the blood pool was diminished. 
‘Large’ was defined as uptake in one or more organs with no evidence of tracer in the blood 
pool despite adjustment of the grey scale to encompass the visceral organs involved. 
Progression of amyloid by SAP scintigraphy was defined as an increment within the 4 category 
staging system and regression of amyloid by SAP scintigraphy was defined as a decrement 
within the categorical staging of amyloid load. 
 
Cardiac Assessment  
Assessment of cardiac amyloidosis is performed using a combination of clinical parameters, 
serum biomarkers and imaging modalities. 
All patients referred to the centre with suspected cardiac amyloidosis underwent testing of 
serum cardiac biomarkers as well as electrocardiography and echocardiography. All new 
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patients where appropriate since December 2015 underwent CMR at the National Amyloidosis 
Centre or if appropriate had their images reviewed by Dr Marianna Fontana or Dr Dan Knight. 
 
Functional Assessment  
Functional evaluation of patients was performed using a combination of subjective and 
objective parameters. New York Heart Association Classification (NYHA) was used to assess 
for symptoms of heart failure (Table 2.1). Eastern Co-operative Group (ECOG) performance 
status was used (Table 2.2), particularly in patients with systemic AL amyloidosis receiving 
cytotoxic therapy in order to assess their tolerance to treatment. A history entailing baseline 
exercise tolerance is taken during the clinical consultation and for all patients able to perform it, 
a 6 minute walk test (6MWT) is completed with both a total number of metres walked and 
percentage predicted for age calculated. 6MWT is performed according to standardised 
criteria(111) and has been shown to be a valuable measure of functional change in patients with 
systemic AL amyloidosis receiving chemotherapy(112). 
 
Table 2.1: NYHA classification  
NYHA Class 
 
Description  
Class 1 No symptoms and no limitation in ordinary physical activity, e.g. shortness 
of breath when walking, climbing stairs etc. 
 
Class 2 Mild symptoms (mild shortness of breath and/or angina) and slight 
limitation during ordinary activity.  
Class 3 Marked limitation in activity due to symptoms, even during less-than-
ordinary activity, e.g. walking short distances (20-100 m). Comfortable 
only at rest.  
Class 4 Severe limitations. Experiences symptoms even while at rest. Mostly 
bedbound patients. 
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Table 2.2 Definition of Eastern Co-operative Group Performance Status 
Grade Summary Description 
0 Normal No restriction to carrying out normal activities 
1 With effort Ambulatory, able to do light work. Restricted only in strenuous 
activity 2 Restricted Self-caring and ambulatory but unable to carry out work 
3 Dependent Capable of limited self-care, confined to bed or chair for over 
50% of waking hours 4 Immobile Unable to carry out self-care, completely confined to bed or chair 
 
Echocardiography 
Echocardiography was performed in all patients with two-dimensional and M-mode 
settings using a GE Vivid 7 system. Parasternal long axis and apical long axis views were 
most commonly used. Evaluation of left ventricular wall thickness, left ventricular 
diastolic function, left ventricular systolic function and atrial diameter were measured using 
defined criteria from the British Society of Echocardiography (http://www.bsecho.org). Left 
atrial area was measured using cr i ter ia  def ined by the  Amer ican Socie ty  of  
Echocardiography (http://www.asecho.org). 
Electrocardiogram 
Low voltage amplitude was defined by a mean QRS amplitude in leads I, II, II, AVL and 
AVF of less than 0.5mV. (113) 
Holter Monitoring 
Twenty-four hour electrocardiographic monitoring (Holter monitoring) was performed 
using a portable cassette recorder with three lead placements (Spacelabs Healthcare 
Lifecard CF). Analysis of the 24 hour records was performed by an experienced electro 
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physiologist using Pathfinder Digital software V8.701 (Spacelabs). Two consultant 
cardiologists reviewed the reports. Referring physicians were contacted with the results of 
significant results and changes to management were recommended based on current clinical 
practice for cardiac rhythm disturbances. 
  
Criteria for Diagnosis of Amyloid and Definition of Organ 
Response 
The definition of organ involvement and organ response was defined according to consensus 
criteria in combination with SAP scintigraphy (Table 2.3). (69) 
Table 2.3 Definition of Organ Involvement and Organ Response 
 
Organ Definition of Organ 
Involvement 
Definition of Organ 
Response 
Heart 
Echocardiogram: Mean wall 
thickness >12mm and no other 
cardiac cause or 
CMR showing late gadolinium 
enhancement 
Mean IVSd decreased by 2mm, 
20% improvement in EF, 
improvement by 2 NYHA 
classes without an increase in 
diuretic use and no increase in 
wall thickness 
Kidneys 
24 hour non Bence Jones 
Proteinuria >0.5g, or uptake on 
SAP scintigraphy 
≥ 50% reduction in proteinuria 
(at least 0.5g/day) without a ≥ 
25% reduction in eGFR, or 
increase in serum creatinine. 
Liver SAP scintigraphy 
50% decrease in abnormal ALP 
or reduced organ uptake on SAP 
scintigraphy 
Spleen SAP scintigraphy Reduced organ uptake on SAP 
scintigraphy 
Adrenal SAP scintigraphy Reduced organ uptake on SAP 
scintigraphy 
Soft Tissue 
Tongue hypertrophy, periorbital 
bruising, spontaneous bruising, 
pseudo hypertrophy, 
lymphadenopathy, carpal tunnel 
syndrome 
Clinical assessment 
of improvement 
Gastrointestinal 
Tract 
Direct biopsy verification with 
symptoms 
 
Lung 
Direct biopsy verification with 
symptoms, interstitial 
radiographic pattern 
Radiographic evidence of 
improvement in pulmonary 
interstitial amyloid (rare) 
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Peripheral 
Neuropathy 
Symmetrical sensorimotor 
peripheral neuropathy in the 
lower limbs 
Clinical assessment 
Autonomic 
Neuropathy 
Impotence, diarrhoea or 
constipation, early satiety and/or 
impaired bladder emptying 
without other overt cause. 
Orthostatic hypotension 
(>20mmHb fall in systolic BP) 
Clinical Assessment 
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Histology 
Congo red Staining 
Formalin fixed de-paraffinised tissue sections 6-8µg thick were rehydrated, and 
counterstained with haematoxylin under running tap water. Sections were then stained using 
the alkaline-alcoholic Congo-red method as previously described by Puchtler et al. (50) A series 
of ascending ethanol concentrations to xylene were used to dehydrate the sections which were 
then mounted in DPX mounting medium. Stained slides were then viewed in bright field and 
under cross polarised light. Positive controls were obtained from a known Congo-red positive 
block validated by laser micro dissection and mass-spectrometry based proteomic analysis 
which was always processed in parallel. 
 
Immunohistochemistry 
The amyloid type was then characterised by immunohistochemical staining. Formalin 
fixed de-paraffinised 2µm sections of amyloidotic tissue were used. Sections were washed 
with water and endogenous peroxidise activity was quenched by incubation in aqueous 
(0.3%) hydrogen peroxide (H2O2) for 30 minutes. They were then rinsed again in 
phosphate-buffered saline (PBS) containing 0.05% Tween (Calbiochem). Prior to the 
application of antisera, non specific tissue binding was abolished by incubation for a further 
30 minutes in normal non-immune serum from the species providing the secondary antibody 
(Vector Part of the ImmPRESS Kit). Sections were then incubated overnight with primary 
antisera at 4oC. They were rinsed with PBS containing 0.05% Tween (Calbiochem) and 
labelled with secondary antibodies. Sections were washed in PBS and bound enzyme-
antibody bound complexes were then visualised using a metal-enhanced DAB (Fisher 
Scientific solution). 
A panel of anti-human monospecific antibodies reactive with: SAA 
(Eurodiagnostica, Huntington UK) AL kappa, lambda, transthyretin and lysozyme (Dako Ltd, 
  
 
68 
Denmark House Ely UK), Apolipoprotein AI (Genzyme Diagnostics) and fibrinogen Aα 
chain (Calbiochem) were used where appropriate. Congo red overlay was used in duplicate 
sections. Immunohistochemically stained sections were counterstained in haematoxylin, 
‘blued’ under running tap water and stained with Congo-red. (114) 
For TTR staining, pre-treatment was performed for enhanced antigen retrieval 
using 10 minute incubation with 1% sodium periodate, slides were then washed and further 
incubated for 10 minutes with 0.1% sodium metabisulphate, washed again and incubated for 
5 hours at room temperature with 6M Guanadine in 0.9% sodium chloride. 
 
Laser Dissection Mass Spectrometry  
For microdissection, stained CR sections were viewed under brightfield and florescence light 
using the Leica LMD7 laser capture microscope.  Areas positive for amyloid when viewed using 
fluorescence light at excitation 497 nm and emission 614 nm wavelengths were laser 
microdissected into micro-centrifuge caps.  Proteins were extracted from each sample into 
10 mM Tris/1 mM EDTA/0.002% Zwittergent buffer solution (35 μl) by heating (99 °C, 1.5 h) 
followed by sonication (1 h) and then digested with trypsin (25 ng/sample) overnight (~ 18 h) at 
37 °C.  Each digested sample was reduced with dithiothreitol (50 μg) at 99 °C for 5 min, freeze 
dried, reconstituted in 0.1% v/v trifluoroacetic acid in HPLC grade water (20 μl) and analysed 
by HPLC-MSMS, as previously described.(115, 116) 
MS raw data files were queried using Mascot and assigned peptide and protein 
probability scores.  Amyloid by LDMS was established on the basis of the presence of the 
‘amyloid signature proteins (ASP)’ defined by presence (≥ 1 unique specific peptide) of two or 
more of the following proteins; apolipoprotein E (APOE), apolipoprotein A-IV (APOA4) and 
serum amyloid P component (SAP), as previously described.(59)  The amyloid fibril protein 
was determined by presence of Mascot score of >80 coupled with at least 2 unique specific 
peptides of a known amyloid fibril protein together with absence (Mascot score < 80 or fewer 
than 2 unique specific peptides) of other known amyloid fibril proteins.   
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Immunoassays 
Serum Amyloid A Protein 
SAA levels were measured using latex nephelometry (BNII autoanalyser Dade, Behring 
Marbury, Germany). (117) The lower limit of detection is 0.7mg/L. Standardisation was 
based on WHO international reference standards 1987. (118) 
 
Serum Free Immunoglobulin Light Chain Assay 
Both kappa and lambda serum free immunoglobulin light chains (FLC) were measured using 
a latex-enhanced immunoassay (The Binding Site, Birmingham, UK) on a ehring BNII 
autoanalyser (Dade Behring, Marburg, Germany). (119-121) Antibodies are directed 
against FLC epitopes hidden within whole immunoglobulin molecules. The sensitivity 
of the assay is <5mg/L. Sera from 100 healthy blood donors were tested in order to determine 
the reference range. The mean concentrations of polyclonal free kappa and free lambda light 
chains were 11.38mg/L (95% CI, 7.41-16.77mg/L) and 17.36mg/L ((%% CI, 8.91-29.87mg/l) 
respectively. The mean kappa/lambda ratio was 0.7 (95% CI, 0.37-0.95). An abnormally 
high kappa or lambda light chain value or abnormal ratio in the context of preserved renal 
function was used as part of the assessment of an underlying clonal disorder in chapter four. 
In patients with renal impairment the ratio alone was used. The definitions of haematologic 
response are outlined in Table 2.4. 
Light chains are metabolised in the kidneys. Polyclonal free light chain levels rise 
in renal failure(122) which makes interpretation of absolute levels of serum free light chains 
difficult to interpret. If the ‘normal’ ratio of kappa/lambda is estimated to be 1:1, the amount 
of monoclonal light chain can be estimated by subtracting the uninvolved light chain from the 
involved light chain, a method previously validated in myeloma.(123) This method has been 
used when calculating the light chain response in chapters five and six. 
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Table 2.4 Haematologic Response Criteria (69) 
Clonal Response Criteria 
Complete 
Response 
Serum and urine negative for a monoclonal protein by 
immunofixation, normal free light chain ratio 
Partial Response 
If serum paraprotein >0.5g/dL, a 50% reduction 
If light chain in the urine with a visible peak and 
>100mg/day and 50% reduction 
If free light chain >10mg/dL (100mg/L) and 50% reduction 
Progression 
From CR, any detectable monoclonal protein or abnormal 
free light chain ratio (doubling of light chain) 
From PR or stable response, 50% increase in serum 
paraprotein to >0.5g/dL or 50% increase in urine 
paraprotein to >200mg/day 
Free light chain increase of 50% to >10mg/dL (100mg/L) 
Stable No CR, no PR, no progression  
Gene Sequencing 
Genotyping was performed in patients with suspected hereditary amyloidosis where 
appropriate. Whole blood taken in an EDTA tube was frozen and stored for gene sequencing 
as required. Genomic DNA was isolated by a rapid method.  The blood was added to NH4CL 
and spun, the sample was then re-suspended in 0.9% NaCl and re-spun. It was then suspended 
again in 0.05M NaOH, incubated, cooled and neutralised with 1M Tris pH8. Polymerase chain 
reaction (PCR) using ‘Ready-To-Go’ tubes (GE Healthcare) were used to amplify the 
coding regions for the following genes: transthyretin (exons 2,3 and 4), apolipoprotein AI 
(exons 3 and 4) and fibrinogen A α-chain (exon 5). HotStar Taq DNA Polymerase kit 
(Qiagen) was used for the lysozyme gene (exon 2). The primers used as part of the PCR process 
are outlined in Table 2.5. 
Table 2.5 Primers Used in the PCR Process for Genotyping Hereditary 
Amyloidosis 
Gen
e 
(exo
n) 
Forward primer sequence Reverse primer sequence 
Transthyretin (2) 5’-TTTCGCTCCAGATTTCTAATAC-3’ 5’-CAGATGATGTGAGCCTCTCTC-3’ 
Transthyretin (3) 5’-GGTGGGGGTGTATTACTTTGC-3’ 5’-TAGGACATTTCTGTGGTACAC-3’ 
Transthyretin (4) 5’-GGTGGTCAGTCATGTGTGTC-3’ 5’-TGGAAGGGACAATAAGGGAAT-3’ 
Apolipoprotein (3) 5’-GGCAGAGGCAGCAGGTTTCTCAC-3’ 5’-
CCAGACTGGCCGAGTCCTCACCTA-3’ Apolipoprotein (4) 5’-CACTGCACCTCCGCGGACA-3’ 5’- 
CTTCCCGGTGCTCAGAATAAACGTT-
3’ 
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Fibrinogen (5) 5’-AGCTCTGTATCTGGTAGTACT-3’ 5’- ATCGGCTTCACTTCCGGC-3’ 
Lysozyme (2) 5’-GTTATATTGTTCGTTGGTGT-3’ 5’- CATTTGTATTGAGTCTCAATTC-3’  
Statistical Analysis 
Statistical analyses were performed using Graph Pad Prism (Version 5.03), 
IBM SPSS Statistics 23 (SPSS Inc, Chicago III) and Stata version 14 
(Statacorp). 
Individual statistical methods are discussed separately in each results chapter. 
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Results 
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Chapter Three: The complementary role of histology 
and proteomics for diagnosis and typing of systemic 
amyloidosis 
 
Introduction 
The amyloidoses are a group of rare diseases caused by extracellular accumulation of amyloid, 
a fibrillar material derived from a variety of precursor proteins that can aggregate in a highly 
abnormal cross B sheet conformation.(1, 2)  Amyloid deposits progressively disrupt tissue 
structure and function,(3) the various clinical syndromes being classified according to the 
respective fibril precursor protein, of which more than 30 are known.(124)  Amyloid is identified 
by the pathognomonic finding of apple-green dichroism when affected tissue sections are 
stained with Congo red dye and visualized under polarized light microscopy.  Under electron 
microscopy, amyloid fibrils have a characteristic appearance of rigid non-branching fibrils with 
a diameter of ~10 nm.(5) 
Systemic amyloidosis is highly heterogeneous not only with respect to amyloid fibril 
protein type but also to the range of organ involvement and broader clinical phenotype.  Therapy 
is aimed at reducing the supply of the respective amyloid fibril precursor protein, and there is 
therefore a critical need to definitively determine the amyloid fibril protein type in every 
patient.(125)  For example, chemotherapy, which can be very toxic, is potentially beneficial 
only in AL amyloidosis, which can be particularly challenging to confirm.(51)   
Congo red (CR) histology followed by immunohistochemical (IHC) staining of biopsy 
samples is the classical and widely available method for identifying amyloid and determining 
the fibril type.  Whilst this is the historical gold standard for diagnosis and typing of amyloid, 
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many different staining methods and antisera are used in different labs, and substantial operator 
experience is required for best results.  The highly idiosyncratic nature of monoclonal 
immunoglobulin light chain (AL) presents particular challenges.  Consequently, the sensitivity 
and specificity of IHC varies with type of amyloid, local methods and experience.(126)  IHC 
studies of thousands of samples in our own centre have failed to confirm amyloid type beyond 
doubt in up to 30% of cases, mostly when AL amyloidosis is probable on clinical grounds.  
Immunofluorescence (IF) is a more reliable technique for the typing of AL amyloid deposits 
than IHC,(127) although it requires frozen amyloidotic tissue. Immunoelectron microscropy 
(IEM) is a technique that combines IHC and electron microscopy and allows for the correct 
characterisation of the amyloid protein in virtually all cases but IEM is not widely available and 
is currently performed in only a select number of specialist centres.(128)  
Laser dissection and tandem mass spectrometry (LDMS) is an alternative, reportedly 
accurate tool for identification and typing of amyloid deposits which has gained popularity.  
Importantly, it can be performed using tiny quantities of formalin fixed amyloidotic tissue.  
LDMS was first validated by the Mayo group in 2009, in 102 predominantly endomyocardial 
biopsy specimens; LDMS was 98-100% sensitive and specific in comparison to 
clinicopathologic criteria for identification and typing of amyloid.(59)  
We sought here to compare and evaluate the roles of CR/IHC and LDMS for identifying 
and typing amyloid in a diverse population of amyloidosis patients referred to our single national 
centre. 
 
Methods 
Samples 
During the calendar year 2017, 1864 formalin–fixed paraffin wax-embedded (FFPE) biopsies 
from various tissues of patients suspected to have amyloid were studied in the UK National 
Amyloidosis Centre (NAC).  They were received from many local hospitals across the UK and 
overseas.  Tissue fixation and processing into paraffin blocks had been performed according to 
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the referring hospitals’ protocols and was therefore not standardized.  Details on the duration of 
fixation and processing were unavailable.   
Sections from all FFPE biopsy samples were cut and stained with Congo red and a panel 
of anti-fibril protein antibodies as described below.  Amyloid, identified by pathognomonic 
green birefringence of Congo red stained tissue sections viewed under crossed polarized light, 
was present in 1109/1864 (59%) biopsy samples (CR+ve); 755 (41%) were negative for 
presence of amyloid (CR-ve).  The amyloid fibril protein was determined by IHC in 789/1109 
(71%) CR+ve samples, but could not be characterised definitively in the remaining 320 CR+ve 
samples.   
For purposes of this study, we processed a total of 700 samples for LDMS comprising 
all 320 CR+ve samples in which IHC was non-diagnostic of the amyloid fibril protein, 320 
randomly selected CR+ve biopsy samples in which the amyloid type was definitively 
determined by IHC, and 60 randomly selected CR-ve biopsy samples.   
All patients were managed in accordance with the declaration of Helsinki and 
institutional review board approval from the Royal Free Hospital Ethics committee was obtained 
for this study (REC/06/Q0501/42). 
 
Congo red (CR) and immunohistochemical (IHC) staining at NAC 
Twenty-two serial sections were cut from each FFPE block for CR and IHC staining.  Sections 
of 2 µm thick were used for IHC and sections of 6 µm thick were used for CR staining and 
IHC/CR overlay.(114)  Congo red staining was by the method of Puchtler et al and amyloid was 
identified by presence of apple green birefringence when viewed under crossed polarised 
light.(50)  Immunohistochemical staining was with a panel of antibodies against known amyloid 
fibril proteins using the Shandon Sequenza™, namely, kappa and lambda immunoglobulin light 
chains, transthyretin, amyloid A protein, fibrinogen, LECT2, apolipoprotein A-I, and lysozyme, 
as previously described.(129)  Antigen retrieval was not performed with the exception of 
transthyretin staining, which uses oxidation steps 1% aqueous sodium periodate (10min) and 
0.1% sodium borohydride (10min) followed by 6 M guanidine (4h).  Sections were blocked for 
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endogenous peroxidases and also blocked with normal serum.  Sections were incubated 
overnight at 4°C with the primary antibodies, rinsed in PBS.  The antibodies were detected with 
the appropriate IMMPRESS™ (Vector Laboratories) polymer detection kit and labelled using 
metal enhanced DAB chromagen (Thermo Scientific).   
Presence of amyloid by CR staining (CR+ve) was defined by presence of 
pathognomonic apple green birefringence when viewed under crossed polarised light.  The 
amyloid fibril protein was established on the basis of unique and specific staining of the amyloid 
with an antibody from the amyloid fibril protein panel.  Interpretation was carried out without 
any clincial information by two independent experienced assessors using a Leica DM4000 with 
and without crossed polarising filters.   
 
Laser capture microdissection and proteomic mass spectrometry analysis 
For microdissection, stained CR sections were viewed under brightfield and florescence light 
using the Leica LMD7 laser capture microscope.  Areas positive for amyloid when viewed using 
fluorescence light at excitation 497 nm and emission 614 nm wavelengths were laser 
microdissected into micro-centrifuge caps.  In tissue samples where Congo red staining was 
equivocal or scanty, usually as a result of presence of areas of amorphous eosinophilic material 
under brightfield light with seemingly white birefringence but bright fluorescence, such areas 
were captured by the same method.  In renal tissues in which the differential diagnosis included 
amyloid or non-amyloid monoclonal gammopathy of renal significance (MGRS) and in which 
presence of amyloid was not confirmed by CR staining, glomeruli were captured by the same 
method.  Proteins were extracted from each sample into 10 mM Tris/1 mM EDTA/0.002% 
Zwittergent buffer solution (35 μl) by heating (99 °C, 1.5 h) followed by sonication (1 h) and 
then digested with trypsin (25 ng/sample) overnight (~ 18 h) at 37 °C.  Each digested sample 
was reduced with dithiothreitol (50 μg) at 99 °C for 5 min, freeze dried, reconstituted in 0.1% 
v/v trifluoroacetic acid in HPLC grade water (20 μl) and analysed by HPLC-MSMS, as 
previously described.(115, 116) 
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MS raw data files were queried using Mascot and assigned peptide and protein 
probability scores.  Amyloid by LDMS was established on the basis of the presence of the 
‘amyloid signature proteins (ASP)’ defined by presence (≥ 1 unique specific peptide) of two or 
more of the following proteins; apolipoprotein E (APOE), apolipoprotein A-IV (APOA4) and 
serum amyloid P component (SAP), as previously described.(59)  The amyloid fibril protein 
was determined by presence of Mascot score of >80 coupled with at least 2 unique specific 
peptides of a known amyloid fibril protein together with absence (Mascot score < 80 or fewer 
than 2 unique specific peptides) of other known amyloid fibril proteins.   
 
Analyses 
Results of CR and IHC were compared with results of LDMS in a total of 700 samples 
(Figure 3.1).  Specifically, they were compared with respect to identification of amyloid and 
identification of the amyloid fibril protein (amyloid type). 
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Figure 3.1 
Flowchart of results of 700 samples processed for CR with IHC and LDMS. 
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Results 
The 700 samples (640 CR+ve and 60 CR-ve) were from a total of 50 different tissue types with 
renal (n=188), cardiac (n=126) and bone marrow trephine (n=44) comprising over 50% of all 
samples processed. 
 
Diagnosis of amyloid 
Six-hundred and two of the 640 (94%) CR+ve samples were ASP+ve by MS and 38 (6%) were 
ASP-ve.  Fifteen of 38 (39%) CR+ve/ASP-ve samples were classified by MS as ‘insufficient 
for analysis’ due to scanty tissue (n=14) or scanty amyloid (n=1) with a total of < 5 proteins 
identified within the sample.  In the remaining 23/38 (61%) CR+ve/ASP-ve samples there was 
adequate tissue for analysis.  The details of these 23 tissues samples (obtained from 20 patients) 
are listed in Table 3.1 which also includes the findings of a comprehensive clinical, biochemical 
and imaging review that was conducted in 15/20 individuals.  In each of the 15 cases, an 
unequivocal diagnosis of amyloidosis was established on the basis of combined clinical, 
biochemical, echocardiographic, cardiac magnetic resonance imaging (CMR), and scintigraphic 
analyses.(130)  The final diagnosis was localised AL amyloidosis in 4 cases, ATTR amyloidosis 
in 4 cases, systemic AL amyloidosis in 3 cases, Leukocyte Chemotactic Factor-2 (ALect2) 
amyloidosis in 2 cases, beta 2 microglobulin (β2M) amyloidosis in 1 case, and the final patient 
was a 59 year old male with carpal tunnel amyloid deposits in the absence of any critical 
amyloidotic organ involvement or dysfunction.  The remaining 5/20 patients were not seen at 
our centre, and their biopsy sample had been sent to NAC solely for histological analysis.  
 Forty-nine of the 60 (82%) CR-ve samples were ASP-ve by MS and 11/60 (18%) were 
ASP+ve (Table 3.2).  There were no CR-ve/ASP+ve cardiac, gastrointestinal, fat or bone 
marrow trephine biopsy samples (Table 3.3).  However, there were 7 renal biopsy specimens, 
all glomerular, from a total of 188 (4%) renal biopsies which were CR-ve/ASP+ve.  In 4/7 such 
cases, a diagnosis of fibrillary glomerulonephritis (GN) was established on the basis of the 
clinical and electron microscopy findings coupled with presence of DNAJB9 protein by 
MS.(131)  One of the remaining 3 patients with a CR-ve/ASP+ve glomerular sample was 
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eventually diagnosed with fibronectin glomerulopathy, and the diagnosis in the remaining 2 
cases was not established at the time of writing (Table 3.2).    
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Table 3.1.  Samples diagnostic of amyloid by Congo red staining but with no amyloid by MS (CR+ve/ASP-ve) 
 
Sample / 
Patient No 
Age & 
Sex 
Tissue Clinical / 
Histology 
review 
Final Diagnosis* Organ Involvement SAP scintigraphy DPD 
scan 
1/1 62 F Lymph node Clinical  Localised AL amyloidosis No vital organ involvement  No visceral amyloid Not done 
2/2 87 M Fat aspirate Clinical ATTR amyloidosis Cardiac No visceral amyloid Grade 2 
3/3 65 M Prostate Clinical  Localised AL amyloidosis No vital organ involvement  No visceral amyloid Not done 
4/4 67 M Renal  Clinical  Systemic AL amyloidosis Renal Isolated renal amyloid Not done 
5/5 84 M Carpal tunnel Clinical Beta 2 microglobulin 
amyloidosis 
No vital organ involvement  No visceral amyloid Not done 
6/6 68 F Renal  Clinical ALECT2 amyloidosis Renal  Amyloid in spleen and 
kidneys 
Not done 
7/7 67 F BMT Histology Uncertain Not done Not done Not done 
8/8 55 M Muscle Histology Uncertain Not done Not done Not done 
9/9 84 M Cardiac Clinical  ATTR amyloidosis Cardiac No visceral amyloid Grade 2 
10/10 68 M Tonsil Clinical Localised AL amyloidosis No vital organ involvement No visceral amyloid Not done 
11/11 82 M Tongue Clinical  ATTR amyloidosis Cardiac No visceral amyloid Grade 2 
12/12 54 M Brain Histology  Uncertain Not done Not done Not done 
13/13 72 M BMT Clinical  Systemic AL amyloidosis Cardiac and soft tissue No visceral amyloid Not done 
14/14 74 M Renal (glomeruli) Clinical  Renal amyloid – uncertain 
type 
Renal  Isolated renal amyloid Not done 
15/14  Renal (medulla) As above As above As above As above As above 
16/15 34 F Mucosa Histology Uncertain Not done Not done Not done 
17/16 63 M Skin Clinical  Localised AL amyloidosis No vital organ involvement No visceral amyloid Not done 
18/17 68 M Renal (interstitium) Histology ALECT2 amyloidosis Not done Not done Not done 
19/18 59 M Carpal tunnel Clinical  Amyloid – uncertain type No vital organ involvement No visceral amyloid Grade 0 
20/19 92 M Prostate Clinical  ATTR amyloidosis Cardiac No visceral amyloid Grade 2 
21/19  Fat aspirate As above As above As above As above As above 
22/19  Fat aspirate #2 As above As above As above As above As above 
23/20 61 F BMT Clinical  Systemic AL amyloidosis Cardiac and soft tissue  Amyloid in liver and spleen  Not done 
 
*The final diagnosis in patients who underwent clinical review was established on the basis of a comprehensive clinical assessment, 
biochemical investigations including serum and urine immunofixation, serum free light chains and cardiac biomarkers and specialist imaging 
including SAP scintigraphy, DPD scintigraphy, echocardiography and cardiac magnetic resonance imaging.    
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Table 3.2.  Samples with no amyloid by Congo red staining but with presence of the ‘amyloid signature’ by MS (CR-ve/ASP+ve) 
Sample / 
Patient No 
Age & 
Sex 
Tissue Clinical / 
Histology 
review 
Final Diagnosis* Organ Involvement SAP scintigraphy  
1/1 58 F Soft tissue Clinical  Localised AL amyloidosis No vital organ involvement  No visceral amyloid 
2/2 52 M Soft tissue Clinical  Systemic AA amyloidosis Renal Amyloid in spleen and kidneys 
3/3 72 F Skin Clinical  Systemic AL amyloidosis Cardiac and soft tissue No visceral amyloid 
4/4 66 M Prostate Clinical  Localised AL amyloidosis No vital organ involvement No visceral amyloid 
5/5 66 F Renal Histology Fibrillary GN  Not done Not done 
6/6 76 M Renal Histology  Fibronectin glomerulopathy Not done Not done 
7/7 39 M Renal Clinical  Fibrillary GN  Renal  No visceral amyloid 
8/8 52 M Renal Clinical  Fibrillary GN Renal  No visceral amyloid 
9/9 46 M Renal Histology Uncertain Not done Not done 
10/10 19 M Renal Histology  Uncertain Not done Not done 
11/11 61 F Renal Clinical  Fibrillary GN  Renal  No visceral amyloid 
 
*The final diagnosis in patients who underwent clinical review was established on the basis of a comprehensive clinical assessment, 
biochemical investigations including serum and urine immunofixation, serum free light chains and cardiac biomarkers and specialist imaging 
including SAP scintigraphy, DPD scintigraphy, echocardiography and cardiac magnetic resonance imaging. 
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Table 3.3.  Comparison of Congo red histology and LDMS findings in commoner tissue types 
 
*Percentages are calculated as the percentage of all CR +ve samples (rather than percentage of all CR +ve/ASP +ve samples) 
 
 
 
 
Tissue Type 
 
Number of 
samples 
(N) 
CR +ve 
 
(N) 
CR –ve 
 
(N) 
CR -ve/ASP + ve 
 
(N) 
CR +ve/ASP –ve 
 
(N; %*) 
Definitive typing of 
amyloid by MS 
(N; %*) 
MS non-diagnostic 
of amyloid type 
(N, %*) 
Inadequate 
Sample 
(N; %*) 
Cardiac 126 117 9 0 7 (6) 103 (88) 4 (3) 3 (3) 
Renal 188 170 18 7 12 (7) 139 (82) 18 (11) 1 (1) 
Gastrointestinal 40 40 0 0 0 (0) 38 (95) 2 (5) 0 (0) 
Fat aspirate 25 23 2 0 4 (17) 18 (78) 1 (4) 0 (0) 
Bone marrow 
trephine 
44 40 4 0 4 (10) 30 (75) 4 (10) 2 (5) 
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Typing of amyloid 
Of the 320 samples in which the amyloid fibril protein was determined by IHC, the amyloid 
type by MS concurred in 290/320 (91%), whereas in 30 samples there was a discrepancy 
between the amyloid type identified by IHC and the MS results.  This discrepancy was due to 
absence of ASP (i.e., CR+ve/ASP-ve) by MS in 13/30 (43%) cases and in the remaining 17 
samples, the MS was either non-diagnostic of amyloid type (n=10) or discordant (n=7) 
(Table 3.4).  Of those 7 cases in which the amyloid fibril protein by IHC and MS were 
discordant, 4 were AL lambda sub-type by IHC but AL kappa sub-type by MS.  Two of the 4 
relevant patients had a circulating monoclonal protein, in both cases, of lambda isotype.  The 
amyloid fibril protein was discordant in a further 3/7 samples; 2 were from the same patient 
(renal and testicular biopsy) in which IHC showed AA amyloid and MS showed AApoAI 
amyloid and in whom a novel APOA1 mutation was discovered, and the remaining sample was 
a bladder biopsy in which AL (lambda sub-type) amyloid was identified by IHC and MS 
revealed ATTR amyloid.  This last patient did not undergo clinical evaluation at our centre.   
Of the 320 CR+ve samples in which the amyloid type was not diagnosed by IHC, 
amyloid was identified and typed by MS in 255 (80%) cases but was not definitively typed in 
the remaining 65 cases. In the 255 samples which were inconclusive by IHC but definitely typed 
by MS, the latter correlated with extensive clinical assessment in 252/255 (99%) cases. In the 
remaining 3 cases, tissue was received for a histology review alone such that limited clinical 
details were available. MS established a diagnosis of; AL kappa in 135 cases, AL lambda in 55 
cases, transthyretin (ATTR) in 26 cases, fibrinogen α chain (AFib) in 8 cases, localised 
semenogelin amyloid deposits in 6 cases, immunoglobulin heavy chain (AH) in 6 cases, 
hereditary apolipoprotein AI (AApoAI) in 6 cases, apolipoprotein C2 (AApoC2) in 4 cases, 
apolipoprotein A-IV (AApoAIV) in 4 cases, galectin 7 (cutaneous) amyloid deposits in 3 
cases, insulin derived (AIns) amyloid deposits in one case and isolated atrial amyloidosis 
(IAA) in the final case. 
Of the 65 cases in which the amyloid type could not be determined by MS, 12 samples 
were ‘insufficient for analysis’ by MS, 25 samples were ASP-ve, and 7 contained no known 
  
85 
amyloid fibril protein.  Twenty one samples contained more than one known amyloid fibril 
protein each with a similar Mascot and specific peptide score including 7 cases with both TTR 
and a light chain (either kappa or lambda), and 5 cases with both kappa and lambda light chains. 
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Table 3.4.  Samples in which MS was either non-diagnostic of amyloid type (n=10) or discordant (n=7) with results of IHC 
Sample / 
Patient No 
Age / 
Sex 
Clinical / 
Histology 
review 
Tissue Final Diagnosis* Organ Involvement Systemic clone  
(N/ κ / λ ) 
IHC  MS SAP 
scintigraphy  
1/1 78 M Clinical  Laryngeal Localised AL amyloidosis No vital organ involvement No AL (λ) AL (κ) No visceral 
amyloid 
2/2 65 F Clinical  Lymph node Localised AL amyloidosis No vital organ involvement Lambda AL (λ) AL (κ) No visceral 
amyloid 
3/3 84 F Clinical  Renal  Systemic AL amyloidosis Renal  Lambda AL (λ) Uncertain Isolated renal 
amyloid 
4/4 83 M Histology Cardiac ATTR amyloidosis Cardiac Not known ATTR Uncertain Not done 
5/5 25 F Clinical  Laryngeal Localised AL amyloidosis No vital organ involvement No AL (λ) Uncertain No visceral 
amyloid 
6/6 58 M Histology Renal Amyloid – uncertain type Renal Not known AL (λ) Uncertain Not done 
7/7 64 F Clinical  Breast Localised AL amylodosis No vital organ involvement  No AL (λ) AL (κ) No visceral 
amyloid 
8/8 79 M Clinical  Renal Systemic AL amyloidosis Renal and Liver Lambda AL (λ) Uncertain Amyloid in 
liver and 
kidneys 
9/9 78 M Clinical  Cardiac ATTR amyloidosis Cardiac Kappa ATTR Uncertain No visceral 
amyloid 
10/10 66 M Clinical  Cardiac Systemic AL amyloidosis Renal and autonomic nerve Lambda AL (λ) Uncertain Amyloid in 
liver, spleen 
and kidneys 
11/11 77 M Histology Bladder Amyloid – uncertain type Bladder Not known AL (λ) TTR Not done 
12/12 67 F Clinical  Lymph node Insulin amyloid No vital organ involvement No AIns Uncertain No visceral 
amyloid 
13/13 46 M Histology Testes Amyloid – uncertain type Renal and testicular Not known AA AApoAI Not done 
14/13  As above Renal As above As above As above AA AApoAI As above 
15/14 74 M Clinical  Renal  Systemic AL amyloidosis  Renal Lambda AL (λ) AL (κ) Amyloid in 
spleen and 
kidneys 
16/15 82 F Histology Soft tissue Insulin amyloid Soft tissue Not known AIns Uncertain Not done 
17/16 47 F Clinical Laryngeal Localised AL amyloidosis No vital organ involvement No AL (λ) Uncertain No visceral 
amyloid 
 
*The final diagnosis in patients who underwent clinical review was established on the basis of a comprehensive clinical assessment, biochemical 
investigations including serum and urine immunofixation, serum free light chains and cardiac biomarkers and specialist imaging including SAP 
scintigraphy, DPD scintigraphy, echocardiography and cardiac magnetic resonance imaging. 
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Discussion  
CR staining and IHC remains the most commonly used method for the diagnosis and typing of 
amyloid worldwide, although some specialist centres have recently moved towards the use of 
LDMS alone.(132)  Here we report for the first time a single centre direct comparison of the 
methods, supported where necessary by correlation with specialist clinical and imaging 
assessments, which highlights the advantages and limitations of each method and argues 
strongly in favour of their use as complementary techniques for diagnosis and typing of amyloid. 
Our study showed a high concordance between CR staining and LDMS for the 
identification of amyloid with 94% of CR+ve samples showing amyloid by LDMS and 82% 
CR-ve samples not showing amyloid by LDMS.  Nonetheless, LDMS in our hands failed to 
identify amyloid in a small proportion of cases, even when an adequate quantity of amyloidotic 
tissue was captured, and the reasons for this remain unclear.  It is also worth highlighting that 7 
of 11 CR-ve/ASP+ve were glomerular and that the final diagnosis in 5 of these 7 glomerular 
samples was either fibrillary GN or fibronectin glomerulopathy.  In 2015 the Mayo group 
reported LDMS in a small cohort of MGRS cases which included 7 cases of renal amyloidosis 
and 8 cases of fibrillary GN.  LDMS revealed the presence of 2 or more ASP (SAP and APOE) 
in all amyloidotic samples and presence of only APOE in fibrillary GN.(133)  However, here 
we show that fibrillary GN and other very rare MGRS lesions, can occasionally cause ‘false 
positives’ for amyloid by LDMS.  In the case of fibrillary GN however, the presence of 
glomerular DNAJB9 by MS should alert one to this potential risk.(131) Importantly, there were 
no CR-ve/ASP+ve cardiac, gastrointestinal, fat or bone marrow trephine samples such that the 
finding of ASP, in the absence of CR staining in these tissues, should be considered definitively 
diagnostic of amyloid.   
With respect to typing of amyloid, MS was superior to IHC.  The amyloid type was 
established by MS in 255 (80%) of the 320 cases that were not typed by IHC and in a total of 
545 of 640 (85%) CR+ve samples.  A sub-analysis according to tissue type showed that the 
amyloid type was definitively determined by MS in 95% of gastrointestinal, 88% of 
endomyocardial, 82% of renal, 78% of fat and 75% of bone marrow trephine CR+ve samples 
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(Table 3.3).  However, despite a very high concordance between the amyloid type established 
by MS and that established by IHC, there were occasional discordant results (n=7; 2%) of which 
a proportion appeared to be more consistent with the IHC finding than that by MS, based on 
clinical and biochemical parameters.  In addition, a number of CR+ve samples that were 
definitively typed by IHC did not contain ASP and the amyloid type could not therefore be 
determined by MS.  Further, a small number of cases were not typed by MS due to presence of 
more than one amyloid fibril protein, each with a similar Mascot and specific peptide score.(62)  
It is noteworthy that these cases frequently contained a combination of immunoglobulins and 
transthyretin, both of which are abundant plasma proteins and may therefore be related to 
fixation and processing factors over which specialist referral centers, such as ours, have no 
control.   
Whilst LDMS may successfully determine the amyloid fibril protein from tiny 
quantities of amyloidotic tissue, there are important factors to consider as to whether a sample 
is sufficient for analysis, including the distribution of amyloid deposits within the specimen.  
The challenges of dissecting ‘chicken-wire’ type amyloid deposits has been noted 
previously,(134) and may result in abundance of other proteins within the microdissected 
sample.  In addition, the limitations of amyloid typing by MS on fat samples containing ‘scanty’ 
amyloid deposits has previously been highlighted.(135)  Further work is needed to avoid the 
small proportion of samples that cannot be typed by MS.  To this end, recent work from our 
center has looked at the role of tissue decellularization in samples in which more than one 
potentially amyloidogenic protein is identified.  In a small case series, pre-treatment of tissue 
with decellularization enhanced the specificity of the identification of the correct amyloid fibril 
protein in samples in which more than one protein was detected.(62)   
In 2015, we undertook a smaller collaborative study of a similar nature in which 142 
biopsy samples were stained with CR and IHC at the NAC and processed for LDMS at the Mayo 
Clinic, USA.  The results of this earlier study were remarkably similar to our findings here; there 
was a very high degree of concordance between the two techniques and LDMS enabled typing 
of amyloid in 74% of 34 cases that could not be typed by IHC compared to 80% here.  
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Furthermore, the reasons for the failure of MS to determine the amyloid type in the earlier study 
were listed as insufficient amyloid, insufficient tissue and technical failure,(136) almost 
identical to our findings here.  
Our study’s main limitation is that it is a retrospective analysis of biopsies from a single 
center.  There is, by definition, a selection bias based on the fact that all patients have been 
suspected of having amyloidosis or MGRS by the referring histopathologist or clinician in order 
to reach us in the first place.  Secondly, due to the fact that fixation and processing of tissue 
occurred in the local referring center, this was not controlled for and may have contributed to 
some of the failures of both IHC and LDMS;(116) as a consequence however, our study does 
reflect ‘real-world’ clinical practice.   
In conclusion we show here that presence of ASP on MS is a sensitive and specific 
method for the identification of amyloid deposits but highlight the fact that, particularly in 
glomerular samples from patients with other deposition diseases such as fibrillary GN, the 
presence of ASP may not be due to amyloid.  The addition of LDMS to CR histology and IHC 
markedly increased the proportion of amyloidotic samples in which the amyloid type was 
definitively determined to between 74% and 95%, depending on the biopsy tissue.  Nonetheless, 
challenges remain; namely the occasional detection of more than one potential amyloid fibril 
protein by LDMS and the laser capture and identification of scanty material.  Whilst LDMS 
remains a powerful tool for the diagnosis and typing of amyloid, our experience suggests that it 
should be used in conjunction with comprehensive clinical and histological assessment to ensure 
optimal patient care. 
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Chapter Four: Diagnosis, pathogenesis and outcome in 
Leucocyte chemotactic factor 2 (ALECT2) amyloidosis 
 
 
Introduction 
Renal amyloidosis results from the pathological deposition of amyloid protein fibrils in glomeruli 
and/or renal parenchyma.  The diagnosis of amyloid is based on light microscopy demonstrating 
characteristic green birefringence in affected tissues that have been stained with Congo red and 
viewed under crossed polarized light.  More than 30 different human proteins can form amyloid 
in vivo, which on electron microscopy appears as randomly orientated non-branching fibrils of 7-
12 nm width.  The commonest form of amyloid diagnosed in kidney biopsies is AL type, in which 
the fibrils are derived from monoclonal immunoglobulin light chain.  Some 13 other proteins that can 
deposit as amyloid in the kidneys include serum amyloid A protein (SAA), apolipoproteins A-I, A-II 
and C-III, fibrinogen, lysozyme, gelsolin and transthyretin.(4) 
Leucocyte chemotactic factor 2 (ALECT2) amyloidosis was first described in 2008 in a 61-
year-old woman who had presented seven years earlier with nephrotic syndrome and glomerular 
amyloid deposits and later underwent nephrectomy for clear cell renal carcinoma.(137)  Murphy et al 
subsequently described a series of ten adults with ALECT2 amyloid who presented with varying 
degrees of renal impairment, proteinuria and extensive interstitial and mesangial amyloid deposits.  
Interestingly, all affected individuals were homozygous for the G allele, a polymorphism which 
results in a substitution of isoleucine with valine at position 40 in the mature LECT2 protein.(138)  
Two recent retrospective studies, one from the Mayo Clinic and the other from Nephropath which 
included 72 and 40 patients respectively have established the clinical and pathological characteristics 
and outcomes in renal ALECT2 amyloidosis in the U.S.(139-141)  A retrospective U.S. renal biopsy 
series of 285 samples identified ALECT2 amyloid as the third most common type of renal amyloid 
at 2.5%.(142)  In a retrospective study of 130 cases of hepatic amyloid, the Mayo Clinic investigators 
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identified ALECT2 amyloid in 25% of cases making it the second commonest form of hepatic 
amyloid.(143)  They identified unique pathological and clinical features, including the fact that the 
diagnosis of amyloid was often incidental, starkly contrasting with hepatic AL amyloid in which 
hepatomegaly and liver dysfunction are typical.   
There have been few studies worldwide and none from Europe exploring long term follow up and 
outcome in ALECT2 amyloidosis.  Here we report the prevalence, clinical presentation, diagnostic 
findings and long term outcome among all 24 patients who were diagnosed with ALECT2 
amyloidosis at the UK National Amyloidosis Centre over a 21 year period. 
 
Methods 
 
Patients and Outcomes 
We included in this study all patients with ALECT2 amyloidosis who attended the UK National 
Amyloidosis Centre over a period of greater than 20 years (1994 to 2015).  Nine of 24 patients were 
identified to have ALECT2 amyloidosis retrospectively and the remainder were diagnosed with 
ALECT amyloidosis at the time of diagnosis of amyloid.  Patients attended the NAC for their initial 
diagnostic evaluation and were followed up at regular (usually 12 monthly) intervals.  Investigations 
undertaken at each visit to the centre included detailed blood and urine biochemistry, 
electrocardiography, echocardiography and monitoring of visceral organ involvement as well as 
whole body amyloid load by 123I-SAP scintigraphy.  Additional investigations were undertaken when 
clinically indicated.  All patients were managed in accordance with the declaration of Helsinki and 
informed patient consent and institutional review board approval from the Royal Free Hospital Ethics 
committee were obtained for this study. 
 
Histology and Immunohistochemistry 
Renal (n=20), hepatic (n=4) and rectal (n=1) biopsies were processed, as previously described (one 
patient had both liver and renal biopsies).  Briefly, serial sections were cut from each formalin fixed 
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paraffin embedded block (FFPE).  Amyloid was diagnosed on Congo red staining by apple green 
birefringence when viewed under cross polarized light microscopy.  Paraffin embedded sections of 
2 µm thickness were used for IHC, and sections of 6 µm thickness were used for Congo red and 
IHC/Congo red overlay, as previously decribed.(114)  Immunohistochemical staining of the amyloid 
deposits was performed using an extensive panel of monospecific antibodies reactive with serum 
amyloid A protein (SAA) (Euro Diagnostica AB), kappa and lambda immunoglobulin light chains 
(Dako), apolipoprotein A-I (Genzyme), fibrinogen Aα-chain (Calbiochem®), transthyretin (Dako), 
and LECT2 (R & D Systems).  The goat anti-human LECT2 antibody (cat no AF722), was used at 
1:600 dilution.  Staining specificity was determined by prior absorption of the antiserum with purified 
human protein, in these cases with human LECT2, which resulted in complete abrogation of staining.  
IHC was performed on the Sequenza™ (Fisher Scientific, UK) platform using Impress™ (Vector 
laboratories UK) detection kit following the standard method, with the use of  a metal enhanced DAB 
Substrate kit (Thermo Scientific, UK) for visualizing the immuno compound. All slides were viewed 
on a DM4000 (Leica Microsystems, UK) and were interpreted independently by two experienced 
operators.   
 
Proteomic analysis of amyloidotic tissue 
Laser micro dissection (LMD) followed by liquid chromatography and tandem mass spectrometry 
(MS) (LC-MS/MS) was performed on Congo red-positive glomeruli or renal tubules as previously 
described by Dogan and colleagues.(115)  For comparison, purified human LECT2 protein was 
trypsinized and analyzed by LC-MS/MS on a Velos orbitrap mass spectrometer.  MS data files were 
analyzed using Mascot(144) to search the SwissProt database (SIB Bioinformatics Resource, 
Bethesda, MD).  Searches were conducted based on trypsin as the digestion enzyme and oxidation of 
methionine set as a variable modification; mass tolerances were 10 ppm for precursor ions and 0.60 
Da for fragment ions. 
 
Genetic Analysis 
Genomic DNA was extracted from whole blood treated with EDTA as previously described.(145)  
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Coding regions of the LECT2 gene (NCBI Ref NC_000005.10) were amplified by 
polymerase-chain-reaction assay (PCR) and analyzed by automated sequencing as previously 
described.(137)  PCR products were purified with a QIAquick PCR purification kit (Qiagen) 
according to the manufacturer’s protocol and sequenced with the Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). The electropherograms of the LECT2 gene were analysed on 
the ABI 3130xl Genetic Analyser using Sequencing Analysis Software version 5.4. 
 
123I-Labelled SAP Scintigraphy 
All patients underwent whole body anterior and posterior scintigraphic imaging 24 h after 
administration of 123I-labelled serum amyloid P component (SAP) using a GE Infinia Hawkeye 
gamma camera (GE Healthcare, Iowa, MN), as previously described.(65)  Labelled SAP studies were 
interpreted by a panel of physicians with experience of over 29 000 SAP scans. 
 
Statistical Methods  
Patient survival, time from diagnosis of amyloidosis to end-stage renal disease defined as 
commencement of renal replacement therapy (renal survival) and survival from commencement of 
renal replacement therapy were estimated by Kaplan-Meier analyses.  Censor date was 1st December 
2015.  Rate of decline of renal function was analyzed in those patients who were not requiring renal 
replacement therapy at the time of diagnosis, and was expressed in ml/min/yr. 
 
Results 
 
Patients 
Twenty-four patients were confirmed to have ALECT2 amyloidosis at the UK National Amyloidosis 
Centre (NAC), comprising 0.36% of 6739 patients with amyloidosis and 1.3% of 1853 patients with 
biopsy proven renal amyloid seen at the centre between 1994 and 2015. Of these 24 cases, 9 were 
diagnosed retrospectively after the discovery of ALECT2 amyloidosis in 2008 having previously 
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been classified as amyloid with no immunospecific staining.  Twenty-two patients had a renal 
presentation with proteinuria and/or impaired renal excretory function, including 20 who had been 
referred to the NAC on the basis of amyloid detected in a kidney biopsy.  Four patients had amyloid 
detected on liver histology (including one with established amyloid deposits in the kidneys), 
performed in 3 of the 4 cases to investigate chronic viral hepatitis infection and in the last case as work 
up for peritoneal pseudomyxoma. The diagnosis of ALECT2 amyloidosis was therefore established 
on renal histology in 20 cases, liver histology in 3 cases and on rectal histology in the remaining case 
(Table 4.1). 
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Table 4.1.  Patient demographics in ALECT2 amyloidosis 
No Age at 
diagnosis 
 
Sex 
Ethnic  
Origin 
Histology Hepatitis  
 
B/C 
Serum 
creatinine 
(µmol/L) 
eGFR  
 
(ml/min) 
Proteinuria  
 
(g/24hr) 
SAP 
scintigraphy 
(Liver/Spleen/ 
Kidneys/Adre
nals) 
1 61 M Egyptian Renal and 
hepatic 
C 201 30 0.17 L/S/K 
2 62 M Egyptian Renal -ve 245 24 0.10 L/S 
3 58 F Egyptian Renal -ve 116 44 0.47 L/S/K/A 
4 62 M Egyptian Renal -ve 219 27 0.48 K/A 
5 57 M Egyptian Hepatic -ve 94 76 1.11 L/S/K/A 
6 66 M Indian Renal -ve 379 15 0.90 L/S 
7 37 M Indian Renal -ve 74 110 0.10 Normal 
8 74 M Indian Renal -ve 181 33 0.10 S/K 
9 63 M Indian Renal -ve 156 40 2.52 S/K/A 
10 62 M Indian Renal -ve 239 25 2.98 S/K 
11 68 F Indian - 
Punjabi 
Renal -ve 186 24 2.97 S/K/A 
12 75 F Indian Renal -ve 183 25 0.10 L/S/K/A 
13 69 M Pakistani Renal -ve 178 34 0.10 L/S/K 
14 66 M Pakistani Renal -ve 424 HD 0.12 A 
15 67 F Pakistani Renal -ve 284 15 1.06 S 
16 59 F Pakistani Renal -ve 131 38 0.20 S/K/A 
17 55 M Pakistani Renal -ve 127 53 0.51 S/K 
18 75 M Pakistani - 
Kashmiri 
Hepatic B & C 114 56 0.10 L/S/K/A 
19 70 M Pakistani - 
Punjabi 
Renal -ve 213 20 0.65 S/K 
20 71 F Punjabi Renal B 143 32 1.74 S/K 
21 53 M Sudanese Hepatic C 80 93 0.10 S 
22 54 F Sudanese Renal -ve 562 HD Anuric L/S/K 
23 56 F Mexican Rectal C 57 100 0.10 L/S 
24 73 F Indian Renal -ve 206 21 0.18 L/S/K 
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Median age at diagnosis was 62 years (range 37–75), and male to female ratio was roughly 
equal (14/10).  Notably, 16 (67%) patients were from the Indian subcontinent (India and Pakistan), 7 
(30%) patients were of Middle Eastern ancestry (Egyptian and Sudanese), and one was of Mexican 
origin.  ALECT2 amyloidosis was not diagnosed in any British Caucasians.  Patient demographics at 
diagnosis are shown in Table 4.1.   
Two patients had established ESRD and were receiving renal replacement therapy in the 
form of hemodialysis at the time of diagnosis of ALECT2 amyloidosis.  Neither had presented with 
nephrotic syndrome.  Among the remaining 22 patients who remained dialysis independent at the 
time of diagnosis, median eGFR was 33 ml/min (range 15-110) and median proteinuria was 
0.5 g/24 hr (range 0.1-2.9).   
Liver function tests were entirely normal among 21 patients.  There was mild elevation of 
transaminases (ALT 54 and 73 U/L) in 2 patients and mildly obstructive liver function in a single 
patient as evidenced by an alkaline phosphatase of 150 U/L.  No patient had hyperbilirubinaemia or 
clinical evidence of jaundice.  No patient had clinical, echocardiographic or cardiac biomarker 
evidence of cardiac amyloidosis or clinical evidence of amyloid peripheral or autonomic neuropathy.  
None of the 24 patients had evidence of a monoclonal gammopathy.  Four patients had a 
concurrent diagnosis of type 2 diabetes mellitus. 
 
Histology 
Renal histology revealed amyloid throughout the kidneys, often with bright congophilia and ‘sparkly 
glistening’ apple green birefringence when viewed under crossed polarized light.  Liver histology 
revealed amyloid deposits with a similar ‘sparkly glistening’ appearance under crossed polarized 
light.   
Among 20 patients who underwent renal biopsies, the vast majority (85%) had amyloid in 
the renal cortical interstitium which was sometimes extensive and often associated with tubular 
atrophy.  Amyloid deposits were identified in the tubular basement membranes in approximately one 
third of renal biopsies and in the vessel walls in two thirds (Table 4.2).  Glomerular amyloid was 
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present in more than 70% of renal biopsies, and was associated with mesangial matrix expansion 
which was usually diffuse and global (Figure 4.1A and 4.1B).  Typically, a proportion of biopsied 
glomeruli were globally sclerosed.  The burden of amyloid within each compartment of the kidney 
varied substantially between patients, and apart from the extensive interstitial amyloid observed in 
some patients, there was no ‘characteristic’ pattern of deposition or apparent relationship between 
ethnicity and localization of renal amyloid deposits.   
 
Table 4.2 Renal histology in relation to clinical presentation in ALECT2 amyloidosis 
 
Patient  
Number 
Interstitial  
Amyloid 
(+/-) 
 
 
 
Glomerular  
Amyloid 
(+/-) 
 
 
 
Tubular  
Amyloid 
(+/-) 
 
 
 
Vascular  
Amyloid 
(+/-) 
 
 
 
Diabetes 
(Y/N) 
 
 
eGFR 
(ml/min) 
 
 
24 
urinary  
protein 
loss 
(g/24hr) 
Hypertension 
(Y/N) 
 
1 + - - - 0 30 0.17 N 
2 + + - - 0 24 0.10 N 
3 + + - + 0 44 0.47 N 
4 + - + - 0 27 0.48 N 
6 + + + + 0 15 0.90 Y 
7 + - - + 0 110 0.10 N 
8 + + - + 0 33 0.10 N 
9 - + + + 0 40 2.52 Y 
10 + - - + 1 25 2.98 N 
11 - + + + 1 24 2.97 Y 
12 - - - + 0 25 0.10 Y 
13 + + - + 0 34 0.10 N 
14 + + - + 1 HD 0.12 N 
15 + + - + 0 15 1.06 Y 
16 + + - + 0 38 0.20 Y 
17 + + - - 0 53 0.51 N 
19 + + - - 0 20 0.65 Y 
20 + + - - 0 32 1.74 Y 
22 + + - + 0 HD Anuric Y 
24 + + + + 1 21 0.18 N 
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Liver histology revealed amyloid deposits in vessel walls and globular deposits in the portal tracts 
(Figure 4.1D and 4.1E).  Gastrointestinal histology showed amyloid in the submucosa.  The amyloid 
stained specifically with anti-LECT2 antibody in every case (Figure 4.1C and 4.1F). 
Figure 4.1 Histology in ALECT2 amyloidosis:  
 
 
A)  Congo red staining of a renal biopsy specimen showing amyloid in all renal compartments 
including the glomeruli, renal tubules, vessels and interstitium.  B)  Apple green birefringence when 
viewed under cross polarized light. C)  Immunohistochemical staining with an antibody against 
LECT2 showing specific staining of the amyloid which is completely abrogated by prior absorption 
of the antibody with purified LECT2.  D)  Congo red staining of a liver biopsy specimen viewed 
under Brightfield light showing amyloid in vessels and portal tract. E)  Characteristic 
immunofluorescence of amyloid after Congo red staining and F) Immunohistochemical staining with 
an antibody against LECT2 showing specific staining of the amyloid. 
 
Proteomic Analyses 
Proteomic analysis of the excised amyloid was performed in 14/24 samples.  LECT2 was identified 
in 12/14 cases; there was insufficient material for valid interpretation of proteomic results in the two 
negative cases, each of which had <30 proteins identified in the sample (both of whom were 
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diagnosed on the basis of immunohistochemistry).  A positive control sample of authentic LECT2 
treated in the same way as the patient samples identified LECT2 with 95% protein coverage.   
 
Genetic Analyses 
All patients underwent genetic analysis and all except one affected individual were found to be 
homozygous for the G allele, a polymorphism which results in a substitution of isoleucine with valine 
at position 40 in the mature protein.  The remaining affected individual was heterozygous for the G 
allele, which as far as the authors are aware, is the first report of ALECT2 amyloidosis in a patient 
who is heterozygous for this allele.   
 
123I-Labelled SAP Scintigraphy 
SAP scintigraphy at diagnosis showed extra-renal amyloid deposits in most patients; 21/24 (88%) 
had splenic amyloid, 11/24 (46%) had hepatic amyloid and 9/24 (38%) had adrenal gland 
involvement by amyloid despite preserved adrenocortical function in every case.  The adrenal glands 
were masked by heavy overlying liver and spleen amyloid deposits in 8 of the 15 remaining cases.  
Serial SAP scintigraphy, with an interval between the diagnostic and latest scan of up to 10 years, 
revealed little change in total body amyloid burden.  There was no evidence of amyloid regression 
from any organ in any patient but, interestingly and uncharacteristically for untreated systemic 
amyloidosis, nor was there evidence of accumulation of amyloid within the liver, kidneys or spleen 
over prolonged periods (Figure 4.2)   
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Figure 4.2: Serial SAP scintigraphy in ALECT2 amyloidosis.  SAP anterior whole body SAP 
scans, taken 10 years apart, in a patient with ALECT2 amyloidosis showing absence of amyloid 
accumulation in the liver or spleen over this time period.   
 
 
 
 
 
Renal and Patient Outcomes 
Median follow up in the whole cohort was 4.8 years (range 0.5–15.2).  During this time, 4 patients 
died.  The cause of death was known in 3 cases who died from bronchopneumonia, cardiac arrest 
secondary to underlying ischaemic heart disease (IHD), and ‘pump failure’ secondary to aortic 
stenosis respectively.  Median age at death was 74 years (range 63–77).  Median estimated patient 
survival from diagnosis of ALECT2 amyloidosis was 15.1 years (Figure 4.3a).   
Among 22 patients who were dialysis independent at diagnosis, mean rate of GFR loss was 
4.2 ml/min/yr (range 0.5-9.6).  Four patients progressed to ESRD during follow up.  Median estimated 
time from diagnosis to ESRD by Kaplan Meier analysis among those 22 patients was 8.2 years 
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(Figure 4.3b).  Proteinuria remained sub-nephrotic and serum albumin remained within the normal 
range in all patients throughout follow up.  Indeed there was no significant change in proteinuria over 
time among most patients (mean change <0.1 g/24hr/yr). 
 
 
 
 
Figure 4.3a: Outcome in ALECT2 amyloidosis.  a)  Patient survival in ALECT2 amyloidosis by 
Kaplan Meier analysis.  Median estimated survival was 15.2 years. 
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Figure 4.3b:  Outcome in ALECT2 amyloidosis.   b)  Renal survival, defined as time from diagnosis 
to renal replacement therapy, in ALECT2 amyloidosis in comparison to other untreated renal 
amyloidoses including AApoAI, ALys, and AFib amyloidosis. 
 
 
 
 
Discussion 
 
LECT2 was reported to be a new amyloid fibril protein by Benson and colleagues in 2008 following 
discovery of unanticipated amyloid within a nephrectomy specimen from an individual with co-
existing clear cell renal carcinoma.(137)  LECT2 is a 16 kDa protein consisting of 151 amino acids, 
including an 18 amino acid signal peptide.  The amyloidogenic fibril protein in ALECT2 amyloidosis 
is composed of the entire 133-residue peptide.  Although there is no mutation in the LECT2 gene 
associated with ALECT2 amyloidosis, nearly all affected individuals in our series, including two 
affected first degree relatives, were found to be homozygous for the G allele, a polymorphism which 
results in a substitution of isoleucine with valine at position 40 in the mature protein, consistent with 
previous reports.(137)  The G/G genotype has an overall frequency of 0.477 and in subjects of 
European descent it is found at a frequency range of 0.6-0.7,(137) although the frequency of this 
polymorphism in the studied population is unknown.  Murphy et al described a clear ethnic 
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distribution in their case series of ten patients with ALECT2 amyloidosis; 7 of the 10 patients were of 
Mexican American origin,(138) a finding corroborated by the Nephropath investigators who found 
that the majority of patients with ALECT2 amyloidosis were of Hispanic origin.(146)  A recent 
biopsy series revealed ALECT2 amyloid to be the second commonest type of renal amyloid in Egypt, 
accounting for almost one third of cases.(147)  Our cohort of 24 patients further supports an ethnic 
bias but includes individuals from the Indian Subcontinent and Egypt/Sudan as well as Hispanics, 
corroborating the recent findings of Larson et al.(146) 
The aetio-pathogenetic mechanisms underlying ALECT2 amyloid formation require further 
evaluation.  LECT2 is mostly produced by the liver and is known to be a chemotactic factor to 
neutrophils while it also stimulates the growth of chondrocytes and osteoblasts.(148)  Lin Bin et al 
identified LECT2 as an acute phase reactant with a high level of induction upon infection,(149) and 
it appears to play a role in liver regeneration.(150)  One might speculate therefore, that LECT2 is an 
acute phase reactant that is specifically triggered by a chronic hepatic infection or chronic hepatic 
inflammation and that the combination of the G/G genotype and excessive production of LECT2 by 
the liver predispose to development of amyloid.  Other proposed mechanisms for ALECT2 
amyloidosis included interference in the catabolic or transport pathways of LECT2 resulting in an 
increased local tissue concentration or alterations in a binding partner of the LECT2 protein in the 
serum resulting in increased free circulating LECT2 levels.(141)  Due to the absence of a 
commercially available LECT2 assay, we were unable to measure plasma LECT2 concentration 
among our patient cohort in order to further explore these possibilities.   
The vast majority of patients diagnosed with ALECT2 amyloidosis had a renal presentation 
characterized by low level proteinuria and a reduced GFR.  Given the frequent (>70%) glomerular 
involvement by amyloid in this cohort, the absence of heavy proteinuria is surprising, and contrasts 
other types of renal amyloid in which the glomeruli are involved which are typically characterized by 
the nephrotic syndrome.  Around half of patients with ALECT2 amyloidosis had evidence of liver 
involvement by SAP scintigraphy but liver synthetic function was preserved in every case and liver 
function abnormalities were absent or mild, consistent with previous reports.(139)  Three patients 
were diagnosed on liver histology, prompted in each case by another potential cause of liver 
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dysfunction; presence of amyloid may have been incidental to the dysfunction since amyloid deposits 
were frequently present among those without derangement of liver function.  No patient had cardiac 
amyloidosis at diagnosis and clinically significant pulmonary or neural amyloid was not observed.   
Staining of formalin fixed paraffin embedded renal and liver sections with an anti-LECT2 
antibody was unequivocally diagnostic in every case.  There was no background or non-specific 
staining of the sections, and the amyloid deposits were avidly and specifically stained by the antibody 
in both tissues.  The immunohistochemistry was corroborated by proteomic analysis of amyloid 
whenever this was undertaken on adequate samples.  The authors would therefore recommend that 
tissue from all cases of suspected ALECT2 amyloidosis is stained immunohistochemically and/or 
analyzed by tandem mass spectrometry. 
Despite absence of amyloid-specific therapy for ALECT2 amyloidosis, its natural history, 
described here in detail for the first time, is slow.  Mean rate of GFR loss was 4.2 mls/min/year 
contrasting the typical decline in other types of renal amyloidosis (Table 4.3), such as untreated renal 
AL amyloidosis in which median time from diagnosis to ESRD is only about 12 months;(151) only 
6 patients in the whole cohort reached ESRD despite prolonged follow up.  Serial SAP scans, 
performed up to a decade apart, revealed absence of amyloid accumulation and similarly, no patient 
developed cardiac or neuropathic amyloid during follow up.  Consequently, median estimated patient 
survival from diagnosis was more than 15 years.   
Given the discrepancy between the clinical and histological prevalence of ALECT2 amyloid 
and the often insidious nature of its clinical manifestations, (142) the true prevalence of this type of 
amyloid may be greater than is currently recognized.  Since promising novel therapies to remove 
existing amyloid deposits are now under development,(25) the diagnosis of ALECT2 amyloidosis 
ought to be considered in any non-Caucasian patient with renal amyloid deposits who has low level 
proteinuria, even when a monoclonal protein is present.   
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Table 4.3.  Comparison of rate of GFR loss in ALECT2 amyloidosis and hereditary renal 
amyloidosis 
 
Type of Amyloid Number Mean eGFR loss per year 
ml/min/year 
Leucocyte chemotactic factor 2 
amyloidosis (ALECT2) 
22 4.2 
Lysozyme (ALys) 7 4.7 
Apolipoprotein A-1 (AApoAI) 24 6.2 
Fibrinogen A α-chain (AFib) 23 11.5(46) 
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Chapter Five: Prolonged renal survival in light chain 
amyloidosis: speed and magnitude of light chain 
reduction is the crucial factor. 
 
Introduction 
 
The amyloidoses are disorders of protein folding, in which a variety of proteins misfold and 
aggregate into amyloid fibrils that accumulate in tissues and disrupt organ function.(152)  
Immunoglobulin light chain (AL) amyloidosis is caused by deposition of fibrils derived from 
monoclonal immunoglobulin light chains and is the most common and serious type of systemic 
amyloidosis.(5)  Renal involvement is present in approximately 70% of patients with systemic 
AL amyloidosis at diagnosis, manifesting with nephrotic syndrome and progressive renal 
impairment.(101)  Progression to end-stage renal disease (ESRD) is one of the main determinants 
of morbidity in AL amyloidosis,(153) whilst presence and severity of cardiac amyloidosis is the 
main determinant of mortality.(67, 68) 
Response to chemotherapy has been shown to be strongly and independently associated 
with both patient survival(101) and renal outcomes in patients with AL amyloidosis.(130, 154)  
Other factors associated with poor renal outcomes in those with renal AL amyloidosis include a 
low GFR and heavy proteinuria at diagnosis.(130, 155)  However, there are no data on whether 
chemotherapy can delay onset of renal replacement therapy in patients with AL amyloidosis who 
present with established advanced CKD and whether speed of clonal response influences renal 
outcome. 
The AL Amyloidosis Chemotherapy study (ALchemy) is a comprehensive prospective 
observational study opened in 2009 into which all patients newly diagnosed with AL amyloidosis 
at the UK National Amyloidosis Centre (NAC) are invited to participate.  We report here the renal 
and patient outcomes among all participants in ALchemy who had advanced CKD at the time of 
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diagnosis (and entry to study) between 2009 and 2015 in relation to the speed and depth of the 
hematologic response to chemotherapy.   
 
Patients and Methods 
Patients  
At the time of censor, 1000 patients with newly diagnosed AL amyloidosis had been enrolled into 
the ALchemy prospective observational study at the National Amyloidosis Centre (NAC).  Renal 
involvement, defined as non-Bence Jones proteinuria of more than 0.5g/24 hr according to the 
amyloidosis international consensus criteria,(69) was present in 672 patients, of whom 84 had 
presented with advanced renal impairment defined by eGFR <20 ml/min/1.73 m2.  The analyses 
presented in this manuscript concern this cohort of 84 patients with eGFR <20 ml/min/1.73 m2 at 
baseline (Figure 5.1; Consort Diagram).   
All patients underwent protocolized assessments every 3-6 months at the NAC, each 
assessment comprising clinical evaluation, serum and urine biochemistry including assessment of 
renal and liver function, N-terminal pro-b-type natriuretic peptide (NT-proBNP), 
echocardiography, SAP scintigraphy,(65) and assessment of hematological disease by serum free 
light chain (FLC) assay, serum and urine immunofixation electrophoresis.  The presence of 
cardiac amyloidosis was defined by echocardiography according to international consensus 
criteria,(69) or in cases in which there was doubt, by additional cardiac magnetic resonance 
imaging on the basis of native T1 and/or extracellular volume measurement, as previously 
reported.(156, 157) 
All patients were managed in accordance with the Declaration of Helsinki and provided 
written informed consent for study entry (REC reference 09/H0715/58) and publication of their 
data. 
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Renal Histology 
Renal biopsies were performed in 57 of 84 patients.  All biopsies were routinely stained with 
Congo red and a panel of amyloid-fibril antibodies, as previously described.(114)  Additionally, 
all biopsies containing sufficient cortical tissue for evaluation (n=49/57) were analysed by a renal 
histopathologist (PB) and assigned an ‘Index of Chronic damage’ category of mild, moderate or 
severe according to the previously described Modified Oxford Score.(158)  
 
Figure 5.1 Consort Diagram showing selection of patients from the prospective UK AL 
chemotherapy study (ALchemy) for analyses.  Patients in shaded boxes were excluded 
from analyses of renal survival. 
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Assessment of Hematologic Response 
Details and doses of chemotherapy regimens were collected.  All patients had serial FLC 
concentration prospectively monitored on blood samples scheduled monthly during periods of 
chemotherapy treatment, and every 1-3 months during subsequent follow up.  Healthy polyclonal 
serum FLC concentrations increase progressively through advancing stages of chronic kidney 
disease (CKD)(122) which hinders the monitoring of monoclonal light chain disorders.  In this 
study, the value of the FLC monoclonal component was estimated by subtracting the 
concentration of the uninvolved light chain from that of the amyloidogenic light chain to obtain 
the FLC difference (dFLC), a strategy previously validated in multiple myeloma and AL 
amyloidosis.(123, 130)   
The FLC response to chemotherapy was determined according to previously validated 
‘consensus criteria’(159) and additionally, by the percentage of the baseline dFLC that remained 
at the time of analysis (percentage method), also validated in AL amyloidosis.(130)  The 
consensus criteria define ‘evaluable’ patients as those with a pre-treatment (baseline) dFLC of 
>50 mg/L, and thus excluded 10/84 (12%) patients in the cohort, whereas the calculation of the 
percentage baseline dFLC remaining after chemotherapy can be applied to patients with low level 
pre-treatment amyloidogenic light chain concentration.  A very good partial response (VGPR) 
was defined according to the consensus criteria as an absolute dFLC of <40mg/L, and by the 
percentage method as a ≥90% reduction of pre-treatment dFLC remaining after chemotherapy, as 
previously described.(130)  When assessing dFLC response, all patients without an FLC assay at 
the relevant timepoint were excluded from analysis.   
 
Patient Outcomes  
Overall survival was defined as the time from baseline evaluation at the NAC to patient death and 
was evaluated in all 84 patients.  Renal survival was defined as the time from baseline evaluation 
at the NAC to requirement for renal replacement therapy (RRT).  For the analyses of renal 
survival, patients who were already established on RRT (n=16) at the time of their baseline 
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evaluation were excluded, and those who died without requiring RRT were censored at the time 
of death.  For analyses of time to the composite endpoint of death or dialysis, patients who were 
on RRT at baseline were excluded and an event was recorded as the first of either death or dialysis.  
Patient follow up was censored on 1st October 2015. 
 
Statistical Analysis 
Survival analysis was performed separately for each of three possible endpoints: patient survival, 
renal survival, and survival to composite endpoint of dialysis or death. We determined Kaplan-
Meier curves, and performed the log rank test to compare the overall survival curves for different 
subgroups.  Cox proportional hazards regression analysis was used to investigate the factors 
independently associated with a particular endpoint. A test based on Schoenfeld residuals was 
used to test the proportional hazards assumption underlying the log rank and the Cox regression 
analyses. Analyses were performed using GraphPad Prism v5.03, IBM SPSS Statistics 23 and 
Stata 14 software. A significance level of 0.05 was used for all hypothesis tests.   
 
Results 
Baseline Characteristics and Patient Survival 
Baseline demographics and clinical characteristics of all 84 patients are listed in Table 5.1. The 
cohort was followed for a median of 16.3 months (range 0.4-68.0) from baseline.  Forty five of 
84 patients had ‘renal isolated’ involvement and 39 had evidence of both cardiac and renal 
involvement (Figure 5.1).  Fifty-seven of 84 patients had renal histology performed and all 
biopsies showed extensive renal infiltration by amyloid; the only other notable pathology being 
hypertensive arteriosclerosis in 2 cases.  Median age at diagnosis in the whole cohort was 68 years 
with an almost equal male to female ratio.  Median eGFR was 10 ml/min/1.73 m2 with a median 
24 hour urinary protein leak of 6.2 grams.  Serum albumin was modestly reduced with a median 
of 31 g/L despite substantial proteinuria in the majority of cases.  Median NT-proBNP was 
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550 pMol/L with 32 patients having a concentration >1000 pMol/L (i.e., Mayo stage 3b 
disease).(68)   
A total of 47/84 (56%) patients from the whole cohort died with median time from 
baseline to death by Kaplan Meier analysis of 25.2 months (CI 9.4-41.1).  Thirty of 39 patients 
with cardio-renal syndrome (due to cardiac and renal involvement by amyloid) died and 17 of 45 
patients with ‘renal isolated’ amyloidosis died.  Median overall survival was significantly longer 
(49.2 months [CI 34.5-undefined]) among those with ‘renal isolated’ amyloidosis compared to 
those with cardio-renal syndrome (8.4 months [CI 4.7-22.9], p<0.001) (Figure 5.2).  Cause of 
death among those with cardio-renal syndrome was invariably from progressive cardiac 
amyloidosis, and in those with renal isolated amyloidosis, was from ‘progressive amyloidosis’ in 
9 cases, and from sepsis, cerebrovascular accident, and incarcerated femoral hernia in one case 
each.  In 5 cases the cause of death was unknown. 
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Table 5.1.  Baseline demographics of all patients 
Demographic or clinical characteristic No. of Patients 
(N =84) 
% 
Male sex 
Female sex 
49 
35 
58 
42 
Age years     Median 
     Range 
68 
40-86 
 
Patients with isolated renal involvement 
 
45 54 
Patients presenting on RRT 
 
16 19 
Index of Chronic Damage on renal histology Mild 
      Moderate 
      Severe 
4/49 
11/49 
34/49 
8 
22 
69 
eGFR (ml/min/1.73 m2)    Median 
      Range 
10 
10-19 
 
Amyloid load by SAP scintigraphy  Small 
     Moderate 
     Large 
27 
19 
38 
32 
23 
45 
Serum albumin (g/L)    Median 
     Range 
31 
14-48 
 
24hr urinary protein loss (g)   Median 
     Range 
6.2 
0.1-29.7 
 
NT-proBNP (pMol/L)    Median 
     Range 
550 
15-8270 
 
Troponin T (ng/L)                                           Median  
                                                                         Range 
120 
10-1870 
 
Amyloidogenic light chain (n)   Lambda 
      Kappa 
55 
29 
65 
35 
Haemoglobin (g/dL)    Median 
     Range 
11.3 
7.8-17 
 
Serum creatinine (µmol/L)   Median  
      Range 
375 
228-979 
 
Bilirubin (µmol/L)    Median 
     Range 
5 
1-59 
 
Alkaline Phosphatase (u/L)   Median 
      Range 
108 
43-1703 
 
Supine systolic blood pressure   Median 
     Range 
137 
79-184 
 
Standing systolic blood pressure   Median 
     Range 
129 
63-180 
 
Bone Marrow Plasmacytosis (%)  Median 
      Range 
7 
0-30 
 
Bence Jones Protein (n)    Present 
      Absent 
44 
40 
 
λ sFLC in AL (lambda) patients (mg/L)  Median 
     Range 
241 
14-5820 
 
Κ sFLC  in AL (kappa) patients (mg/L)  Median 
     Range 
431 
56-10300 
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Figure 5.2.  Patient survival calculated by Kaplan Meier analysis in all evaluable patients 
with renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at presentation.  Survival 
among those with ‘renal isolated’ amyloidosis was significantly longer (median 49.2 
months) than in those with both cardiac and renal (cardio-renal) involvement (median 8.4 
months) (p<0.001).  Number at risk at certain timepoints is shown in panel below graph.   
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Chemotherapy 
Chemotherapy was planned in all 84 cases, but was actually administered to 78 patients.  Reasons 
for non-administration of chemotherapy were patient death from progressive amyloidosis in 4/6 
patients, and dialysis-dependence in 2 patients who did not have significant extra-renal amyloid.  
Among those who did receive chemotherapy, 43 (55%) received bortezomib-based regimens first 
line, 22 (28%) received thalidomide-based regimens first line, and 13 (17%) received a first line 
regimen containing neither bortezomib nor thalidomide.  Median (range) number of 
chemotherapy cycles administered first line was 4 (1-8) for each of bortezomib-based, 
thalidomide-based and non-bortezomib, non-thalidomide containing regimens.  No patient 
discontinued bortezomib therapy, but 1 patient discontinued thalidomide, and 1 patient 
discontinued non-bortezomib, non-thalidomide chemotherapy due to toxicity.  As-treated analysis 
of the 78 patients who received chemotherapy showed a dFLC response at 3 months of ≥90% in 
15/43 (34%) who received bortezomib compared to 4/22 (18%) who received thalidomide 
(bortezomib vs thalidomide, p=0.09, Fisher’s exact test) and 2/13 (15%) who received neither 
drug first line (bortezomib vs neither bortezomib nor thalidomide, p=0.12, Fisher’s exact test).   
 
Overall survival (OS) in relation to response to chemotherapy 
Seventy-four patients were evaluable for dFLC response by consensus criteria (i.e., had a dFLC 
at baseline of >50mg/L). Of those 74 patients, 15 did not have a dFLC measurement at 3 months, 
in 11 cases due to prior death, and were therefore excluded from the analysis of survival in relation 
to hematologic response at this timepoint.  Of the 11 patients who died, 6 did so before receiving 
chemotherapy, 4 died from progressive amyloidosis and one died from chemotherapy-related 
complications (sepsis).  There was no significant difference in overall survival between 26 
evaluable patients who achieved a dFLC of <40mg/L within 3 months of baseline (median 
49.2 months [CI 25.0–undefined]) and 33 evaluable patients who achieved lesser degrees of 
clonal response at the same timepoint (median 37.4 months [CI 11.3–undefined]) (log rank test, 
p=0.40) (Figure 5.3a).  Using the ‘percentage of baseline dFLC’ method to calculate hematologic 
response enabled all patients to be considered ‘evaluable’ at baseline although, as described 
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above, the 15 patients who did not have a dFLC measurement at 3 months were again excluded 
from this analysis.  Median overall survival among 21 evaluable patients who achieved a dFLC 
response of ≥90% within 3 months of baseline was undefined compared to 31.8 months (CI 15.7–
55.1) among 48 patients who achieved lesser degrees of clonal response at the same timepoint 
(log rank test, p=0.02) (Figure 5.3b).  There was no significant difference in overall survival 
between those patients who achieved a <50% dFLC response at 3 months and those who achieved 
a dFLC response of 50-89% (log rank test, p=0.09) (Figure 5.3c).  
  
  
116 
Figure 5.3.  Patient survival calculated by Kaplan Meier analysis in all evaluable patients with 
renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at presentation.  A)  Patients were stratified 
according to degree of clonal response at 3 months into absolute dFLC <40 mg/L and ≥40 mg/L 
(p=0.40).  B)  Patients were stratified according to degree of clonal response at 3 months into 
dFLC response ≥90% and dFLC response <90% (p=0.02).  C)  Patients were stratified according 
to degree of clonal response at 3 months into dFLC response of <50% and 50-89% (p=0.09).  
Number at risk at certain timepoints is shown in panel below graph.   
Figure 5.3a 
 
Figure 5.3b  
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Figure 5.3c 
By Cox regression analysis, independent factors associated with death in the whole cohort 
of 84 patients were elevated NT-proBNP at presentation (HR 2.72 [CI 1.451-5.088], p=0.002) 
and achieving a dLFC response ≥90% at 3 months (HR 0.36 [CI 0.138-0.935], p=0.036).  
Percentage dFLC response was also highly significant when incorporated as a continuous variable 
(HR 0.980 [CI 0.968-0.992], p=0.001) 
 
Renal survival in relation to response to chemotherapy 
Among 68 patients who were dialysis-independent at baseline and therefore evaluable for 
analyses of renal survival, there were 46 patients who were evaluable for hematologic response 
at 3 months according to consensus criteria.  Among 22/46 who achieved an absolute dFLC of 
<40mg/L within 3 months of baseline, median time to dialysis dependence was 9.7 months (CI 
3.4–undefined) compared to 5.2 months (CI 1.9-17.1) among 24/46 patients who achieved lesser 
degrees of clonal response at the same timepoint (log rank test p=0.18) (Figure 5.4a).  Using the 
‘percentage of baseline dFLC’ method to calculate hematologic response, there were 56 patients 
who were evaluable for hematologic response at 3 months.  Median renal survival among 18/56 
patients who achieved a dFLC response of ≥90% within 3 months of baseline was 23.0 months 
(CI 9.7–undefined) compared to 6.1 months (CI 3.4-12.5) among 38/56 patients who achieved 
lesser degrees of clonal response at the same timepoint (log rank test, p=0.003) (Figure 5.4b).  
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Renal outcomes were equally poor among those who achieved a delayed ≥90% dFLC response, 
classified as only after 6 months from baseline (n=5) or only after 12 months from baseline (n=6) 
(dFLC response ≥90% within 3 months vs 6 months (log rank test, p=0.001) or vs 12 months (log 
rank test, p<0.003) (Figure 5.4c).   
 
Figure 5.4.  Renal survival calculated by Kaplan Meier analysis in all evaluable patients with 
renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at presentation.  A)  Patients were stratified 
according to degree of clonal response at 3 months into absolute dFLC <40 mg/L and ≥40 mg/L 
(p=0.18).  B)  Patients were stratified according to degree of clonal response at 3 months into 
dFLC response ≥90% and dFLC response <90% (p=0.003).  C)  Patients were stratified according 
to speed of clonal response comparing those who achieved a dFLC ≥90% within 3 months of 
baseline with those who achieved an equally good dFLC response, but only after 12 months 
(p<0.003).  Number at risk at certain timepoints is shown in panel below graph.   
Figure 5.4a 
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Figure 5.4b 
Figure 5.4c  
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By Cox regression analysis, the only independent factor associated with a requirement 
for RRT among the 68 patients who were dialysis independent at baseline was achieving a dFLC 
response of ≥90% within 3 months (HR 0.24 [CI 0.106-0.547], p=0.001) (Table 5.2). Percentage 
dFLC response at 3 months was also significant when incorporated as a continuous variable (HR 
0.978 [CI 0.958-0.998], p=0.031). Interestingly, presenting eGFR, presenting NT-proBNP, and 
proteinuria at presentation did not predict progression to dialysis.  Furthermore, stratification of 
patients by index of chronic damage on renal histology was not predictive of progression to 
dialysis, although it should be noted that the vast majority of patients had moderate or severe 
chronic damage on renal biopsy (Table 5.1).   
 
Table 5.2.  Independent risk factors associated with dialysis 
Variables 
 
Estimated 
Hazard Ratio  
95% Confidence 
Interval 
p value 
 
dFLC ≥90% at 3 months 
 
0.24 
 
0.106 - 0.547 
 
0.001 
Log NT-proBNP 1.35 0.773 – 2.369 0.289 
eGFR  0.97 0.878 – 1.068 0.564 
Proteinuria 1.01 0.961 – 1.054 0.618 
 
Forty-five of 84 patients from the whole cohort had renal amyloidosis in the absence of 
cardiac involvement and were defined as ‘renal isolated.’  Nine such patients were on RRT at 
baseline and 2 died before the 3 month evaluation.  In light of our previous results, the remaining 
34 ‘evaluable’ patients were stratified using the ‘percentage of baseline dFLC’ method to ≥90% 
or <90% dFLC response within 3 months of baseline.  Median renal survival among 11 patients 
who achieved a dFLC response of ≥90% within 3 months of baseline was 23.0 months (CI 7.3–
undefined) compared to only 6.2 months (CI 3.0–12.5) among 23 patients who achieved lesser 
degrees of clonal response at the same timepoint (log rank test, p<0.007) (Figure 5.5), and 5.7 
months (CI 1.9-undefined) among those who achieved a ≥90% dFLC response, but only after 12 
months from baseline (log rank test, p<0.03).  There was no significant difference in renal survival 
between those who achieved a dFLC response within 3 months of 50-89% compared to a dFLC 
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response of <50% (log rank test, p=0.83).  By Cox regression analysis, the only independent factor 
associated with a requirement for RRT in the 45 patients with ‘renal isolated’ amyloidosis was 
achieving a dFLC response of ≥90% at 3 months (HR 0.62 [CI 0.057-0.655], p=0.008).  
 
Figure 5.5.  Renal survival calculated by Kaplan Meir analysis in evaluable patients with ‘renal 
isolated’ AL amyloidosis and eGFR <20ml/min/1.73 m2 at presentation.  Patients were stratified 
according to degree of clonal response at 3 months into dFLC response ≥90% and dFLC response 
<90% (p<0.007).  Number at risk at certain timepoints is shown in panel below graph. 
Figure 5.5 
 
Time to composite endpoint of death or dialysis in relation to response to 
chemotherapy 
Sixteen patients, who were dialysis dependent at baseline, were excluded from all analyses of 
time to the composite endpoint of death or dialysis.  Twelve patients did not have an FLC assay 
measured at 3 months from baseline, in 10 cases due to death.  Of the 10 patients who died, 4 died 
before receiving chemotherapy, 5 died during chemotherapy from progression of their systemic 
amyloidosis and 1 died from chemotherapy-related complications (sepsis).  The remaining 56 
patients were stratified according to dFLC response of <90% or ≥90% at 3 months.  Among 18 
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patients who achieved a ≥90% dFLC response, median time to composite endpoint of death or 
dialysis was 17.3 months (CI 7.3-46.1) compared to 5.3 months (CI 3.4-7.6) among 38 patients 
who achieved a <90% response (log rank test, p<0.001) (Figure 5.6).  The first event was death 
in 9 patients and dialysis in 27 patients.  There was no significant difference in median time to 
death or dialysis between those patients who achieved a <50% dFLC response at 3 months and 
those who achieved a dFLC response of 50-89% (log rank test, p=0.53).  
 
Figure 5.6  Time to composite endpoint of death or dialysis calculated by Kaplan Meier analysis 
in all evaluable patients with renal AL amyloidosis and eGFR <20 ml/min/1.73 m2 at 
presentation, stratified according to degree of clonal response at 3 months into dFLC response 
≥90% and dFLC response <90% (p<0.001).  Number at risk at certain timepoints is shown in 
panel below graph.   
 
 
 Figure 5.6 
By Cox regression analysis, independent factors significantly associated with the 
composite endpoint of death or dialysis among all 68 patients who were dialysis 
independent at baseline were elevated NT-proBNP at presentation (HR 2.40 [CI 1.293-
4.463], p=0.006) and achieving a dFLC response ≥90% at 3 months (HR 0.23 [CI 0.102-
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0.505], p<0.001). Percentage dFLC response was also highly significant when 
incorporated as a continuous variable (HR 0.981 [CI 0.971-0.992], p=0.001)(Table 5.3). 
Neither presenting eGFR, nor proteinuria at presentation were significant predictors of 
the composite endpoint.  Due to the high clonal response rates observed with bortezomib, 
a multivariable model in which dFLC response at 3 months of <90% or ≥90% was 
replaced by bortezomib vs no bortezomib was undertaken.  The only factor independently 
associated with the same composite endpoint in this model was serum NT-proBNP 
concentration at presentation (HR 2.48 [CI 1.350-4.535], p=0.003) (Table 5.3). 
 
Table 5.3.  Independent risk factors associated with composite endpoint of death or dialysis 
Variables 
 
Estimated 
Hazard Ratio  
95% 
Confidence 
Interval 
p value 
 
dFLC ≥90% 3 months 
 
0.23 
 
0.102 - 0.505 
 
<0.001 
Log NT-proBNP 2.40 1.293 – 4.463 0.006 
eGFR  0.98 0.893 – 1.068 0.61 
Proteinuria 1.01 0.962 – 1.064 0.66 
    
Bortezomib vs No 
Bortezomib 
0.57 0.317 – 1.011 0.054 
Log NT-proBNP 2.48 1.350 – 4.535 0.003 
eGFR  1.01 0.927 – 1.100 0.83 
Proteinuria 1.02 0.966 – 1.070 0.53 
 
 
Discussion 
Response to chemotherapy is known to be one of the main determinants of patient survival in 
systemic AL amyloidosis.(81, 101)  Two thirds of patients with systemic AL amyloidosis have 
renal involvement at diagnosis and renal outcome, as well as patient survival, is known to be 
influenced by response to chemotherapy.(130)  However, no studies have been performed to 
specifically investigate whether the magnitude and speed of clonal response to chemotherapy in 
  
124 
patients who present with established advanced renal impairment influences time to requirement 
for RRT.  Similarly, the merits of administering chemotherapy, which is invariably associated 
with substantial short-term morbidity, remain uncertain among AL amyloidosis patients who 
present with advanced CKD but do not have clinically significant extra-renal organ involvement 
by amyloid.  Here we show for the first time, that the speed and magnitude of clonal response in 
patients presenting with a GFR of <20 ml/min/1.73 m2 due to renal amyloidosis, directly 
influence the clinically important outcome measures of death, dialysis and the composite endpoint 
of death or dialysis, with markedly extended renal and patient survival among patients who 
achieved a clonal response of ≥90% within 3 months of baseline.  Furthermore, we show that in 
patients with an eGFR of <20 ml/min/1.73 m2 who do not have cardiac amyloidosis, 
chemotherapy can substantially delay the requirement for RRT.  The findings presented here are 
analogous to the effect of chemotherapy in patients with advanced (Mayo stage 3) cardiac AL 
amyloidosis, (160) in which the speed and depth of clonal response directly influence patient 
survival.  Until now it has not been clear whether the same degree and speed of clonal response 
can salvage renal function or if not, delay RRT in those who do not have cardiac involvement and 
whether patients with isolated renal amyloidosis require chemotherapy with the same degree of 
urgency as those with cardiac AL amyloidosis.   
 Importantly, this study does not prove beyond all doubt that aggressive chemotherapy 
aimed at achieving a rapid and deep clonal response delays dialysis and/or improves survival in 
this cohort of patients, since there was no prospective randomisation to a placebo arm or ‘low 
intensity’ chemotherapy arm.  It does not therefore take into account those whose death or 
requirement for RRT may have been accelerated by chemotherapy.  Nonetheless, the evidence 
for pursuing chemotherapy that is likely to achieve a rapid and deep clonal response in such 
patients is compelling; among the 47 patients in the whole cohort who died, 26 did so from 
progressive amyloidosis, including 4 patients who died before receiving chemotherapy; with only 
one death of the 26 deaths attributable to complications of chemotherapy.  Similarly, there was 
no evidence of acute kidney injury complicating CKD among those in the cohort who received 
chemotherapy and only 2 patients out of the 78 who received chemotherapy required 
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discontinuation due to toxicity, one of whom was already receiving RRT at the time of 
commencement of chemotherapy, and the other of whom received a total of 8 cycles (first line 
thalidomide switched to bortezomib) to a complete clonal response and remains dialysis 
independent.  Given that it would probably be considered unethical to withhold chemotherapy 
from patients with advanced renal dysfunction due to AL amyloidosis, particularly in light of the 
findings reported here, a prospective randomised trial to definitively answer this question will 
probably never be possible.  Although bortezomib was associated with higher rates of rapid 
(within 3 months) and deep (≥90%) clonal response compared to non-bortezomib containing 
regimens, we were unable to demonstrate that administration of bortezomib was an independent 
predictor of outcome in this cohort.  Nonetheless, we would encourage the use of bortezomib first 
line in patients with advanced renal impairment from AL amyloidosis due to the fact that it is 
generally well tolerated, no dose modification is necessary in patients with advanced renal 
impairment, and due to the speed and efficacy with which it can suppress the underlying clonal 
dyscrasia.   
 It is noteworthy that use of the established AL amyloidosis consensus criteria for 
measuring clonal response to chemotherapy, in which patients are required to have an absolute 
pre-treatment dFLC concentration of >50 mg/L to be evaluable, was associated with 
categorization of 12% patients as ‘not evaluable’, in accordance with the 15% patients reported 
in the consensus document.(159)  However, it is interesting that, in this cohort of patients, the 
consensus criteria did not even predict patient survival, which is well known from larger studies 
of patients with AL amyloidosis to be associated with depth of hematologic response at 3 
months.(161)  However, the ‘percentage of baseline dFLC’ method used in our analyses, which 
has also been previously validated in AL amyloidosis,(130) predicted both patient and renal 
survival.  Whilst the consensus criteria may be appropriate for determining eligibility of patients 
with AL amyloidosis for formal clinical trials, our ‘real world’ data indicates that the ‘percentage 
of baseline dFLC’ method is valid and applicable to all patients in a clinical practice setting, and 
may be superior in patients with established advanced CKD.  This study is of insufficient size to 
recommend a change in the consensus criteria, but given the relative rarity of the disease, the need 
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for a true representation of clinical practice within clinical trials, and the established difficulties 
associated with enrolling sufficient numbers of patients with AL amyloidosis into most clinical 
trials, we believe that a specific comparison of these two methods among a large cohort of AL 
amyloidosis patients with established advanced CKD is warranted and, depending on the findings, 
may merit considering a change to the consensus criteria. In summary, chemotherapy should not 
be withheld from patients with advanced CKD due to renal AL amyloidosis.  On the contrary, 
such patients should be treated urgently with the aim of achieving a rapid and deep clonal 
response, the result of which may be delayed dialysis and prolonged survival.   
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Chapter Six: Cardiorenal AL amyloidosis: risk 
stratification and outcomes based upon cardiac and 
renal biomarkers 
 
 
Introduction 
 
The amyloidoses are disorders of protein folding, in which a variety of proteins misfold and 
aggregate into fibrils that accumulate in tissues and disrupt organ function.(152)  Immunoglobulin 
light chain (AL) amyloidosis is caused by deposition of fibrils derived from monoclonal 
immunoglobulin light chains and is the most common and serious type of systemic 
amyloidosis.(5)  Renal and cardiac involvement respectively are present in approximately 70% 
and 50% of patients with systemic AL amyloidosis at diagnosis.  Renal involvement manifests 
with nephrotic syndrome and progressive renal impairment,(101) and cardiac involvement with 
congestive cardiac failure.   Progression to end-stage renal disease (ESRD) is one of the main 
determinants of morbidity in AL amyloidosis, whilst presence and severity of cardiac amyloidosis 
is the main determinant of mortality.(67, 68) 
Cardiorenal syndrome is increasingly being recognised as a distinct clinical entity.  
Recent classifications have separated cardiorenal syndrome into 5 types; acute heart failure 
leading to acute kidney injury (Type 1), chronic abnormalities in cardiac function leading to 
progressive chronic kidney disease (CKD) (Type 2), acute deterioration in renal function leading 
to acute cardiac dysfunction (Type 3), chronic kidney disease contributing to progressive cardiac 
impairment (Type 4) and systemic diseases affecting both the heart and kidneys in both the acute 
and chronic setting (Type 5).  Systemic AL amyloidosis is one of the main causes of type 5 
cardiorenal syndrome.(162, 163)  
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The main established determinant of outcome in systemic AL amyloidosis is the depth of 
serum free light chain response to chemotherapy.(101, 155)  Patients who achieve either a very 
good partial response (VGPR) or a complete response (CR) of the underlying hematologic 
condition have the highest chance of subsequent improvement in amyloidotic organ dysfunction, 
termed an ‘organ’ response.(101, 130, 154)  In 2005, amyloidosis consensus criteria (ACC) were 
established to define individual organ involvement in systemic AL amyloidosis as well as 
individual organ responses.   
In 2014, renal staging and ‘early’ renal response criteria (at 6 months) using eGFR and 
proteinuria to predict renal survival were developed for renal AL amyloidosis.  Despite concurrent 
cardiac amyloidosis among 70% of the cohort that were employed to establish these criteria, 
alternative biomarkers such as N-terminal pro-b-type natriuretic peptide (NT-proBNP) were not 
included in the analysis.(154)  Whilst early renal response was highly predictive of renal survival, 
it was not predictive of overall survival; furthermore, a composite endpoint including first of 
either death or dialysis was not explored. The current ACC response criteria have not therefore 
been specifically validated in patients with cardiorenal syndrome due to AL amyloidosis and have 
not been examined with respect to the key outcome measures in this population of death, dialysis 
or the composite endpoint of either death or dialysis.   
 We report renal and patient outcomes among 318 patients with systemic AL amyloidosis 
and cardiorenal syndrome who were prospectively enrolled into the UK AL Amyloidosis 
Chemotherapy (ALchemy) study between 2009 and 2016, in relation to their baseline clinical 
parameters and stratify them at different timepoints according to their amyloidotic organ function. 
 
 
 
 
  
129 
Patients and Methods 
Patients  
At the time of censor, 1000 patients with newly diagnosed AL amyloidosis had been enrolled into 
the prospective ALchemy study at the UK National Amyloidosis Centre (NAC).  Cardiorenal 
syndrome was defined by the combination of more than 0.5g/24 hr of non-Bence Jones proteinuria 
and presence of cardiac involvement by echocardiography according to amyloidosis consensus 
criteria.(69)  In rare cases in which echocardiography was suggestive but not conclusive with 
respect to presence of cardiac amyloidosis, it was supplemented by assessment of late gadolinium 
enhancement images on CMR, as previously defined.(157, 164)  All analyses presented in this 
manuscript were performed in the cohort of patients with systemic AL amyloidosis who satisfied 
the above criteria for cardiorenal syndrome. 
All patients underwent protocolized assessments at the NAC at baseline, 3, 6 and 12 
months and subsequently at 6 monthly intervals, each comprising a complete clinical evaluation 
including volume status evaluation and medication review, as well as serum and urine 
biochemistry including assessment of renal and liver function, NT-proBNP, echocardiography, 
NYHA functional class, 6 minute walk test (6MWT), SAP scintigraphy,(65) and assessment of 
hematologic disease by serum free light chain (FLC) assay along with serum and urine 
immunofixation electrophoresis.   
All patients were managed in accordance with the Declaration of Helsinki and provided 
written informed consent for study entry (REC reference 09/H0715/58) and publication of their 
data. 
 
Assessment of Hematologic response 
Details and doses of chemotherapy regimens were collected.  All patients had serial FLC 
concentration prospectively monitored on blood samples obtained monthly during periods of 
chemotherapy treatment, and 1-3 monthly (depending on depth and stability of response) 
thereafter.  Healthy polyclonal serum FLC concentration increases progressively through 
  
130 
advancing stages of chronic kidney disease (CKD)(122) which hinders the monitoring of 
monoclonal light chain disorders.  In this study, the value of the FLC monoclonal component was 
estimated by subtracting the concentration of the uninvolved light chain from that of the 
amyloidogenic light chain to obtain the FLC difference (dFLC), a strategy previously validated 
in multiple myeloma and AL amyloidosis.(123, 130)   
The FLC response to chemotherapy was determined according to previously validated 
ACC.(159)  Since ACC define “evaluable” patients as those with a pre-treatment (baseline) dFLC 
of >50 mg/l, thus excluding 27/318 (9%) patients in this cohort, the percentage of the baseline 
dFLC that remained at the time of analysis (percentage method), also validated in AL 
amyloidosis,(130, 165) was additionally used to determine response to chemotherapy.  A very 
good partial response (VGPR) was defined according to the ACC as an absolute dFLC of 
<40mg/L and by the percentage method as a ≥90% reduction of pre-treatment dFLC remaining 
after chemotherapy, as previously described.(130, 165)   
 
Assessment of Organ Response  
Organ responses were defined according to ACC;(91) cardiac progression as an increase in NT-
proBNP of >30% and >300 ng/L and cardiac response as a reduction of NT-proBNP of >30% 
(and >300 ng/L decrease in patients with baseline NT-proBNP ≥ 650 ng/L).  Renal progression 
was defined as a ≥ 25% reduction in eGFR and or a ≥ 50% increase in proteinuria and renal 
response was defined as a ≥ 50% reduction in proteinuria without a ≥ 25% reduction in eGFR.  
Additionally, ‘early’ renal progression was defined at six months from baseline as a ≥ 25% 
reduction in eGFR and ‘early’ renal response was defined at six months from baseline as a ≥ 30% 
reduction in proteinuria without a ≥ 25% reduction in eGFR, according to previously published 
amyloidosis consensus criteria.(154) 
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Patient and Renal Survival  
Overall survival (OS) was defined as the time from baseline diagnostic evaluation at the NAC to 
patient death and was evaluated in all 318 patients.  Renal survival was defined as the time from 
baseline diagnostic evaluation at the NAC to requirement for renal replacement therapy (RRT).  
For the analyses of renal survival, patients who were already established on RRT (n=7) at the time 
of their baseline evaluation were excluded, and those who died without requiring RRT were 
censored at the time of death.  For analyses of time to the composite endpoint of death or dialysis, 
patients who were on RRT at baseline were excluded and an event was recorded as the first of 
either death or dialysis.  Patient follow up was censored on 1st September 2016. 
 
Statistical Analysis 
Median patient survival, renal survival, and survival to the composite endpoint of ‘dialysis or 
death’, were determined by Kaplan-Meier (KM) survival analysis using GraphPad Prism v5.03 
software.  All analyses examining clonal or organ response at set time points were performed as 
landmark analyses.  Univariable Cox regression was used to investigate the factors associated 
with the endpoints of death, dialysis, or the composite endpoint of ‘dialysis or death’ at baseline 
and at relevant time points for each of the three endpoints using SPSS software (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp).  
Multivariable Cox proportional hazards regression analysis was subsequently used to investigate 
factors independently associated with each of the three endpoints at the relevant time points.  A 
significance level of 0.05 was used for all hypothesis tests.   
 
Results 
Baseline Characteristics and Patient Survival 
Type 5 cardiorenal syndrome, defined by the combination of renal amyloidosis (more than 
0.5g/24 hr of non-Bence Jones proteinuria by ACC organ involvement criteria) and cardiac 
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amyloidosis (>12 mm IVSd thickness on echocardiography without an alternative cause), was 
present in 318 patients at the time of diagnosis.  Histological proof of amyloid was established in 
all patients including renal biopsy evidence of AL amyloid deposits in 150/318 (47%) cases and 
endomyocardial biopsy evidence of AL amyloid deposits in a further 6 patients; no patient in the 
whole cohort of 318 patients had either a cardiac or renal biopsy which failed to show amyloid.  
Among 162/318 cases who did not have endomyocardial or renal biopsy ‘proof’ of AL amyloid 
deposits, all had clear evidence of cardiac and renal amyloidosis on the basis of existing ACC 
accompanied by AL amyloid deposits in a biopsy specimen from an alternative site.  In 310/318 
patients, cardiac amyloidosis was definitively diagnosed by echocardiography (although 
frequently supplemented by characteristic CMR findings) but in the remaining 8 cases in which 
echocardiography was not definitively diagnostic of cardiac amyloidosis, its presence was 
confirmed by the finding of characteristic late gadolinium enhancement by CMR.  Of the 168 
patients who did not undergo a renal biopsy, 80/168 (47%) had nephrotic range proteinuria 
(≥ 3g/24hr).   
Baseline demographics and clinical characteristics of the whole cohort of 318 patients 
with cardiorenal syndrome are listed in Table 6.1.  Median age at diagnosis was 66 years with 
M:F ratio of 1:1.  Median eGFR was 55 ml/min/1.73 m2 (range 10-100) with a median 24 hour 
urinary protein leak of 4.6 grams (range 0.5-26.8) and median serum albumin of 30 g/L (14-49).  
Mayo disease Stage was 1, 2 and 3 in 4 (1%), 92 (29%) and 222 (70%) of patients respectively.  
Median NT-proBNP was 5568 ng/L (range 145-70,295) with 66 (21%) patients having a 
concentration of >8500 ng/L (defined by amyloidosis staging criteria as Stage 3b disease).(68)  
Median follow up by reverse Kaplan-Meier (KM) analysis for the whole cohort was 47.5 months 
(range 0.1-83.5).  A total of 199/318 (63%) patients died with a median overall survival of only 
18.5 months by KM analysis.  Among the 199 patients who died, median time to death was 5.0 
months (range 0.1-54.8); 114/199 (57%) patients died within 6 months and 146/199 (73%) within 
12 months of baseline. 
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Table 6.1 Baseline characteristics of 318 patients with systemic AL amyloidosis and 
cardiorenal syndrome 
 
Demographic or clinical characteristic No. of Patients 
(N =318) 
% 
Male sex    N 
Female sex    N 
177 
141 
55 
45 
Age (years)    Median 
    Range 
66 
39-89 
 
Patients presenting on RRT  N 7 2 
eGFR (ml/min/1.73 m2)   Median 
     Range 
55 
10-100 
 
CKD Stage 
                             1 
                           2 
                             3 
                             4 
                            5 
  
18 
26 
32 
16 
8 
Serum albumin (g/L)   Median 
    Range 
30 
14-49 
 
24hr urinary protein loss (g)  Median 
    Range 
4.6 
0.5-26.8 
 
NT-proBNP (ng/L)   Median 
    Range 
5568 
145-70,295 
 
Troponin T (ng/L)                                     Median  
                                                                       Range 
87 
<10-1870 
 
Mayo Stage 
  1 
  2 
  3a 
  3b 
  
1 
29 
49 
21 
Amyloidogenic light chain (n)  Lambda  N 
     Kappa  N 
260 
58 
82 
18 
λ sFLC concentration in  
AL (λ) patients (mg/L)                              Median 
    Range 
 
253 
7-6500 
 
κ sFLC concentration in  
AL (κ) patients (mg/L)                                 Median 
    Range 
 
575 
10-10300 
 
 
Haemoglobin (g/dL)   Median 
    Range 
12.9 
8.3-18.1 
 
Serum creatinine (µmol/L)  Median  
     Range 
107 
26-979 
 
Bilirubin (µmol/L)   Median 
    Range 
6 
1-70 
 
Alkaline Phosphatase (u/L)  Median 
     Range 
98 
35-2142 
 
Supine systolic blood pressure (mmHg) Median 
    Range 
112 
78-194 
 
Standing systolic blood pressure (mmHg) Median 
    Range 
108 
63-192 
 
6 minute walk test (6MWT) metres     Median 
    Range 
276 
0-578 
 
 
NYHA class    0-2 
     3-4 
236 
82 
 
 
Amyloid load by SAP scintigraphy (n=312) None  N 
     Small  N 
                 Moderate  N 
50 
102 
86 
15 
33 
28 
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    Large  N 74 24 
Left ventricular posterior wall thickness 
end diastole (LVPWd) (mm)               Median 
    Range 
 
14 
11-24 
 
E/E’ Prime                                                       Median 
    Range 
14 
4.5-48 
 
Lateral S Wave (m/s)                                      Median 
    Range 
0.07 
0.02-0.17 
 
Left Ventricular Ejection Fraction  
(LVEF) (%)                                                    Median 
    Range 
 
56 
23-80 
 
 
 
Fifty (16%) patients in the whole cohort required RRT during follow up (of whom 7 were 
already dialysis dependent at baseline).  Median time to commencement of dialysis among those 
50 patients was 6.6 months (range 0-57.8). Twenty-four patients commenced dialysis within 6 
months and 31 within 12 months of baseline.  Median overall survival from diagnosis in the cohort 
of 50 patients who required RRT by KM analysis was 37.4 months, and median survival from 
commencement of RRT in those 50 patients was 23.0 months.  
 
Chemotherapy 
Chemotherapy was planned in all 318 patients but was not delivered in 23 (7%) cases, all of whom 
died prior to starting treatment (median time to death in these 23 patients was 26 days).  Among 
those 295 patients who did receive chemotherapy, 156 (53%) received a bortezomib-based 
regimen first line, 104 (35%) received a thalidomide-based regimen first line and 35 (12%) 
received a first line regimen containing neither bortezomib nor thalidomide. Only one patient 
received upfront high dose melphalan conditioning with autologous stem cell transplantation 
(ASCT).  Median number of chemotherapy cycles administered first line was 4 (1-9). 
 
Disease-related Predictors of Outcome at Baseline 
Univariable analysis of baseline parameters associated with death, dialysis, and the composite 
endpoint of death or dialysis are listed in Table 6.2a as continuous and categorical variables.  
Baseline parameters that were significantly associated with death were NT-proBNP concentration 
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(p<0.001), Mayo Stage (p<0.001), eGFR (p<0.001), supine systolic blood pressure (p<0.001), 6 
minute walk test (6MWT) distance (p<0.001), NYHA class (p<0.001) and ECOG performance 
status (p<0.001).  Baseline parameters that were significantly associated with dialysis were NT-
proBNP (p<0.001), Mayo Stage (p<0.001) and eGFR (p<0.001). Degree of proteinuria alone was 
not significantly associated with risk of dialysis, although ‘Renal Stage’ (eGFR 
<50ml/min/1.73m2 and/or >5g/24hr of proteinuria)(154) was (Stage 3 vs Stage 1; HR 9.40 [3.11-
28.37], p<0.001) (Table 6.2a). 
Multivariable analyses including baseline eGFR, NT-proBNP and supine systolic BP as 
categorical variables revealed NT-proBNP >8500ng/L to be a significant predictor of death (HR 
3.01 [2.22-4.10], p<0.001), dialysis (HR 1.98 [1.01-3.88], p=0.045) and the composite endpoint 
(HR 2.91 [2.16-3.91], p<0.001).  Supine systolic BP <100mmHg was an independent predictor 
of death (HR 1.70 [1.23-2.35], p=0.001) and the composite endpoint (HR 1.45 [1.06-1.99], 
p=0.021), whereas eGFR <30ml/min/1.73 m2 was an independent predictor of dialysis (HR 4.86 
[2.55-9.25], p<0.001) and the composite endpoint (HR 1.73 [1.26-2.39], p=0.001) (Table 6.2b). 
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Table 6.2a.  Univariable analysis of disease-related predictors of death, dialysis and the composite endpoint at the time of diagnosis 
Variable Death  Dialysis  Death or Dialysis  
 HR (CI) P value HR (CI) P value HR (CI) P value 
       
Supine systolic BP 
 Continuous 
 Categorical  ≥ 100mmHg 
   < 100mmHg 
 
0.98 (0.97-0.99) 
1 
1.84 (1.35-2.50) 
 
<0.001 
 
<0.001 
 
1.02 (1.00-1.03) 
1 
0.31 (0.10-1.02) 
 
0.036 
 
0.050 
 
0.99 (0.98-1.00) 
1 
1.52 (1.12-2.05) 
 
0.006 
 
0.007 
24 hour proteinuria 
 Continuous 
 Categorical 0-3g/24h 
   3-5g/24h 
   > 5g/24h 
 
0.97 (0.93-0.99) 
1 
1.40 (1.0-1.9) 
1.00 (0.7-1.5) 
 
0.050 
 
0.040 
0.990 
 
1.07 (1.01-1.12) 
1 
0.50 (0.23-1.10) 
0.68 (0.31-1.51) 
 
0.013 
 
0.084 
0.344 
 
0.98 (0.95-1.01) 
1 
1.29 (0.95-1.76) 
0.91 (0.63-1.33) 
 
0.212 
 
0.101 
0.638 
Serum albumin 
 Continuous 
 Categorical > 30g/L 
   < 30g/L 
 
1.00 (0.98-1.10) 
1 
1.07 (0.85-1.50) 
 
0.960 
 
0.390 
 
1.01 (0.97-1.05) 
1 
1.16 (0.64-2.11) 
 
0.690 
 
0.615 
 
1.01 (0.99-1.02) 
1 
1.27 (0.96-1.66) 
 
0.455 
 
0.089 
Renal Stage  
                 Categorical  
                                                 Stage 1 
                                                 Stage 2 
                                                 Stage 3 
 
 
1 
0.93 (0.67-1.30) 
1.28 (0.85-1.92) 
 
 
 
0.675 
0.232 
 
 
1 
3.55 (1.23-10.29) 
9.40 (3.11-28.37) 
 
 
 
0.019 
<0.001 
 
 
1 
1.15 (0.83-1.59) 
1.73 (1.15-2.58) 
 
 
 
0.399 
0.007 
eGFR 
 Continuous 
 Categorical CKD 1 
   CKD 2 
   CKD 3a 
   CKD 3b 
   CKD 4 
   CKD 5 
 
0.99 (0.99-0.99) 
1 
1.08 (0.68-1.72) 
1.50 (0.94-2.40) 
1.31 (0.76-2.31) 
1.89 (1.16-3.08) 
1.83 (1.06-3.18) 
 
<0.001 
 
0.730 
0.086 
0.331 
0.011 
0.031 
 
0.97 (0.96-0.98) 
1 
0.55 (0.17-1.80) 
1.10 (0.35-2.40) 
1.61 (0.49-5.29) 
6.37 (2.40-16.88) 
7.33 (2.53-21.29) 
 
<0.001 
 
0.321 
0.876 
0.431 
<0.001 
<0.001 
 
0.99 (0.98-0.99) 
1 
0.98 (0.63-1.53) 
1.36 (0.87-2.14) 
1.39 (0.83-2.34) 
2.65 (1.67-4.21) 
3.26 (1.86-5.71) 
 
<0.001 
 
0.938 
0.179 
0.215 
<0.001 
<0.001 
NT-proBNP 
 Continuous 
 Categorical ≤ 8500ng/L 
 > 8500ng/L 
 
1.00 (1.00-1.00) 
1 
3.30 (2.50-4.42) 
 
<0.001 
 
<0.001 
 
1.00 (1.00-1.00) 
1 
3.00 (1.70-5.40) 
 
<0.001 
 
<0.001 
 
1.00 (1.00-1.00) 
1 
3.50 (2.62-4.61) 
 
<0.001 
 
<0.001 
Mayo Stage 
                 Categorical 
                                                 Stage 2 
                                                 Stage 3a 
                                                 Stage 3b 
 
 
1 
2.47 (1.69-3.61) 
3.64 (2.39-5.53) 
 
 
 
<0.001 
<0.001 
 
 
1 
1.17 (0.56-2.44) 
4.14 (1.92-8.95) 
 
 
 
0.673 
<0.001 
 
 
1 
2.29 (1.61-3.27) 
4.17 (2.78-6.25) 
 
 
 
<0.001 
<0.001 
NYHA Class 
 Categorical Class 1 
   Class 2 
   Class 3 
   Class 4 
 
1 
1.86 (1.07-3.21) 
4.71 (2.65-8.35) 
18.6 (6.01-57.70) 
 
 
0.027 
<0.001 
<0.001 
 
1 
2.64 (0.79-8.79) 
2.48 (0.59-10.49) 
0.00 (0.00-undefined) 
 
 
0.114 
0.216 
0.987 
 
1 
2.16 (1.25-3.72) 
5.07 (2.86-8.99) 
17.44 (5.65-53.84) 
 
 
0.006 
<0.001 
<0.001 
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ECOG Performance Status 
 Categorical Class 0 
   Class 1 
   Class 2 
   Class 3&4 
 
1 
1.60 (0.73-3.50) 
4.10 (1.90-8.83) 
6.10 (2.60-14.0) 
 
 
0.240 
<0.001 
<0.001 
 
1 
1.61 (0.49-5.36) 
1.85 (0.53-6.43) 
1.30 (0.22-7.91) 
 
 
0.435 
0.332 
0.770 
 
1 
1.46 (0.73-2.93) 
3.29 (1.64-6.52) 
4.62 (2.17-9.86) 
 
 
0.282 
0.001 
<0.001 
6 minute walk test (6MWT) distance 
 Continuous 
                Categorical  
                                                <300 metres 
                                                ≥300 metres 
 
0.99 (0.99-0.99) 
 
1 
0.26 (0.16-0.41) 
 
<0.001 
 
 
<0.001 
 
1.00 (0.99-1.02) 
 
 
0.68 (0.22-2.20) 
 
0.496 
 
 
0.530 
 
0.99 (0.99-0.99) 
 
 
0.31 (0.20-0.48) 
 
<0.001 
 
 
<0.001 
Echocardiographic parameters 
   LVSd mm 
   LVPW mm 
   E/E’ 
   LVEF % 
 
 
1.06 (0.92-1.23) 
0.99 (0.85-1.15) 
1.03 (1.01-1.04) 
0.97 (0.95-0.98) 
 
 
0.416 
0.905 
0.001 
<0.001 
 
0.90 (0.64-1.27) 
1.20 (0.84-1.71) 
0.97 (0.93-1.02) 
1.01 (0.98-1.05) 
 
0.555 
0.315 
0.347 
0.334 
 
1.07 (0.93-1.24) 
0.98 (0.85-1.13) 
1.02 (1.01-1.04) 
0.97 (0.96-0.99) 
 
0.300 
0.755 
0.012 
<0.001 
 
 
Table 6.2b.  Multivariable analysis of disease-related predictors of death, dialysis and the composite endpoint at diagnosis, 6 months and 12 
months 
Multivariable Death  Dialysis  Death or Dialysis  
 HR (CI) P value HR (CI) P value HR (CI) P value 
At diagnosis       
 
NT-proBNP >8500ng/L 
eGFR < 30ml/min 
Supine systolic BP <100mmHg 
 
 
3.01 (2.22-4.10) 
1.14 (0.81-1.60) 
1.70 (1.23-2.35) 
 
<0.001 
0.445 
0.001 
 
1.98 (1.01-3.88) 
4.86 (2.55-9.25) 
0.39 (0.12-1.27) 
 
0.045 
<0.001 
0.117 
 
2.91 (2.16-3.91) 
1.73 (1.26-2.39) 
1.45 (1.06-1.99) 
 
 
<0.001 
0.001 
0.021 
Change at 6 months from baseline       
 
Increase NT-proBNP >30%  
Reduction eGFR ≥ 25% 
dFLC response ≥ 90% 
 
 
2.17 (1.22-3.88) 
1.54 (0.90-2.65) 
0.42 (0.24-0.73) 
 
0.009 
0.120 
0.002 
 
1.55 (0.77-3.10) 
3.07 (1.51-6.26) 
0.54 (0.28-1.07) 
 
 
0.215 
0.002 
0.078 
 
1.70 (1.03-2.81) 
1.95 (1.20-3.18) 
0.42 (0.26-0.69) 
 
0.037 
0.007 
0.001 
 
Change at 12 months from baseline       
 
Increase NT-proBNP >30%  
Reduction eGFR ≥ 25% 
dFLC response ≥ 90% 
 
 
3.67 (1.79-7.53) 
1.23 (0.63-2.42) 
0.50 (0.24-1.02) 
 
<0.001 
0.546 
0.060 
 
 
2.85 (1.29-6.32) 
3.04 (1.28-7.25) 
0.62 (0.29-1.34) 
 
0.010 
0.012 
0.230 
 
 
3.05 (1.68-5.52) 
1.70 (0.96-3.05) 
0.58 (0.33-1.04) 
 
<0.001 
0.070 
0.068 
 
  138 
Table 6.2c.  Univariable analysis of hematologic responses at 3, 6 and 12 months as predictors of death, dialysis and the composite 
endpoint 
Variable  
 
Response Rate 
% 
Death  Dialysis  Death or Dialysis  
  HR (CI) P value HR (CI) P value HR (CI) P value 
dFLC <40mg/L at 3 months 
 Categorical N 
   Y 
 
 
 
1 
0.28 (0.17-0.46) 
 
 
<0.001 
 
1 
0.31 (0.14-0.70) 
 
 
0.005 
 
1 
0.32 (0.20-0.50) 
 
 
<0.001 
% dFLC response at 3 months 
 Continuous 
 Categorical < 50%  
   50-89% 
   ≥ 90% 
 
 
28 
33 
39 
 
0.98 (0.97-0.99) 
1 
0.43 (0.27-0.68) 
0.17 (0.10-0.29) 
 
<0.001 
 
<0.001 
<0.001 
 
0.99 (0.98-1.00) 
1 
0.63 (0.28-1.43) 
0.24 (0.10-0.61) 
 
0.018 
 
0.274 
0.003 
 
0.98 (0.98-0.99) 
1 
0.46 (0.29-0.72) 
0.20 (0.12-0.33) 
 
<0.001 
 
0.001 
<0.001 
dFLC <40mg/L at 6 months 
 Categorical N 
   Y 
  
1 
0.22 (0.13-0.36) 
 
 
<0.001 
 
1 
0.32 (0.13-0.75) 
 
 
0.009 
 
1 
0.23 (0.14-0.40) 
 
 
<0.001 
% dFLC response at 6 months 
 Continuous 
 Categorical < 50% 
   50-89% 
   ≥ 90% 
 
 
15 
31 
54 
 
0.98 (0.97-0.99) 
1 
0.41 (0.23-0.73) 
0.18 (0.10-0.33) 
 
<0.001 
 
0.003 
<0.001 
 
0.99 (0.97-1.00) 
1 
0.69 (0.28-1.73) 
0.24 (0.09-0.64) 
 
0.004 
 
0.965 
0.004 
 
0.98 (0.97-0.99) 
1 
0.51 (0.27-0.84) 
0.17 (0.09-0.33) 
 
<0.001 
 
0.027 
<0.001 
dFLC <40mg/L at 12 months 
 Categorical N 
   Y 
  
1 
0.39 (0.20-0.76) 
 
 
0.006 
 
1 
0.47 (0.17-1.34) 
 
 
0.161 
 
1 
0.47 (0.23-0.96) 
 
 
0.039 
% dFLC response  at 12 months 
 Continuous 
 Categorical < 50% 
   50-89% 
   ≥ 90% 
 
 
11 
28 
61 
 
0.98 (0.97-0.99) 
1 
0.42 (0.19-0.92) 
0.15 (0.06-0.33) 
 
<0.001 
 
0.030 
<0.001 
 
0.98 (0.97-0.99) 
1 
0.48 (0.12-1.89) 
0.20 (0.05-0.78) 
 
0.053 
 
0.297 
0.021 
 
0.98 (0.97-0.99) 
1 
0.77 (0.28-2.09) 
0.31 (0.11-0.84) 
 
<0.003 
 
0.610 
0.022 
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Outcome in Relation to Hematologic Responses at 3, 6 and 12 months from 
Baseline 
Univariable analyses of outcome in relation to hematologic response to chemotherapy using both 
the ACC dFLC method (dFLC <40mg/L) and ‘percentage’ dFLC method are listed in Table 6.2c.  
As expected, depth of clonal response was a highly significant predictor of all three outcome 
measures.  Specifically, achieving a dFLC of ≥ 90% at 3, 6 and 12 months was a highly significant 
(protective) predictor of death (HR 0.15 [0.06-0.33], p<0.001), dialysis (HR 0.20 [0.05-0.78], 
p=0.021) and the composite endpoint (HR 0.31, [0.11-0.84], p=0.022), compared to lesser degrees 
of clonal response. 
 
Outcomes in Relation to Change in Organ Function at 6 months from Baseline 
In light of the 2014 ‘early’ amyloidosis renal response criteria,(154) we assessed renal response 
at 6 months from baseline and its influence on death, dialysis and the composite endpoint.  
Univariable analyses revealed that early renal progression (reduction in eGFR of ≥ 25%) was 
predictive of death (HR 1.80 [1.07-3.05], p=0.028), dialysis (HR 3.45 [1.44-8.23], p=0.005) and 
the composite endpoint of death and dialysis (HR 1.96 [1.16-3.32], p=0.012).  Interestingly 
however, ‘early’ renal response (≥ 30% reduction in proteinuria without a ≥ 25% reduction in 
eGFR) was not significantly associated with death (HR 0.76 [0.41-1.42], p=0.389), dialysis (HR 
0.69 [0.25-1.93], p=0.490) or the composite endpoint (HR 0.80 [0.49-1.47], p=0.478).  
In view of the univariable findings, multivariable analyses were performed with increase 
in NT-proBNP >30%, reduction in eGFR of ≥ 25%, and dFLC response of ≥90% at 6 months 
from baseline (Table 6.2b), as categorical variables.  Increase in NT-proBNP >30% was 
predictive of death (HR 2.17 [1.22-3.88], p=0.009) and the composite endpoint (HR 1.70 [1.03-
2.81], p=0.037) but not dialysis.  Reduction in eGFR of ≥ 25% was highly predictive of dialysis 
(HR 3.017 [1.51-6.26], p=0.002) and the composite endpoint (HR 1.95 [1.20-3.18], p=0.007) but 
not death, and dFLC response of ≥90% was (protectively) predictive of death (HR 0.42 [0.24-
0.73], p=0.002) and the composite endpoint (HR 0.42 [0.26-0.69], p=0.001) but not dialysis. 
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Outcomes in Relation to Change in Organ Function at 12 months from Baseline 
Univariable analyses using the ACC for renal organ response at 12 months were performed. Renal 
progression (≥ 25% reduction in eGFR and/or a ≥ 50% increase in proteinuria) was not 
significantly associated with death (HR 1.63 [0.86-3.08], p=0.127) or the composite endpoint (HR 
1.70 [0.91-3.20], p=0.096) but was significantly associated with dialysis (HR 3.29 [1.17-9.24], 
p=0.024).  Renal response (≥ 50% reduction in proteinuria without a ≥ 25% reduction in eGFR) 
was not significantly associated with death (HR 0.96 [0.43-2.14], p=0.925), dialysis (HR 0.58 
[0.16-2.06], p=0.406) or the composite endpoint (HR 0.98 [0.47-2.02], p=0.947).  Univariable 
analyses using the ACC for cardiac organ response at 12 months were performed. Cardiac 
progression (increase in NT-proBNP of >30%) was a highly significant predictor of death (HR 
5.32 [2.78-10.16], p<0.001) and the composite endpoint (HR 3.10 [1.61-5.96], p<0.001) but not 
dialysis, although demonstrated a trend to significance (HR 2.49 [0.91-6.78], p=0.075).  Cardiac 
response (reduction in NT-proBNP of >30%) was a highly significant (protective) predictor of 
death (HR 0.24 [0.12-0.51], p<0.001) and the composite endpoint (HR 0.42 [0.22-0.80], p=0.009) 
but not dialysis (HR 0.54 [0.20-1.42], p=0.214). 
Multivariable analyses for predictors of death, dialysis and the composite endpoint were 
performed including increase in NT-proBNP >30%, reduction in eGFR of ≥ 25%, and dFLC 
response of ≥90% at 12 months from baseline as categorical variables (Table 6.2b).  An increase 
in NT-proBNP of >30% was a highly significant predictor of all three outcomes; death (HR 3.67 
[1.79-7.53], p<0.001), dialysis (HR 2.85 [1.29-6.32], p=0.010) and the composite endpoint (3.05 
[1.68-5.52], p<0.0001).  Reduction in eGFR of ≥ 25% was not significantly associated with death 
(HR 1.23 [0.63-2.42], p=0.546) or the composite endpoint (HR 1.70 [0.96-3.05], p=0.070) but 
was associated with dialysis (HR 3.04 [1.28-7.25], p=0.012) and dFLC response of ≥90% was 
not significantly associated with any of the three outcomes.  
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Discussion 
Systemic AL amyloidosis is a multisystem disease with a heterogeneous clinical presentation and 
clinical course, as well as a widely varying prognosis.  Symptoms, quality of life and patient 
survival are dependent upon the presence and severity of individual organ involvement and the 
hematologic response to chemotherapy, the mainstay of treatment for the disease.  International 
amyloidosis consensus criteria (ACC) exist to define individual organ involvement by amyloid at 
the time of diagnosis as well as to define response of individual organs to chemotherapy.  It is 
well established that presence and severity of cardiac amyloidosis at diagnosis is the main 
determinant of patient survival in AL amyloidosis,(68) whilst presence and severity of renal 
dysfunction from amyloid determines the risk of progression to end stage renal disease (ESRD), 
a major determinant of quality of life.  Systemic AL amyloidosis is a cause of cardiorenal 
syndrome, but there are no studies that have specifically looked at patient and renal survival in 
patients with systemic AL amyloidosis presenting with combined cardiac and renal amyloidotic 
dysfunction.  Here we show for the first time that almost one third of patients diagnosed with 
systemic AL amyloidosis present with Type 5 cardiorenal syndrome, and that their outcomes are 
poor despite chemotherapy.  Nearly two thirds of patients in the cardiorenal cohort died, among 
whom median time to death was only 5 months; median overall survival in this cohort by Kaplan 
Meier analysis was only ~18 months.  In addition, 16% patients developed ESRD, the majority 
of whom reached dialysis within 12 months of diagnosis and median (range) time to the composite 
endpoint of either death or dialysis by KM analysis in the whole cohort was only 9.3 (5.5-13.1) 
months.   
The data presented here are novel in that they concern three hard outcome measures, 
patient survival, dialysis, and the composite of either death or dialysis in the one third of patients 
with AL amyloidosis who present specifically with cardiorenal syndrome.  At the time of 
diagnosis, the three disease-related parameters that were highly significant independent predictors 
of all three outcomes were NT-proBNP concentration, Mayo Stage and eGFR.  As previously and 
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extensively reported,(101, 130, 155) the clonal response to chemotherapy within 12 months of 
diagnosis was also predictive of both patient and renal survival.   
Interestingly, an increase or reduction in proteinuria at 12 months, both of which are 
included in the ACC renal response criteria, did not predict death, dialysis, or the composite 
endpoint.  Additionally, an ‘early’ renal response (at 6 months from baseline) was not 
significantly associated with any of the three outcome measures.  A reduction of eGFR of ≥ 25% 
at 6 months was predictive of dialysis and the composite endpoint in keeping with previous 
findings by Palladini and colleagues,(154) whilst an increase in NT-proBNP of >30% at 12 
months was predictive of all three outcome measures.  This highlights for the first time the strong 
association between both baseline NT-proBNP concentration, its increase at 12 months (ACC 
cardiac progression) and each of the three hard outcome measures of death, dialysis and the 
composite endpoint.  Furthermore, whilst renal stage (eGFR <50ml/min and proteinuria of 
>5g/24hr) at baseline was highly predictive of renal survival alone; proteinuria, both at baseline 
and its change at 6 and 12 months was not predictive of any of the three outcomes in this cohort 
of patients, possibly due to the high early ‘event’ rate for both death and dialysis.  
An increase or reduction in proteinuria in the absence of worsening GFR has previously 
been shown to be predictive of renal survival in patients with isolated renal AL amyloidosis.(130)  
The pathophysiology of reduction in proteinuria in AL amyloidosis is thought to relate to amyloid 
regression, or perhaps absence of ongoing amyloid accumulation, which is dependent upon 
adequate suppression of the underlying clonal disorder.(166)  However, in clinical practice, a 
significant improvement in proteinuria rarely occurs before six months to one year; it may be 
therefore, that in this distinct cohort of patients with cardiorenal AL amyloidosis, the high early 
death, and to a lesser degree dialysis rates, preclude the use of proteinuria as a prognostic 
biomarker within the first year of diagnosis.   
Based upon our study, we aimed to risk stratify patients with cardiorenal syndrome; at 
baseline, based upon eGFR and NT-proBNP (Table 6.3) and thereafter, based upon change in 
biomarkers within 12 months from diagnosis (Figure 6.1).  At baseline, low risk was defined as 
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an NT-proBNP of ≤8500ng/L and eGFR ≥ 30 ml/min/1.73 m2, intermediate risk as either NT-
proBNP of >8500ng/L or eGFR <30 ml/min/1.73 m2 and high risk as NT-proBNP of >8500ng/L 
and eGFR <30 ml/min/1.73 m2 at baseline.  High risk patients had a substantially increased risk 
of death (HR 3.12 [2.18-4.64], p<0.001), dialysis (HR 10.34 [4.66-22.91], p<0.001) and the 
composite endpoint (HR 4.76 [3.24-7.00], p<0.001) (Table 3).  In all patients with systemic AL 
amyloidosis and cardiorenal syndrome, the outcome of dialysis was predominantly dictated by 
≥ 25% reduction in eGFR at 6 months, but at 12 months an increase in NT-proBNP of >30% was 
the most significant predictor of death, dialysis and the composite endpoint (Figure 6.1).  
 
Table 6.3 Risk stratification of patients with systemic AL amyloidosis and cardiorenal 
syndrome based upon baseline NT-proBNP and eGFR 
 
Variable Death  Dialysis  Death or Dialysis  
 HR (CI) P value HR (CI) P value HR (CI) P value 
Cardiorenal Risk 
Stage 
 
Low risk 
Intermediate risk                                   
High risk 
 
 
 
1 
2.66 (1.93-3.66) 
3.12 (2.18-4.64) 
 
 
 
 
<0.001 
<0.001 
 
 
 
1 
2.82 (1.37-5.77) 
10.34 (4.66-22.91) 
 
 
 
 
0.005 
<0.001 
 
 
 
1 
2.89 (2.12-3.92) 
4.76 (3.24-7.00) 
 
 
 
 
<0.001 
<0.001 
 
 
Limitations of our study include the relatively low incidence of dialysis in this cohort of 
patients.  A total of 50 patients required dialysis of whom 50% were on dialysis by 6 months. 
Hemodialysis is the acute RRT therapy of choice in the UK and it may be that a small number of 
patients were deemed unsuitable to receive hemodialysis due to concurrent advanced cardiac 
amyloidosis, autonomic nerve dysfunction and associated hypotension, as well as patient choice.  
Due to the nature of our referral centre, these details were not available to us.  Nonetheless, the 
authors feel that this ‘real world’ data regarding the specific cohort of patients with systemic AL 
amyloidosis who have type 5 cardiorenal syndrome is key in guiding clinicians who counsel such 
patients about their treatment and outcomes within the first year of diagnosis.  
In summary, approximately one third of patients with systemic AL amyloidosis have 
cardiorenal syndrome at the time of diagnosis.  Despite the complex relationship between NT-
proBNP, renal excretory function, and cardiac function, our data indicates that hard outcome 
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measures in patients with systemic AL amyloidosis and type 5 cardiorenal syndrome are 
predominantly dictated by both baseline NT-proBNP and its change at 12 months.  The key renal 
biomarker in this cohort is eGFR and not proteinuria.  The initial aim of therapy, be it 
chemotherapy to prevent ongoing accumulation of amyloid and progressive amyloidotic organ 
dysfunction or symptomatic management of fluid balance, should be to prevent loss of ≥ 25% of 
baseline eGFR within 6 months and an increase in NT-proBNP of >30% within 12 months of 
diagnosis.  Our data suggest that, irrespective of changes in proteinuria, and to some degree, GFR, 
changes in NT-proBNP (ACC cardiac progression) may be the most important independent 
predictor of death or a requirement for renal replacement therapy in such patients.  Further work, 
possibly including novel methods of tracking end organ response, is needed to refine the current 
amyloid consensus criteria in order to reflect the needs of patients with multi-system disease from 
AL amyloidosis. 
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Figure 6.1 
Risk stratification of patients with systemic AL amyloidosis and cardiorenal syndrome 
based upon NT-proBNP and eGFR at different timepoints within the course of the first 
year after diagnosis.  
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Chapter Seven: Bioimpedance vector analysis for the 
detection of extra-cellular volume overload, a new 
prognostic biomarker, coupled with sarcopenia in 
systemic AL amyloidosis 
Introduction 
The amyloidoses are disorders of protein folding, in which a variety of proteins misfold and 
aggregate into fibrils that accumulate in tissues and disrupt organ function.(152)  Immunoglobulin 
light chain (AL) amyloidosis is caused by deposition of fibrils derived from monoclonal 
immunoglobulin light chains and is the most common and serious type of systemic 
amyloidosis.(5)  Renal and cardiac involvement are present in approximately 70% and 50% of 
patients with systemic AL amyloidosis at diagnosis respectively. Renal involvement manifests 
with nephrotic syndrome and progressive renal impairment(101) and cardiac involvement with 
elevated plasma N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentration and 
congestive cardiac failure such that both extracellular volume overload and sarcopenia are 
common.   
Body composition assessment using bioimpedance vector analysis (BIVA) is a non-
invasive tool that has been validated in patients with both chronic kidney disease and 
cardiovascular disease.(90, 167)  It provides information on diagnosis,(168) volume status,(169) 
cachexia,(170) and overall prognosis(170) in patients with chronic diseases, including those with 
heart failure.(171)  Abnormalities in volume status are common in cardiac amyloidosis and 
nutritional status at the time of diagnosis has been shown to influence prognosis in systemic AL 
amyloidosis.(172) and nutritional counselling has been shown to preserve body weight and 
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quality of life.(173)   Nonetheless, body composition assessment via BIVA has not previously 
been described in patients with systemic AL amyloidosis.  
We undertook a pilot study of BIVA to evaluate body composition in 300 patients at the 
time of diagnosis of systemic AL amyloidosis who were prospectively enrolled into the UK AL 
amyloidosis chemotherapy (ALchemy) study. 
 
Patients and Methods 
Patients 
All patients who attended the National Amyloidosis Centre (NAC) with newly diagnosed 
systemic AL amyloidosis between April 2016 to April 2017 and were enrolled into ALchemy, a 
prospective observational AL Chemotherapy study, underwent body composition assessment via 
BIVA using InBody 770 in conjunction with routine clinical, biochemical, echocardiographic and 
scintigraphic assessments.(130)   
Renal involvement was defined as non-Bence Jones proteinuria of more than 0.5g/24 hr 
according to the amyloidosis international consensus criteria,(69) and cardiac involvement was 
defined by echocardiography according to international consensus criteria.(69)  In cases in which 
there was uncertainty regarding involvement of the heart by amyloid on the basis of 
echocardiography, additional cardiac magnetic resonance imaging was performed and cardiac 
involvement was defined on the basis of native T1 and/or extracellular volume measurement, as 
previously reported.(156, 157) 
All patients underwent protocolized assessments every 3-6 months at the NAC, each 
assessment comprising clinical evaluation, serum and urine biochemistry including assessment of 
renal and liver function, NT-proBNP, echocardiography, SAP scintigraphy,(65) and assessment 
of hematological disease by serum free light chain (FLC) assay, and serum and urine 
immunofixation electrophoresis.   
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All patients were managed in accordance with the Declaration of Helsinki and provided 
written informed consent for study entry (REC reference 09/H0715/58) and publication of their 
data. 
 
Bioelectrical impedance vector analysis (BIA) 
Single frequency BVIA was performed, as previously described.(174)  Extracellular 
water (ECW), total body water (TBW), fat-free mass (FFM), body fat mass (BFM), percentage 
body fat (%BF) and skeletal muscle mass (SMM) were calculated according to the manufacturer’s 
software (InBody 770, Derwent Health Care, Seoul, South Korea).  In order to confirm 
repeatability of BIA measurements in this patient population, 28 patients with systemic 
amyloidosis underwent serial BIA measurements across 3 consecutive days.  Lin’s concordance 
correlation coefficient was calculated and revealed good reproducibility for all four measurements 
of weight, SMM, %BF and ECW/TBW ratio with Rho_C of 0.999, 0.996, 0.992 and 0.986 
respectively. 
The presence of extracellular volume overload was defined according to ECW/TBW 
ratio.(175)  Patients were categorised into 3 grades of ECV state; normal (0.360-0.390), 
mild/moderate overload (0.390-0.410), and severe overload (>0.410). 
Sarcopenia was defined as Skeletal Mass Index (SMI) calculated as skeletal 
muscle/height2 (kg/m2) where skeletal muscle was estimated using BIA.  For men, moderate 
sarcopenia was SMI between 8.51 and 10.75 kg/m2 and severe sarcopenia was SMI < 8.50 kg/m2.  
For women moderate sarcopenia was SMI between 5.76 and 6.75 kg/m2 and severe sarcopenia 
was SMI < 5.75 kg/m2, as previously described.(176, 177) 
 
Chemotherapy 
Chemotherapy was undertaken as per UK amyloidosis guidelines.(178)  Twenty-three of 300 
(6%) patients died prior to receiving systemic chemotherapy, 238/277 (86%) patients received a 
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first line bortezomib regimen, 5/277 (1%) a first line thalidomide regimen and 34//277 (13%) 
received first line chemotherapy containing neither thalidomide nor bortezomib.  Median number 
of cycles administered first line was 3 (Range 1-7). 
 
Statistical Analysis 
Correlation was performed using Pearson correlation coefficient.  Means within subgroups were 
compared by one way Anova tests.  Analyses were performed using Graphpad Prism v5.03 and 
IBM SPSS Statistics 23 software.  A significance level of 0.05 was used for all hypothesis tests.  
Censor date was the 1st October 2017. 
 
Results 
Baseline demographics of the cohort are listed in Table 7.  Median age was 68 years (40-89) with 
a M:F ratio of 1:1. Median serum creatinine was 98 µmol/L (32-610), eGFR 63 ml/min/1.73 m2 
(10-100) and NT-proBNP 2340 ng/L (12-42209). Median intraventricular septal thickness (IVSd) 
by echocardiography was 13 mm (7-22) with median left ventricular ejection fraction (LVEF) of 
60% (20-77).  208/300 (69%) patients had renal involvement at baseline, 196/300 (65%) cardiac 
involvement, and 49/300 (16%) liver involvement. Visceral amyloid was evident by SAP 
scintigraphy in 237/300 (80%) patients; 72/237 (30%) had a large visceral amyloid load, 76/237 
(32%) had a moderate visceral amyloid load and 89/237 (38%) had a small visceral amyloid load, 
as previously described.(65) Median survival by Kaplan Meier analysis was not reached although 
median time to death among 70/300 (23%) patients who died was only 3.4 (range 0.3-9.3) months.  
Two hundred and eighty-two (94%) patients underwent BIA at baseline. Eighteen 
patients were too unwell to complete BIA analysis, 17 of whom had advanced cardiac amyloidosis 
(Mayo Stage 3b disease) and one of whom was unable to stand due to hypotension from amyloid-
related autonomic neuropathy. One hundred and twenty patients underwent BIA at first follow 
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up, six months from baseline.  The drop off in patient numbers at follow up was due to patient 
death in 70 cases; the remainder had not completed 6 months of follow up at the time of censor. 
Table 7 Patient demographics and bioimpedence results at diagnosis 
Demographics All  Male  Female P value 
Sex 
 
174 (58%) 126 (42%)  
Median Age (years) (Range) 68 (40-89)    
Median eGFR (ml/min) (Range) 63 (10-100)    
Median serum creatinine (µmol/L) (Range) 98 (32-610)    
Median serum Albumin (g/L) (Range) 34 (14-53)    
Median C-Reactive Protein (mg/L) (Range) 3 (<1-137)    
Visceral amyloid burden by SAP 
scintigraphy 
  Large 
  Moderate 
  Small 
  None 
 
 
72 (30%) 
76 (32%) 
89 (38%) 
63 (20%) 
   
Median IVSd (mm) (Range) 13 (7-22)    
Median LVEF (%) (Range) 60 (20-77)    
Median LVPW (mm) (Range) 13 (7-21)    
Median NT-proBNP (ngl/L) (Range) 2340 (12-42,209)    
Median 6MWT (metres) (Range) 374 (19-708)    
Mayo Disease Stage  
 1 
 2 
 3 
 
48 (16%) 
87 (29%) 
165 (55%) 
   
Bioimpedance     
Extracellular Water (ECW) (Litres) (Range) 17.1 (9.5-32.4)    
Total Body Water (TBW) (Litres) (Range) 41.4 (23.6-74.0)    
Intracellular Water (ICW) (Litres) (Range) 24.4 (14.0-41.6)    
ECW/TBW ratio (Range) 0.410 (0.366-0.450)    
ECW/TBW Median (range) 
 Mayo Stage 1 
 Mayo Stage 2  
 Mayo Stage 3  
 
0.401 (0.386-0.439) 
0.406 (0.379-0.450) 
0.416 (0.366-0.446) 
   
 
 
<0.0001 
Weight (kg) (Range)  82 (50.6-125) 67 (39.1-107.8)  
Body Mass Index (BMI) (Range)  27.2 (17.4-38.4) 25.5 (16.8-41.6)  
Fat Free Mass (kg) (Range)  65.4 (46.3-99.6) 46.7 (32.2-66.9)  
Skeletal Muscle Mass (SMM) (kg) (Range)  34.9 (24.3-52.2) 24.1 (16.3-34.3)  
Skeletal Muscle Mass/h2 (Range)  11.3 (8.5-14.6) 9.51 (6.8-12.75)  
SMM (kg) Median (Range) 
 Mayo Stage 1 
 Mayo Stage 2 
 Mayo Stage 3 
  
39.05 (28.9-46.2) 
35.05 (28-52.20) 
34.60 (25-34.60) 
 
24 (19.3-30.1) 
23.95 (16.3-32.7) 
24.7 (16.6-32.7)  
 
 
 
0.1024 
Body Fat Mass (kg) (Range)  16.8 (2.3-48.9) 20.5 (1.5-46.9)  
Body Fat Mass (kg) Median (Range) 
 Mayo Stage 1 
 Mayo Stage 2 
 Mayo Stage 3 
  
25.25 (5.9-45.1) 
18.95 (2.6-41) 
15.7 (2.6-35.10) 
 
21.9 (7.4-39.8) 
21.85 (9.4-22.7) 
15.25 (1.5-42.1) 
 
 
 
p=0.0008 
Percentage Body Fat (%) (Range)  21 (3-40) 31 (3-49)  
IVSd – Interventricular septal diameter; LVPW - Left Ventricular Posterior Wall; 6MWT - Six minute walk test; 
ECW/TBW ratio – extracellular water/total body water ratio. 
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Extracellular water, Intracellular water and Total body water at baseline 
At baseline; Median ECW, ICW and TBW were 17.1 L, 24.4 L and 41.4 L respectively. Median 
ECW/TBW ratio was 0.410 (normal range 0.360-0.390).  Two hundred and sixty-four of 282 
(94%) patients had ECW/TBW ratio above the normal range. The degree of fluid overload at 
baseline was a highly significant predictor of overall survival (p<0.0001) (Figure 7.1). There was 
a weak but significant correlation between baseline Log NT-proBNP concentration and 
ECW/TBW ratio (R2 0.1139, p<0.001). ECW/TBW ratio ((R2 0.098, p<0.0001) differed 
significantly between Mayo Disease Stages (Table 7).  
 
Figure 7.1.  Patient survival by Kaplan Meier stratified according to degree of ECV 
overload at the time of diagnosis.  Patients were categorised as follows; normal ECV 
(ECW/TBW ratio 0.36-0.39), mild/moderate ECV overload (ECW/TBW ratio 0.39-
0.41) and severe ECV overload (ECW/TBW >0.41) (p<0.0001). 
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Weight, Skeletal muscle mass and body fat mass at baseline 
Male and female baseline skeletal muscle mass and body fat mass calculations are listed in Table 
7.  Median age in the male cohort was 68 years and median weight 82 kg.  Median skeletal muscle 
mass (SMM) was 34.9 kg, median body fat mass (BFM) was 16.8 kg with a median percentage 
body fat (%BF) of 21% (normal range 10-20%).  Median age in the female cohort was 69 years 
and median weight 67 kg.  Median SMM was 24.1 kg, median BFM was 20.5 kg and median 
%BF was 31% (normal range 18-28%).  SMM/h2 revealed that no patient had severe sarcopenia 
at baseline, moderate sarcopenia was present in 53 (19%) patients and 227 (81%) patients had 
normal muscle mass. BFM (R2 0.1330, p=0.0008) but not SMM differed significantly between 
Mayo Disease Stages.  
 
BIA at first follow up (6 months from baseline) 
Waterfall plots of change in weight, ECW/TBW and SMM at 6 months from baseline are shown 
in Figure 7.2 (a, b and c respectively).  BIA revealed an absolute median weight change at first 
follow up of -2.8 kg (range: -28.4 to +13.6), comprising a median loss of total body weight of 
4%. Median ECW/TBW ratio change was + 0.005 (-0.04 to +0.05), representing a 2% median 
increase in ECW/TBW ratio.  ECW/TBW increased in 77/120 patients, and remained the same 
or decreased in 43/120; the median increase in ECW/TBW ratio among the 77 patients in whom 
it increased was 0.01, equivalent to approximately 1.8 litres.  Median change in SMM was -0.9 kg 
(range: -13.2 to +3.6).  SMM decreased in 76/120 patients and remained the same or increased in 
44/120 patients; median loss of SMM in the 76/120 patients in whom it decreased was 2kg.  
Follow up SMM/h2 revealed development of severe sarcopenia in 2/120 (2%), moderate 
sarcopenia in 25/120 (22%) and normal muscle mass in 85/120 (76%) patients respectively.  
Median change in BFM was -2kg (range -13.7-8.4). BFM decreased in 75/120 patients and 
remained the same or increased in 45/120 patients; median loss of BFM in the 75 patients in 
whom it was decreased was 3.9kg. 
There was a weak correlation between percentage change in ECW/TBW ratio and 
percentage change in Log NT-proBNP at 6 months (R2 0.0852, p=0.008). There was no 
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association between number of cycles of chemotherapy administered and change in ECW/TBW 
(p=0.906) or SMM (p=0.875).  However, failing to achieve a dFLC response of ≥ 90% at 6 months 
was associated with an increase in ECW/TBW ratio (p=0.006).  There was a reasonable 
correlation between change in body weight and change in ECW/TBW (R2 0.1011, p=0.006) but 
a far stronger correlation between change in body weight and SMM (R2 0.5548, p<0.0001). 
 
Figure 7.2 Waterfall plot of change in BIA parameters at 6 months from baseline. 
A) Weight; B) Extracellular water/total body water (ECW/TBW) ratio; C) Skeletal 
muscle mass (SMM). 
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Discussion 
Current management of fluid balance in AL amyloidosis is predominantly through clinical 
assessment and weight measurement despite their established limitations in diseases associated 
with sarcopenia.(175)  Here we show for the first time that, prior to receiving systemic 
chemotherapy, ~95% of patients with systemic AL amyloidosis have significant fluid retention 
and ~20% of patients are sarcopenic.  Additionally for the first time we show that the presence 
and degree of ECV overload (as defined by ECW/TBW ratio) at diagnosis is highly predictive of 
overall survival in patients with systemic AL amyloidosis.  
Despite an overall loss of weight of 4% between baseline and follow up, there was an 
increase rather than a reduction in ECV overload in the majority of patients.  Median loss of SMM 
and BFM was 1 kg and 2 kg respectively and this was accompanied by an increased incidence of 
sarcopenia.  These data highlight that measurement of weight alone in patients with AL 
amyloidosis receiving chemotherapy is likely to underestimate loss of SMM due to worsening co-
existing volume overload and that weight loss is often due to loss of SMM and BFM rather than 
adequate diuresis.  The commonest reason for acute admission to hospital during chemotherapy 
among UK AL amyloidosis patients is fluid retention (unpublished) which ought to be preventable 
but is entirely consistent with the present findings.  Serial BIA measurements, by identifying 
progressive fluid retention despite loss of muscle mass, would enable targeted management of 
fluid balance as well as nutritional status.   
BIA measurements in patients with systemic AL amyloidosis revealed a correlation, 
albeit relatively weak, between baseline NT-proBNP and ECW/TBW ratio and also between 
change in NT-proBNP and change in ECW/TBW ratio.  This correlation has previously been 
shown in dialysis cohorts where BIA is known to aid assessment and management of volume 
status (175).  NT-proBNP is a key prognostic biomarker in patients with systemic AL 
amyloidosis, usually indicating presence and severity of cardiac infiltration;(101) however, here 
we show for the first time the association between degree of ECV overload and patient survival.  
Marked fluctuations in NT-proBNP concentration occur, particularly during chemotherapy and 
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our findings highlight the need for further work to better understand the precise relationship 
between BIA assessment of ECV overload and NT-proBNP in patients with AL amyloidosis. 
Interestingly, achieving less than a hematologic very good partial response (VGPR) was 
associated with an almost 8 fold increase in mean ECW/TBW change compared to achieving a 
VGPR or CR.  It is well established that achieving a hematologic VGPR or CR is prognostically 
beneficial in AL amyloidosis,(68) and one might postulate that the worsening fluid retention in 
patients who fail to achieve adequate clonal responses is directly related to worsening amyloidotic 
organ dysfunction.   
Treatment of systemic AL amyloidosis is associated with major morbidity and 
occasionally, mortality. Sarcopenia is an increasingly recognised independent risk factor for 
treatment intolerance,(179) and fluid retention commonly prompts emergency hospital admission 
among AL amyloidosis patients receiving chemotherapy.  BIA may enable early recognition and 
intervention of changes in body composition during chemotherapy. Further work to assess the 
role of BIA in predicting and influencing clinical outcomes in AL amyloidosis is warranted. 
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Chapter Eight: Role of implantable intracardiac 
defibrillators in patients with cardiac immunoglobulin 
light chain amyloidosis 
 
Introduction 
Immunoglobulin associated light chain (AL) amyloidosis is a rare clonal plasma cell disorder 
characterized by the deposition of misfolded amyloid proteins in vital organs including the 
kidneys and heart(5). Over half of patients present with cardiac involvement and prognosis is 
predominantly dictated by the presence and severity of cardiac involvement (180).  Severity of 
cardiac organ involvement is assessed by serum biomarkers, echocardiography and increasingly 
cardiac magnetic resonance (CMR)(72). One third of patients with cardiac AL amyloidosis 
present with a significant elevation of both N-terminal pro-brain natriuretic peptide (NT-proBNP) 
and troponin T (TnT) concentration (68) and are classified according to the widely used Mayo 
Clinic criteria (86) to have Stage III disease which is associated with a poor overall survival 
(median of 9-12 months)(181). 
The particular challenge in systemic AL amyloidosis is a very high early mortality, often 
within the first few months of diagnosis (30-40%), despite significant improvement in treatment 
regimes(75). In addition, only 29% of those with very advanced cardiac AL survive longer than 
12 months from diagnosis (68, 182).  The main cause of this significant and early mortality is 
sudden cardiac death (SCD) – the trigger (and consequently treatment) of which remains unclear.  
Whilst the prevalence of ventricular arrhythmias is as high as 27% in patients with cardiac AL 
amyloidosis(76), both ventricular tachyarrhythmias(77, 183) and bradycardia (78) have been 
observed as terminal events.  This lends to ICD implantation being a logical therapeutic 
intervention but efficacy, criteria for patient selection and more importantly long term survival 
benefit have yet to be determined.  To date only one study has suggested a long term survival 
benefit of ICD implantation in a select cohort of patients with cardiac amyloidosis (184).  
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In this study, we report the UK experience with ICD implantation in a cohort of patients 
with cardiac AL amyloidosis managed by a uniform supportive care and treatment pathway.   
 
Methods 
This study included all newly diagnosed patients with systemic AL amyloidosis who had an ICD 
implantation as part of the treatment plan and managed according to our protocolised 
multidisciplinary treatment pathway at the Royal Free Amyloidosis treatment centre from June 
2010 to November 2015.  The diagnosis of amyloidosis was confirmed in all cases with a tissue 
biopsy demonstrating characteristic birefringence on Congo red staining viewed under cross 
polarized light.  Typing of AL amyloidosis was confirmed by immunohistochemical staining with 
appropriate antibodies to kappa or lambda light chains and by exclusion of hereditary 
amyloidosis, where necessary, by genetic sequencing of the relevant genes.   
All patients underwent a comprehensive clinical consultation, evaluation at baseline and 
then subsequently every six months in a protocolised manner including electrocardiogram (ECG), 
transthoracic echocardiogram including tissue Doppler imaging, whole body 123I-serum amyloid 
P component scintigraphy (SAP scan)(185), standardized 6 minute walk test, lying and standing 
blood pressure measurements, New York Heart Association (NYHA) and Eastern Cooperative 
Group (ECOG) Grading. Clonal disease was assessed serologically by serial identification and 
quantitation of any circulating monoclonal protein and serum free light chains (Freelite™ assay 
[The Binding site, Birmingham, United Kingdom]) measured monthly.  Conduction abnormalities 
on ECG were defined as per standard accepted criteria(186, 187). Detailed echocardiogram 
included assessment of diastolic dysfunction, 2-D left ventricular strain and tissue Doppler 
imaging were performed as previously described (188).  Organ involvement and hematological 
responses were defined as per the international amyloidosis consensus criteria (69).  Cardiac 
disease stage was defined as per the criteria described (86).  Additionally, patients with Mayo 
cardiac stage III disease were divided as stage IIIa if the NT-proBNP was <8500 ng/L and stage 
IIIb if NT-proBNP was ≥8500 ng/L(68, 160). 
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Chemotherapy treatment was undertaken as per the UK amyloidosis treatment guidelines 
(178).  As a precautionary measure, due to the known high early mortality, most patients with 
stage III cardiac amyloidosis in the UK are admitted for 48-72 hours of continuous ECG 
monitoring at the start of chemotherapy typically starting at least 24 hours before the first 
chemotherapy dose.  ICD implantation was considered as per the UK guidelines 
(https://www.nice.org.uk/guidance/ta314/evidence).  Serious recurrent ventricular arrhythmias 
defined as non-sustained ventricular tachycardia on more than one occasion in the presence of 
syncope/presyncope or sustained VT were considered for ICD implantation.  Patients undertook 
routine downloads from their devices on a weekly basis and additional download at the time of 
symptoms. These were reviewed by the ICD team including a cardiologist.   
Where relevant, time to death was recorded and every effort was made to obtain clinical 
details and ICD recordings of the terminal event. Where these showed a rhythm compatible with 
a cardiac output in the absence of such an output, the cause of death was attributed to PEA. Censor 
date for surviving patients was 1 January 2016.   
All patients were treated in accordance with the Declaration of Helsinki and provided 
informed consent for insertion of the ICD and publication of data.  
 
Statistical analysis 
All statistical analyses were carried out using the SPSS 16.0 statistical software package. 
Estimated median patient survival was calculated by Kaplan-Meir analysis using GraphPad Prism 
v5.03 software.  
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Results 
Patients 
A total of 15 patients who underwent ICD implantation from 2010 to 2015 were identified. 
Baseline characteristics are found in Table 8.1. Median age at diagnosis was 51 years (range 37-
80) M: F ratio 3:2. Median serum high-sensitivity TnT was 60ng/L (range 22-326 ng/L) and 
median NT-proBNP concentration was 5178 ng/L (range 2220 – 34,153). Mayo Staging II, IIIa 
and IIIb were 4/15, 8/15 and 3/15 respectively.  One patient had Mayo stage II disease but an NT-
proBNP >8500 ng/mL.  All patients had cardiac involvement with renal, liver and nerve 
involvement in 7/15 (47 %%), 5/15 (33%) and 1/15 (7%) patients respectively.  At presentation, 
five patients were receiving β-blocker therapy. No patients were receiving amiodarone or other 
antiarrhythmics. All patients received chemotherapy as per standard UK treatment guidelines with 
front line Bortezomib or Thalidomide based regime.  
The baseline electrocardiogram showed that: 13 (87%) patients were in sinus rhythm. 2 
(13%) had atrial fibrillation.  Only one patient had evidence of 1st degree atrio-ventricular 
conduction block (normal PR interval in 12 of the 13 patients in sinus rhythm). There was 
intraventricular conduction delay in 7 (46 %) patients – right bundle branch block in 1/7 (14%) 
and non-specific intraventricular conduction defects with prolonged QRS in 6/7 (84%).  On 
echocardiography, the median left ventricular wall thickness was 15mm (range 12-19mm).  On 
categorical scoring, the diastolic dysfunction was mild, moderate and severe in 2 (13%), 6 (40%) 
and 7 (47%), respectively.  Median global left ventricular strain was −9.5% (range −0.08 to 
−18.2%) and median left ventricular ejection fraction (LVEF) was 53% (range 40-65 %).  
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Table 8.1. Baseline Demographics in ICD cohort 
 
 
 
Demographic N (%) or Median (Range) 
Male: Female 9 (60%):6 (40%) 
Age (years) 51(37-80) 
Systolic BP (mmHg) 110 (79-133) 
Diastolic BP (mmHg) 68 (29-83) 
NYHA class 
 1 or 2 
 3  
 
 
14 (93%) 
1 (7%) 
6 Minute walk distance (metres) 370 (138-607) 
Clonal disease markers  
Paraprotein present 
 
 IgG 
8 (53%) 
 
8 (100%) 
Serum Free light chains  
Kappa (n) 
 
Starting light chains (mg/L) 
4 
 
610 (319-690) 
Lambda (n) 
 
Starting light chains (mg/L) 
11 
 
418 (82-3260) 
dFLC (mg/L) 482 (60 -3245) 
Cardiac Markers:  
High sensitivity Troponin T (ug/L) 60 (22-326) 
NT pro-BNP (ng/L) 5178 (2220-34,153)  
Echocardiographic parameters:  
 LVEF by Biplane Simpson (%) 
 Septal wall thickness (mm) 
 Global LV strain by tissue Doppler imaging. 
 
 
53 (40-65) 
15 (12-19) 
-9.5% (-0.08 to – 18.2%) 
ECG parameters: 
 Sinus rythmn 
 Atrial Fibrillation 
 PR interval (ms) 
 QRS interval (ms) 
 QTc duration (ms) 
 
13 (87%) 
2 (13%) 
164 (138-242) 
98 (84-162) 
481 (401-520) 
Mayo Disease Stage 
 2 
 3a 
 3b 
 
4 (27%) 
8 (53%) 
3 (20%) 
Organ involvement (Liver, Kidney, Spleen, Nerve) 
 Liver 
 Kidney 
 Spleen 
 Nerve 
 
5 (33%) 
7 (47%) 
8 (53%) 
1 (7%) 
Renin Angiotensin Blockade  5 (33%) 
Diuretic treatment 
 Loop diuretic 
 Mineralocorticoid receptor antagonist 
 
11 (73%) 
5 (33%) 
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ICD implantation and arrhythmias 
Median time to ICD implantation was 13 days from their first presentation to the NAC and median 
follow-up from diagnosis was 4.9 months (range 1.35 – 66.12).  All arrhythmias were detected 
by continuous cardiac monitoring when patients were admitted for assessment prior to starting 
chemotherapy as per our standard protocol.  Only 4 (27%) patients gave a history of recurrent 
syncope.  Fourteen patients (93%) underwent ICD implantation for primary prevention and only 
one patient underwent implantation for secondary prevention after a cardiac arrest due to 
ventricular fibrillation.  The underlying arrhythmia in the 14 patients who underwent ICD 
implantation for primary prevention were:  non-sustained ventricular tachycardia in 12 patients 
(80%) and sustained ventricular tachycardia with spontaneous reversion in 2 (13%).  
13/15 (87%) of the patients were started on oral amiodarone after ICD implantation.  The 
remaining 2 patients received beta blocker therapy (one of whom was intolerant of amiodarone).  
All patients routinely downloaded their data via a modem or had their ICD routinely assessed for 
the presence of arrhythmia after implantation.  The presence of NSVT was detected in 6 (40%) 
patients, of which 5/6 (83%) were on amiodarone therapy and 1/6 (17%) was receiving beta 
blocker therapy.   
 
Appropriate ICD device therapy and impact on survival 
A total of four patients had appropriate therapy from their ICD.  Three (20%) patients received 
appropriate therapy from their ICD for ventricular arrhythmias and one patient had pacing for 
bradyarrhythmia.  Overall, 13 out of 15 patients are alive with overall survival at 3, 6 and 12 
months of 93%, 82% and 82% respectively (Figure 8.1).  Two out of the four patients who had 
appropriate ICD therapy from their device have since died. 
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Figure 8.1. Overall survival in cohort by Kaplan Meir Analysis. Overall survival at 3, 6 
and 12 months was 93%, 82% and 82% respectively. 
 
 
Patient 1 (Mayo Stage 2) developed VF and had antitachycardia pacing followed by a 
single 41J shock.  The patient suffered no ill effects.  This patient is still alive 41 months after 
having achieved a complete response with a Bortezomib based treatment.  This patient had a 
subtle clonal relapse and had two further episodes of VF needing two shocks – both successfully 
reverting her back to sinus rhythm.  Figure 8.2 shows this patient’s clinical course.  Patient 2 
(Mayo Stage 2 with NT-proBNP >8500ng/L) developed VF during the first cycle of 
chemotherapy within 8 days of commencing treatment and successfully reverted to sinus rhythm.  
However, ten days later, the patient had further VF which was appropriately shocked but was 
intractable and the patient died.  There was no evidence of a clonal response at the time of death.  
Patient number 3 (Mayo stage 3b disease) developed VF during her 2nd cycle of chemotherapy 
and was also appropriately shocked.  She remained in sinus rhythm after the shock until death.  
She had refractory clonal disease and died over 3 months later with end stage heart failure. 
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Patient 4 who underwent ICD implantation for NSVT, developed marked bradycardia 
with symptomatic hypotension/syncope and required pacing.  The lower pacing threshold was 
increased from 40 bpm to 60 bpm and the symptoms resolved.  
 
Figure 8.2 
Graph showing (patient 1) lambda light chains from diagnosis, chemotherapy with 
Cyclophosphamide Thalidomide and Dexamethasone (CTD), Cyclophosphamide 
Velcade and Dexamethasone (CVD) and the number of cycles. Arrows indicate the time 
point of appropriate ICD therapy with 41J shock. 
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Discussion 
Survival in systemic AL amyloidosis has substantially improved over the last two decades, 
however early mortality has essentially remained unchanged with SCD almost always the cause 
of death.  With the increasing use of continuous electrocardiographic monitoring, arrhythmias are 
frequently detected in cardiac AL amyloidosis.  There is no clear consensus on either the best 
immediate treatment or indeed long term management.  ICD implantation is a potentially 
attractive option addressing both the ventricular tachyarrhythmias and bradycardias.  Studies 
reporting the outcomes of ICD implantation in cardiac amyloidosis remain limited and 
conflicting.  We report a quarter of the patients in the current cohort received appropriate therapy 
from the ICD, an additional third of patients had NSVT which did not need ICD intervention and 
a good overall survival of 82% at 12 months.  In the immediate short term, ICD was life-saving 
in all cases who received appropriate ICD therapy but only two out of the four patients achieved 
longer term survival.   One patient died prior to completion of their first cycle of chemotherapy 
(before a clonal response could be achieved) and the second was a non-responder to chemotherapy 
(a very poor prognostic parameter)(189). 
The key to improved outcomes in AL amyloidosis is achieving a very good free light 
chain response to therapy along with a reduction in cardiac biomarkers which heralds an end 
organ response(101).  However, a third of the patients succumb to cardiac death before such a 
response can be achieved.  Attempts to reduce this early mortality have varied from admission 
for cardiac monitoring during the early cycles (standard UK practice), use of anti-arrhythmic 
therapy(190) and dose modified chemotherapy to reduce the potential risk of death attributable to 
toxic adverse effects.  Small molecules which block light chain mediated cardiac toxicity such as 
doxycycline(191) or Epigallocatechin-3-gallate (EGCG)(192) have been attractive agents but 
compelling prospective data on their activity is not available.   
ICDs have a clear role in improving outcomes in systolic heart failure and arrhythmogenic 
disorders such as hypertrophic cardiomyopathy but not in non-ischemic heart failure(193).  As 
cardiac arrhythmias are supposedly the main cause of early death in cardiac AL amyloidosis, ICD 
implantation is a logical but unproven solution.  Assessing the impact of ICD implantation in 
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cardiac AL amyloidosis focuses on two separate issues - the appropriateness of ICD therapy in 
terminating a life threatening cardiac arrhythmia (i.e. improvement in immediate survival) and its 
role in improving long term survival (Table 8.2).  A study from the German amyloidosis group 
failed to demonstrate any benefit with a high mortality of 47% - including appropriate shock 
therapy in only 2 patients (11%) and only one patient surviving post therapy (194).  Contrarily, 
two other studies from the US, reported appropriate shock therapy in just over a third of patients 
(184, 195), data which is similar to our current results. In the current series, all four patients with 
serious arrhythmias post ICD implantation had appropriate therapy – similar to reports from the 
two US series with up to 80% immediate survival post ICD therapy.  In our series, the long term 
impact is challenging to interpret due to the small number of events – clearly there was no impact 
on long term survival in two patients and was life prolonging in the longer term for the remaining 
two patients.  
Meta-analysis of the data available (including our cohort) contains 82 reported patients 
with AL amyloidosis (Table 8.2).  It is clear that patients with cardiac AL amyloidosis have a 
high burden of ventricular arrhythmias and the majority of ICD implantation was for primary 
prevention.  Only 28% of patients actually required device therapy.  Importantly, nearly three 
quarters of all patients who had therapy from their ICD survived immediately following the 
therapy.  This is a crucial point – in patients with AL amyloidosis, survival in the early months is 
important to allow delivery of chemotherapy which will reduce the light chain burden and hence, 
potentially allow for benefit from treatment and longer term survival.  Only half of all patients 
reported, including the current series, survived long term following the ICD therapy.  This data 
would suggest that, in appropriately selected patients with cardiac AL amyloidosis, ICDs will 
deliver appropriate therapy that is lifesaving, in the short term, in the majority of patients.  
Nonetheless, other factors including initial amyloid burden, clonal response, toxicity from 
chemotherapy and concurrent vital organ involvement, are likely determinants of the longer term 
outcomes and not impacted by ICDs.  Based on this, we propose an algorithm for consideration 
of ICD implantation in patients with AL amyloidosis (Figure 8.3).     
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Table 8.2. Meta-analysis of studies to date on ICD implantation in patients with cardiac 
amyloidosis. 
 
Study/Date Patients 
with AL 
Primary/ 
secondary 
prevention 
Appropriate 
therapy from 
device (%) 
Survival 
post 
therapy 
(%) 
Survival 
during follow 
up of patients 
who received 
appropriate 
therapy (%) 
Overall 
survival 
for 
cohort 
Varr et al 
(2014) 
15 11 Primary 
prevention 
4 Secondary 
prevention 
5/15 (33%) 4/5 (80%) 1/4 (25%)  
Lin G et al 
(2013) 
33 25 Primary 
prevention 
8 Secondary 
prevention 
12/33 (36%)   10/33 
(30%) 
Kristen et al 
(2008) 
19 19 Primary 
prevention 
2/19 (11%) 1/2 (50%) 1/2 (50%) 10/19 
(53%) 
Current 
series 
15 14 Primary 
prevention 
1 Secondary 
prevention 
4/15 (27%) 3/4 (75%) 2/4 (50%) 13/15 
(87%) 
ALL Studies 82 69 Primary 
prevention 
13 
Secondary 
prevention 
23/82 (28%) 8/11 
(73%) 
4/10 (40%) 33/67 
(49%) 
 
Limitations of our study include patient selection, which was restricted to those treated at 
our centre. Alongside this the majority of our patients were on routine amiodarone after ICD 
implantation although amiodarone has not been shown to be better than placebo with regards to 
survival in congestive heart failure (196).  Finally our sample size was small, limiting our ability 
to interpret sub-group data.    
In conclusion, ICDs deliver appropriate therapy in the majority of patients with cardiac 
AL amyloidosis – although lifesaving in the short term, their long term survival benefit remains 
unclear.  Appropriate patient selection is crucial to the rationalized use of scarce resources and 
patients with moderate cardiac amyloidosis, who are likely to benefit most, should be considered.  
Efforts directed at the prevention of arrhythmias may be more appropriate for the most advanced 
disease (Mayo stage IIIb).  Formal prospective studies of device therapy in AL amyloidosis is 
urgently needed to confirm the validity of this approach.   
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Figure 8.3: Approach to ICD implantation in cardiac AL amyloidosis. 
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Chapter Nine: General Conclusions  
The studies presented in this thesis address key areas of diagnosis, monitoring and outcome 
of patients with cardiac and renal amyloidosis. Definitive diagnosis of amyloidosis and 
confirmation of fibril protein type, along with evaluation of vital organ involvement, are 
critical for optimal clinical management. I have characterized the importance of using both 
CR and IHC staining alongside LDMS to correctly identify both the presence and type of 
amyloid deposits across a range of different tissues. The strength of IHC staining and 
limitations of mass spectrometry in renal tissue is demonstrated in our series of patients 
with ALECT2 amyloidosis, in which LDMS is complimentary but not superior to IHC. The 
ALECT2 study also provides novel information on the prevalence of this non-hereditary 
and slowly progressive form of renal amyloidosis, describing a more distinct ethnic 
preponderance than previously noted; unusually, renal ALECT2 amyloidosis does not 
present with classical nephrotic range proteinuria. Its association with hepatitis infection 
and a potential state of low grade chronic inflammation offers potential insight into the 
pathogenesis of this curious disease.  
The management of systemic AL amyloidosis is influenced strongly by assessment 
of individual organ involvement despite it being a complex multisystem disease in which 
the various involved organ systems must necessarily affect others. To date, management of 
renal AL amyloidosis with advanced renal excretory impairment at presentation has 
focused upon preserving renal function and in clinical practice this has led to a reluctance 
to deliver systemic chemotherapy to patients deemed at ‘high risk’ of reaching RRT. As 
part of our work, here we show, for the first time, that in patients with systemic AL 
amyloidosis and advanced renal excretory impairment at presentation both the speed and 
depth of clonal response is crucial to protect against death, dialysis and their composite 
endpoint. Alongside this almost one third of patients with systemic AL amyloidosis have 
combined cardiac and renal organ dysfunction at presentation (Type 5 cardiorenal 
syndrome), and their outcomes are poor despite chemotherapy. Our study demonstrated that 
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nearly two thirds of the cohort died, among whom median time to death was 5 months and 
16% developed ESRD, the majority of whom reached dialysis within 12 months of 
diagnosis. Our data is novel in that it concerns three hard outcome measures: death, dialysis 
and their composite endpoint. Following this work we propose a novel risk stratification 
tool, in patients with systemic AL amyloidosis and cardiorenal syndrome based upon 
cardiac (NT-proBNP) and renal (eGFR) biomarkers during the first 12 months following 
diagnosis.  
Cardiac and renal AL amyloidosis often lead to both ECV overload and sarcopenia. 
Nutritional status both at diagnosis and throughout treatment has been shown to influence 
prognosis and quality of life respectively. Our study looking at the role of body 
composition using BIVA in patients with systemic AL amyloidosis demonstrated that 94% 
of patients at baseline had ECV overload and almost 20% had sarcopenia. The degree of 
fluid overload at baseline was highly predictive of overall survival and whilst there was a 
weak correlation between ECV overload and NT-proBNP, this study offerred some insight 
into the relationship between fluid status and NT-proBNP, which is a key predictor of 
mortality in systemic AL amyloidosis. 
Cardiac involvement remains the main determinant of death in systemic AL 
amyloidosis. Whilst treatment options and chemotherapy responses have improved 
significantly over the past decade, sudden and early cardiac death remains common. Our 
work looking at the role of ICDs has shown that there is a significant incidence of 
ventricular arrhythmias in patients with cardiac AL amyloidosis and whilst ICD 
implantation offered appropriate and lifesaving therapy in a quarter of our cohort, there was 
no clear survival benefit. This seems to be particularly relevant to those patients with the 
most advanced disease (Mayo Stage IIIb) and in those cases, where ICD implantation may 
not offer a survival benefit, efforts should be directed at oral anti-arrhythmic therapy.  
Nonetheless in light of the high incidence of sudden cardiac death, importance of delivering 
early chemotherapy and the significant cost associated with ICD implantation, formal 
prospective studies are urgently needed to confirm the validity of this approach. 
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Appendix I – Future Work 
The results of chapter 4, exploring the role of proteomics in the diagnosis and typing of 
amyloid deposits has demonstrated the superior role of proteomics in the typing of 
amyloidosis. Currently, target organ biopsies, typically of the heart or kidneys, are regarded 
to be the ‘gold standard’ for definitive histological diagnosis. Cardiac biopsies are not 
without risk, require specialist training and are available in a limited number of centres in 
the U.K, often leading to a delay in diagnosis. Fat aspiration is a simple, safe and quick 
bedside test, potentially allowing for a histological diagnosis without the need for a target 
organ biopsy. Following on from chapter 4, we will conduct a prospective study, 
comparing proteomic analysis of fat aspirates to both CR and IHC, and whether proteomic 
analysis of adipose tissue can improve the diagnosis and typing of systemic amyloidosis.  
Renal involvement in AL amyloidosis is the commonest organ manifestation and the aim of 
treatment is to prevent worsening of renal function and the need for RRT. Chapter 5 has 
identified the importance of a rapid and deep clonal response in patients with systemic AL 
amyloidosis and advanced renal excretory function at presentation whilst Chapter 6 has 
helped risk stratify patients with combined renal and cardiac amyloidotic organ dysfunction 
at baseline. Nonetheless, kidneys infiltrated with amyloid are exquisitely vulnerable to 
intercurrent insults, often leading to AKI in CKD. The role of proximal tubular dysfunction 
(PTD) in renal AL amyloidosis is not clear however, plasma cell dyscrasias are known to 
cause PTD (92). Urinary retinol binding protein (uRBP), a low molecular weight protein 
which is freely filtered at the glomerulus and almost completely reabsorbed at the proximal 
tubule(197) is a well-recognized marker for proximal tubular dysfuction. We plan to study 
baseline uRBP levels in all patients with newly diagnosed systemic AL amyloidosis, 
referred to our national centre, prior to receiving systemic chemotherapy and its correlation 
with both biochemical and histological parameters as well as renal and overall survival.  
The role of nutritional status and its effect on both morbidity and mortality in AL 
amyloidosis has been previously reported. Chapter 7 has identified the incidence of both 
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ECV overload and sarcopenia in patients with AL amyloidosis receiving systemic 
chemotherapy. We plan to expand on this work with a prospective randomized controlled 
trial comparing the role of supervised exercise and dietetic support compared to best 
clinical care during the first 12 months of chemotherapy and its effect on exercise tolerance 
(6MWT), body composition as assessed by BIVA, quality of life and survival in patients 
with systemic AL amyloidosis.  
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Appendix II - Publications Arising from Thesis 
Work 
1. Systemic Amyloidosis. Rezk T, Hawkins PN, Textbook of Autoinflammation, 
Edition 15. 2019 
 
2. The complementary role of histology and proteomics for diagnosis and typing of 
systemic amyloidosis. Rezk T, Gilbertson JA, Mangione PP, Rowczenio D, Rendell 
N, Canetti D, Lachmann HJ, Wechalekar AD, Bass P, Hawkins PN, Bellotti V, 
Taylor GW, Gillmore JD. J Pathol Clin Res 2019 
 
3. Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) 
amyloidosis. Rezk T, Gilbertson JA, Rowczenio D, Bass P, Lachmann HJ, 
Wechalekar AD, Fontana M, Mahmood S, Sachchithanantham S, Whelan CJ, 
Wong J, Rendell N, Taylor GW, Hawkins PN, Gillmore JD. NDT 2016 
 
4. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light 
chain reduction is the crucial factor. Rezk T, Lachmann HJ, Fontana M, 
Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, 
Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore JD. Kidney 
Int. 2017. 
 
5. Cardiorenal AL amyloidosis: Risk stratification and outcomes based upon cardiac 
and renal biomarkers. Rezk T, Lachmann HJ, Fontana M, Martinez De Azcona 
Naharro A, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, 
Foard D, Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore 
JD. Br J Haematol. 2019. 
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6. Bioimpedance vector analysis for the detection of extra-cellular volume overload, a 
new prognostic biomarker, coupled with sarcopenia in systemic AL amyloidosis. 
Rezk T, Davenport A, Gan JJ, Lachmann HJ, Fontana M, Martinez-Naharro A, 
Sachchithanantham S, Guillotte C, Mahmood S, Petrie A, Whelan CJ, Pinney JH, 
Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD. Br J 
Haematol. 2018. 
 
 
7. Role of implantable intracardiac defibrillators in patients with cardiac 
immunoglobulin light chain amyloidosis. Rezk T, Whelan CJ, Lachmann HJ, 
Fontana M, Sachchithanantham S, Mahmood S, Khan F, Khiani R, Tomson J, 
Youngstein T, Gillmore JD, Hawkins PN, Wechalekar AD. Br J Haematol. 2017. 
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